Compounds > 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione

Page last updated: 2024-08-01 03:49:36

4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione

Description

4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor [MeSH]

TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease. [CHeBI]

Cross-References

ID Source	ID
PubMed CID	4124851
CHEMBL ID	284861
SCHEMBL ID	139834
CHEBI ID	147411
MeSH ID	M0478412

Synonyms (53)

Synonym
LS-13757
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
bdbm7781
thiadiazolidinone (tdzd) deriv. 8
HSCI1_000174
NCGC00165913-01
tdzd-8
gsk-3beta inhibitor i
BRD-K45685959-001-02-7
CHEMBL284861
HMS3229G12
FT-0662841
np 01139
thiadiazolidinone-8
CHEBI:147411
327036-89-5
NCGC00165913-02
AKOS016004653
FS-2551
S2926
4-benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione
gtpl5977
CCG-206841
CS-1671
HY-11012
mfcd04973552
tdzd 8
SCHEMBL139834
1,2,4-thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-
B4436
DTXSID30399590
J-514480
2-methyl-4-(phenylmethyl)-1,2,4-thiadiazolidine-3,5-dione
EX-A109
tdzd-8; gsk-3\|a inhibitor i; np 01139
tdzd8
gsk-3b inhibitor i
tdzd-8, >=98% (hplc), needles
J-018843
NCGC00165913-03
JDSJDASOXWCHPN-UHFFFAOYSA-N
gsk-3\|a inhibitor i;np 01139
BCP07657
gsk-3beta inhibitor i - cas 327036-89-5
fmoc-l-?-homo-val-oh
Q27077898
gsk-3beta inhibitor i;np 01139
NCGC00165913-12
A875545
gsk-3 inhibitor i;np 01139
gsk-3 beta inhibitor i
u3w ,
AC-35779

Roles (5)

Role	Description
EC 2.7.11.26 (tau-protein kinase) inhibitor	An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of tau-protein kinase inhibitor (EC 2.7.11.26).
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
neuroprotective agent	Any compound that can be used for the treatment of neurodegenerative disorders.
anti-inflammatory agent	Any compound that has anti-inflammatory effects.

Drug Classes (2)

Class	Description
thiadiazolidine	A organic heteromonocyclic compound that consists of a cylcopentane ring in which two carbon atoms are replaced by a sulfur and nitrogen atom respectively.
benzenes	Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.

Protein Targets (26)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
phosphopantetheinyl transferase	Bacillus subtilis	Potency	0.1413	AID1490
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	5.0119	AID504847
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	4.7360	AID2546; AID2551
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	19.9526	AID504327

Inhibition Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
[tau protein] kinase	Oryctolagus cuniculus (rabbit)	IC50	2.0000	AID1796093
G2/mitotic-specific cyclin-B2	Homo sapiens (human)	IC50	55.0000	AID512487; AID55523
cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)	IC50	100.0000	AID1796094
Beta-casein	Bos taurus (cattle)	IC50	100.0000	AID1796094
Protein kinase C alpha type	Rattus norvegicus (Norway rat)	IC50	100.0000	AID1872911
Cyclin-dependent kinase 1	Homo sapiens (human)	IC50	82.0000	AID1796094; AID512487; AID55523
Protein kinase C delta type	Rattus norvegicus (Norway rat)	IC50	100.0000	AID1872911
Protein kinase C epsilon type	Rattus norvegicus (Norway rat)	IC50	100.0000	AID1872911
Protein kinase C zeta type	Rattus norvegicus (Norway rat)	IC50	100.0000	AID1872911
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	IC50	2.1500	AID1805801
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	IC50	1.1450	AID1640021; AID1805801
G2/mitotic-specific cyclin-B1	Homo sapiens (human)	IC50	82.0000	AID1796094; AID512487; AID55523
Casein kinase II subunit alpha'	Homo sapiens (human)	IC50	100.0000	AID49336
Glycogen synthase kinase-3 alpha	Homo sapiens (human)	IC50	4.5000	AID282721; AID512486
Glycogen synthase kinase-3 beta	Homo sapiens (human)	IC50	9.0564	AID1261874; AID1298644; AID1356765; AID1484860; AID1727768; AID1814364; AID1872907; AID282721; AID512484; AID512486; AID718829; AID729990; AID73980; AID74100
Protein kinase C gamma type	Rattus norvegicus (Norway rat)	IC50	100.0000	AID1872911
Casein kinase II subunit beta	Homo sapiens (human)	IC50	100.0000	AID49336
Casein kinase II subunit alpha	Homo sapiens (human)	IC50	100.0000	AID49336
Protein kinase C beta type	Rattus norvegicus (Norway rat)	IC50	100.0000	AID1796095; AID1872911
Protein kinase C eta type	Rattus norvegicus (Norway rat)	IC50	100.0000	AID1872911
G2/mitotic-specific cyclin-B3	Homo sapiens (human)	IC50	55.0000	AID512487; AID55523
Protein kinase C theta type	Rattus norvegicus (Norway rat)	IC50	100.0000	AID1872911

Bioassays (543)

Assay ID	Title	Year	Journal	Article
AID1796094	Kinase Inhibition Assay from Article 10.1021/jm011020u: \\First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.\\	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID1796095	PKC Inhibition Assay from Article 10.1021/jm011020u: \\First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.\\	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID1796093	GSK-3 Inhibition Assay from Article 10.1021/jm011020u: \\First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.\\	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID1805801	Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23 ISSN: 1520-4804	Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID720395	Millipore: Percentage of residual kinase activity of TSSK1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720089	Millipore: Percentage of residual kinase activity of CLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720384	Millipore: Percentage of residual kinase activity of MUSK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720201	Millipore: Percentage of residual kinase activity of PRKCH at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720125	Millipore: Percentage of residual kinase activity of EPHA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720432	Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720155	Millipore: Percentage of residual kinase activity of FGFR4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID282725	Inhibition of IRK at 10 uM	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 ISSN: 0022-2623	SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
AID720241	Millipore: Percentage of residual kinase activity of ROCK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720455	Millipore: Percentage of residual kinase activity of MARK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720400	Millipore: Percentage of residual kinase activity of TEK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720352	Millipore: Percentage of residual kinase activity of MINK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720362	Millipore: Percentage of residual kinase activity of CDC42BPA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720107	Millipore: Percentage of residual kinase activity of DAPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720225	Millipore: Percentage of residual kinase activity of PIM2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720046	Millipore: Percentage of residual kinase activity of BTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720167	Millipore: Percentage of residual kinase activity of FLT4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720141	Millipore: Percentage of residual kinase activity of EPHB3 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID282721	Inhibition of rabbit GSK3	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 ISSN: 0022-2623	SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
AID720114	Millipore: Percentage of residual kinase activity of DDR2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720206	Millipore: Percentage of residual kinase activity of PRKD1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1261874	Non-competitive inhibition of human GSK-3beta in presence of ATP	2015	Journal of medicinal chemistry, Nov-25, Volume: 58, Issue:22 ISSN: 1520-4804	Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
AID720026	Millipore: Percentage of residual kinase activity of PRKAA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720310	Millipore: Percentage of residual kinase activity of INSRR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720148	Millipore: Percentage of residual kinase activity of PTK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720224	Millipore: Percentage of residual kinase activity of PIM2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720173	Millipore: Percentage of residual kinase activity of GCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720469	Millipore: Percentage of residual kinase activity of AKT2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720280	Millipore: Percentage of residual kinase activity of PLK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720059	Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720471	Millipore: Percentage of residual kinase activity of AKT3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720112	Millipore: Percentage of residual kinase activity of DCLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720433	Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: PI-103 at 30.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720119	Millipore: Percentage of residual kinase activity of DYRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID282728	Inhibition of protein kinase p56 at 10 uM	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 ISSN: 0022-2623	SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
AID720022	Millipore: Percentage of residual kinase activity of ACVR1B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720325	Millipore: Percentage of residual kinase activity of KDR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720458	Millipore: Percentage of residual kinase activity of PDGFRA at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720086	Millipore: Percentage of residual kinase activity of CSNK2A1 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720355	Millipore: Percentage of residual kinase activity of MAP2K6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720484	Millipore: Percentage of residual kinase activity of PRKCZ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720383	Millipore: Percentage of residual kinase activity of MKNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1872907	Inhibition of GSK-3beta (unknown origin) using GS-1 as substrate incubated for 20 mins	2022	European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254	Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.
AID1818083	Induction of apoptosis in human SH-SY5Y cells assessed as necrotic cells at 10 uM preincubated for 2 hrs followed by coincubation with Abeta42 and measured after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb=0.7%)	2021	European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254	Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease.
AID720281	Millipore: Percentage of residual kinase activity of PLK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512487	Inhibition of CDK1/cyclinB	2004	Trends in pharmacological sciences, Sep, Volume: 25, Issue:9 ISSN: 0165-6147	Pharmacological inhibitors of glycogen synthase kinase 3.
AID720302	Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720422	Millipore: Percentage of residual kinase activity of DAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720445	Millipore: Percentage of residual kinase activity of PAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720176	Millipore: Percentage of residual kinase activity of GRK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720232	Millipore: Percentage of residual kinase activity of PRKX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID55523	Inhibition of Cyclin dependent kinase 1-cyclinB	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID720132	Millipore: Percentage of residual kinase activity of EPHA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720078	Millipore: Percentage of residual kinase activity of CSNK1G1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720138	Millipore: Percentage of residual kinase activity of EPHB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720364	Millipore: Percentage of residual kinase activity of CDC42BPB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720316	Millipore: Percentage of residual kinase activity of JAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720179	Millipore: Percentage of residual kinase activity of GRK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720153	Millipore: Percentage of residual kinase activity of FGFR3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720324	Millipore: Percentage of residual kinase activity of KDR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1872908	Inhibition of CDK-1/cyclin B (unknown origin) using histone H1 as substrate incubated for 20 mins by liquid scintillation counter analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254	Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.
AID720336	Millipore: Percentage of residual kinase activity of LYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720295	Millipore: Percentage of residual kinase activity of TGFBR1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720099	Millipore: Percentage of residual kinase activity of CAMK2G at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720116	Millipore: Percentage of residual kinase activity of DMPK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720288	Millipore: Percentage of residual kinase activity of TAOK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720263	Millipore: Percentage of residual kinase activity of MAPK12 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720294	Millipore: Percentage of residual kinase activity of TGFBR1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720429	Millipore: Percentage of residual kinase activity of SRC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720035	Millipore: Percentage of residual kinase activity of AURKA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720381	Millipore: Percentage of residual kinase activity of MET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720251	Millipore: Percentage of residual kinase activity of RPS6KA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720161	Millipore: Percentage of residual kinase activity of FGR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720081	Millipore: Percentage of residual kinase activity of CSNK1G3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720315	Millipore: Percentage of residual kinase activity of JAK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720124	Millipore: Percentage of residual kinase activity of EPHA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720293	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720450	Millipore: Percentage of residual kinase activity of PAK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720219	Millipore: Percentage of residual kinase activity of FRK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720479	Millipore: Percentage of residual kinase activity of PRKCG at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720196	Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720147	Millipore: Percentage of residual kinase activity of PTK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720072	Millipore: Percentage of residual kinase activity of CDK9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID282723	Inhibition of CAMK2 at 10 uM	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 ISSN: 0022-2623	SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
AID720255	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720115	Millipore: Percentage of residual kinase activity of DMPK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720448	Millipore: Percentage of residual kinase activity of PAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720031	Millipore: Percentage of residual kinase activity of ABL1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720052	Millipore: Percentage of residual kinase activity of BRSK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720200	Millipore: Percentage of residual kinase activity of PRKCH at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720276	Millipore: Percentage of residual kinase activity of SRPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID471624	Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 2.5 ug/disk after 72 hrs at 37 degreeC by disc diffusion method	2009	Journal of natural products, Aug, Volume: 72, Issue:8 ISSN: 1520-6025	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp.
AID720117	Millipore: Percentage of residual kinase activity of STK17A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720380	Millipore: Percentage of residual kinase activity of MET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720098	Millipore: Percentage of residual kinase activity of CAMK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720292	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720348	Millipore: Percentage of residual kinase activity of MAP2K1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720318	Millipore: Percentage of residual kinase activity of MAPK8 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720222	Millipore: Percentage of residual kinase activity of PIM1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720106	Millipore: Percentage of residual kinase activity of CAMK1D at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720093	Millipore: Percentage of residual kinase activity of CSK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720472	Millipore: Percentage of residual kinase activity of PRKCA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720207	Millipore: Percentage of residual kinase activity of PRKD1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720262	Millipore: Percentage of residual kinase activity of MAPK12 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720199	Millipore: Percentage of residual kinase activity of PRKCZ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720387	Millipore: Percentage of residual kinase activity of NEK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720467	Millipore: Percentage of residual kinase activity of AKT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720277	Millipore: Percentage of residual kinase activity of SRPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720273	Millipore: Percentage of residual kinase activity of SIK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720113	Millipore: Percentage of residual kinase activity of DDR2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1459308	Inhibition of recombinant rabbit N-terminal His-tagged GSK3beta expressed in Escherichia coli using GS-1 as substrate after 20 mins in presence of [gamma32P]ATP by liquid scintillation counting method	2017	European journal of medicinal chemistry, Jan-05, Volume: 125ISSN: 1768-3254	Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
AID1484862	Antiproliferative activity against human OVCA433 cells measured after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135ISSN: 1768-3254	The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
AID720328	Millipore: Percentage of residual kinase activity of STK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720174	Millipore: Percentage of residual kinase activity of GCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720370	Millipore: Percentage of residual kinase activity of SRPK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720186	Millipore: Percentage of residual kinase activity of HIPK1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720057	Millipore: Percentage of residual kinase activity of CDK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720440	Millipore: Percentage of residual kinase activity of NEK7 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720480	Millipore: Percentage of residual kinase activity of PRKCD at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720435	Millipore: Percentage of residual kinase activity of MTOR at 10uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720017	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720021	Millipore: Percentage of residual kinase activity of ACVR1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720105	Millipore: Percentage of residual kinase activity of CAMK1D at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720341	Millipore: Percentage of residual kinase activity of MAPK1 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720333	Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720077	Millipore: Percentage of residual kinase activity of CSNK1G1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1814364	Inhibition of recombinant human GSK-3beta using GS-2 peptide as substrate incubated for 30 mins in presence of ATP by kinase-glo luminescence assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11 ISSN: 1520-4804	Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia.
AID1298646	Anifungal activity against Aspergillus nidulans MAD4096 assessed as growth inhibition at 50 uM after 72 hrs by Neubauer chamber analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116ISSN: 1768-3254	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth.
AID720210	Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720274	Millipore: Percentage of residual kinase activity of SRPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720044	Millipore: Percentage of residual kinase activity of PTK6 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720237	Millipore: Percentage of residual kinase activity of RIPK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1818123	Induction of apoptosis in human SH-SY5Y cells assessed as late apoptotic cells at 10 uM preincubated for 2 hrs followed by coincubation with Abeta42 and measured after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb=3.5%)	2021	European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254	Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease.
AID720245	Millipore: Percentage of residual kinase activity of MST1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720066	Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720228	Millipore: Percentage of residual kinase activity of PLK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720363	Millipore: Percentage of residual kinase activity of CDC42BPA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720244	Millipore: Percentage of residual kinase activity of MST1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720417	Millipore: Percentage of residual kinase activity of WNK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720449	Millipore: Percentage of residual kinase activity of PAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720178	Millipore: Percentage of residual kinase activity of GRK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720143	Millipore: Percentage of residual kinase activity of EPHB4 at 1uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID471618	Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 20 ug/disk after 72 hrs at 37 degreeC by disc diffusion method	2009	Journal of natural products, Aug, Volume: 72, Issue:8 ISSN: 1520-6025	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp.
AID720071	Millipore: Percentage of residual kinase activity of CDK9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720102	Millipore: Percentage of residual kinase activity of CAMK2D at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720144	Millipore: Percentage of residual kinase activity of EPHB4 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720358	Millipore: Percentage of residual kinase activity of MYLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720079	Millipore: Percentage of residual kinase activity of CSNK1G2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1822759	Inhibition of wild type Candida albicans Fructose-1,6-Bisphosphate Aldolase transfected in Escherichia coli BL21 (DE3) at 50 uM incubated for 3 mins in presence of NADH by spectrophotometric analysis relative to control	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3 ISSN: 1520-4804	Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID720097	Millipore: Percentage of residual kinase activity of CAMK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1175332	Increase in glucose incorporation in mouse 3T3L1 cells at 2 uM after 12 hrs by glucose assay	2014	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24 ISSN: 1464-3405	Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
AID720282	Millipore: Percentage of residual kinase activity of SYK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720477	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID729990	Inhibition of human recombinant GSK3beta using 650HSSPHQ(pS)EDEEE as substrate after 30 mins by luminescence assay	2013	European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254	Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
AID720133	Millipore: Percentage of residual kinase activity of EPHA7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720182	Millipore: Percentage of residual kinase activity of GSK3A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720190	Millipore: Percentage of residual kinase activity of HIPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720158	Millipore: Percentage of residual kinase activity of FER at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720385	Millipore: Percentage of residual kinase activity of MUSK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720434	Millipore: Percentage of residual kinase activity of MTOR at 1uM relative to control. Control inhibitor: Rapamycin at 10.0uM. Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 0.01% Tween 20, 10 uM FKBP12	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720278	Millipore: Percentage of residual kinase activity of STK33 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720218	Millipore: Percentage of residual kinase activity of FRK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720299	Millipore: Percentage of residual kinase activity of CHUK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720045	Millipore: Percentage of residual kinase activity of BTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720285	Millipore: Percentage of residual kinase activity of MAP3K7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720373	Millipore: Percentage of residual kinase activity of STK4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1818125	Induction of apoptosis in human SH-SY5Y cells assessed as early apoptotic cells at 10 uM preincubated for 2 hrs followed by coincubation with Abeta42 and measured after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb=1%)	2021	European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254	Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease.
AID720354	Millipore: Percentage of residual kinase activity of MAP2K6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4, 1 mg/mL BSA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720329	Millipore: Percentage of residual kinase activity of STK11 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% v/v Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720104	Millipore: Percentage of residual kinase activity of CAMK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1484861	Antiproliferative activity against human A2780 cells measured after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135ISSN: 1768-3254	The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
AID720259	Millipore: Percentage of residual kinase activity of MAPK14 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720029	Millipore: Percentage of residual kinase activity of MAP3K5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720265	Millipore: Percentage of residual kinase activity of MAPK13 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720145	Millipore: Percentage of residual kinase activity of ERBB4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720140	Millipore: Percentage of residual kinase activity of EPHB2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID609926	Cytotoxicity against human hematopoietic stem cells assessed as reduction of cell viability after 24 hrs by Annexin V-Fluorescein isothiocyanate and 7-aminoactinomycin D staining	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16 ISSN: 1464-3405	Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture.
AID720023	Millipore: Percentage of residual kinase activity of PRKAA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720074	Millipore: Percentage of residual kinase activity of CHEK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720386	Millipore: Percentage of residual kinase activity of NEK11 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720091	Millipore: Percentage of residual kinase activity of CLK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720036	Millipore: Percentage of residual kinase activity of AURKA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720410	Millipore: Percentage of residual kinase activity of ULK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720027	Millipore: Percentage of residual kinase activity of NUAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720461	Millipore: Percentage of residual kinase activity of PDGFRB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720226	Millipore: Percentage of residual kinase activity of PIM3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720267	Millipore: Percentage of residual kinase activity of SGK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720398	Millipore: Percentage of residual kinase activity of TEC at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720101	Millipore: Percentage of residual kinase activity of CAMK2D at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720402	Millipore: Percentage of residual kinase activity of NTRK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720129	Millipore: Percentage of residual kinase activity of EPHA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720426	Millipore: Percentage of residual kinase activity of KIT at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720194	Millipore: Percentage of residual kinase activity of HCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720331	Millipore: Percentage of residual kinase activity of STK10 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720257	Millipore: Percentage of residual kinase activity of RPS6KA6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720159	Millipore: Percentage of residual kinase activity of FES at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720388	Millipore: Percentage of residual kinase activity of NEK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720416	Millipore: Percentage of residual kinase activity of WNK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720482	Millipore: Percentage of residual kinase activity of PRKCE at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720041	Millipore: Percentage of residual kinase activity of AXL at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720030	Millipore: Percentage of residual kinase activity of MAP3K5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720326	Millipore: Percentage of residual kinase activity of LIMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720064	Millipore: Percentage of residual kinase activity of CDK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720357	Millipore: Percentage of residual kinase activity of MAP2K7 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID609924	Cytotoxicity against human MV411 cells after 24 hrs by Annexin V-Fluorescein isothiocyanate and 7-aminoactinomycin D staining	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16 ISSN: 1464-3405	Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture.
AID720393	Millipore: Percentage of residual kinase activity of TLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720122	Millipore: Percentage of residual kinase activity of EGFR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720428	Millipore: Percentage of residual kinase activity of SRC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720376	Millipore: Percentage of residual kinase activity of STK24 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720168	Millipore: Percentage of residual kinase activity of FLT4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720468	Millipore: Percentage of residual kinase activity of AKT2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720476	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720464	Millipore: Percentage of residual kinase activity of PRKACA at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720062	Millipore: Percentage of residual kinase activity of CDK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID471620	Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 10 ug/disk after 72 hrs at 24 degreeC by disc diffusion method	2009	Journal of natural products, Aug, Volume: 72, Issue:8 ISSN: 1520-6025	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp.
AID720430	Millipore: Percentage of residual kinase activity of EEF2K at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720418	Millipore: Percentage of residual kinase activity of YES1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720283	Millipore: Percentage of residual kinase activity of SYK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720205	Millipore: Percentage of residual kinase activity of PRKCI at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720223	Millipore: Percentage of residual kinase activity of PIM1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720110	Millipore: Percentage of residual kinase activity of DAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720095	Millipore: Percentage of residual kinase activity of CAMK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720415	Millipore: Percentage of residual kinase activity of WNK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720080	Millipore: Percentage of residual kinase activity of CSNK1G2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720320	Millipore: Percentage of residual kinase activity of MAPK9 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720069	Millipore: Percentage of residual kinase activity of CDK7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720414	Millipore: Percentage of residual kinase activity of WNK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1484860	Inhibition of recombinant N-terminal His6-tagged human GSK3beta H350L mutant expressed in baculovirus infected Sf21 insect cells using polypeptide GS-2 as substrate after 30 mins in presence of ATP by kinase-glo luminescence assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135ISSN: 1768-3254	The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
AID720483	Millipore: Percentage of residual kinase activity of PRKCE at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1298645	Anifungal activity against Aspergillus nidulans MAD4100 deficient in crzA assessed as growth inhibition after 72 hrs by Neubauer chamber analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116ISSN: 1768-3254	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth.
AID1872909	Inhibition of bovine brain CK2 using stathmin as substrate	2022	European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254	Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.
AID720164	Millipore: Percentage of residual kinase activity of FLT1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720335	Millipore: Percentage of residual kinase activity of LCK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720446	Millipore: Percentage of residual kinase activity of PAK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID471621	Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 5 ug/disk after 72 hrs at 24 degreeC by disc diffusion method	2009	Journal of natural products, Aug, Volume: 72, Issue:8 ISSN: 1520-6025	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp.
AID720442	Millipore: Percentage of residual kinase activity of NLK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720211	Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720253	Millipore: Percentage of residual kinase activity of RPS6KA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720478	Millipore: Percentage of residual kinase activity of PRKCG at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720175	Millipore: Percentage of residual kinase activity of GRK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720189	Millipore: Percentage of residual kinase activity of HIPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720447	Millipore: Percentage of residual kinase activity of PAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720049	Millipore: Percentage of residual kinase activity of BMX at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720055	Millipore: Percentage of residual kinase activity of CDK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID74100	Inhibition of Glycogen synthase kinase-3 beta	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID720411	Millipore: Percentage of residual kinase activity of ULK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720403	Millipore: Percentage of residual kinase activity of NTRK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720344	Millipore: Percentage of residual kinase activity of MAPKAPK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720453	Millipore: Percentage of residual kinase activity of PAK6 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720234	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720372	Millipore: Percentage of residual kinase activity of STK4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720401	Millipore: Percentage of residual kinase activity of TEK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720412	Millipore: Percentage of residual kinase activity of VRK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720025	Millipore: Percentage of residual kinase activity of PRKAA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720134	Millipore: Percentage of residual kinase activity of EPHA7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720209	Millipore: Percentage of residual kinase activity of PRKD2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720184	Millipore: Percentage of residual kinase activity of GSK3B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720405	Millipore: Percentage of residual kinase activity of NTRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720019	Millipore: Percentage of residual kinase activity of ALK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720309	Millipore: Percentage of residual kinase activity of IRAK4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID282727	Inhibition of MEK1K at 10 uM	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 ISSN: 0022-2623	SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
AID720303	Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720438	Millipore: Percentage of residual kinase activity of NEK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720290	Millipore: Percentage of residual kinase activity of TAOK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID718829	Inhibition of GSK3beta by kinase-glo assay method	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 ISSN: 1464-3405	Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
AID720103	Millipore: Percentage of residual kinase activity of CAMK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 40 mM HEPES pH 7.4, 5 mM CaCl2, 30 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720171	Millipore: Percentage of residual kinase activity of FYN at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720118	Millipore: Percentage of residual kinase activity of STK17A at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720172	Millipore: Percentage of residual kinase activity of FYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720135	Millipore: Percentage of residual kinase activity of EPHA8 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720366	Millipore: Percentage of residual kinase activity of RPS6KA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1356765	Inhibition of GSK3beta (unknown origin) using GS-2 peptide substrate incubated for 30 mins by kinase-Glo luminescent assay	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17 ISSN: 1520-4804	Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors.
AID720359	Millipore: Percentage of residual kinase activity of MYLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720185	Millipore: Percentage of residual kinase activity of HIPK1 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID609925	Cytotoxicity against human MV411 cells assessed as reduction of cell viability at 20 uM after 2 hrs by Annexin V-Fluorescein isothiocyanate and 7-aminoactinomycin D staining	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16 ISSN: 1464-3405	Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture.
AID720108	Millipore: Percentage of residual kinase activity of DAPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720137	Millipore: Percentage of residual kinase activity of EPHB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1261860	Inhibition of amphetamine-induced hypermotility in C57BL/6J mouse at 3 to 30 mg/kg, ip measured for 90 mins	2015	Journal of medicinal chemistry, Nov-25, Volume: 58, Issue:22 ISSN: 1520-4804	Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
AID720236	Millipore: Percentage of residual kinase activity of RIPK2 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720050	Millipore: Percentage of residual kinase activity of BMX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720481	Millipore: Percentage of residual kinase activity of PRKCD at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720096	Millipore: Percentage of residual kinase activity of CAMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720375	Millipore: Percentage of residual kinase activity of STK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720154	Millipore: Percentage of residual kinase activity of FGFR3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512486	Inhibition of GSK3alpha/beta	2004	Trends in pharmacological sciences, Sep, Volume: 25, Issue:9 ISSN: 0165-6147	Pharmacological inhibitors of glycogen synthase kinase 3.
AID720195	Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720215	Millipore: Percentage of residual kinase activity of MAPKAPK5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720136	Millipore: Percentage of residual kinase activity of EPHA8 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720242	Millipore: Percentage of residual kinase activity of RET at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1872910	Inhibition of bovine heart PKA using stathmin as substrate incubated for 20 mins by liquid scintillation counter analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254	Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.
AID720327	Millipore: Percentage of residual kinase activity of LIMK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720151	Millipore: Percentage of residual kinase activity of FGFR2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720076	Millipore: Percentage of residual kinase activity of CHEK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720243	Millipore: Percentage of residual kinase activity of RET at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720307	Millipore: Percentage of residual kinase activity of IRAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID164469	Inhibition of catalytic subunit of protein kinase A (PKA) from bovine heart	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID1727768	Inhibition of GSK3beta (unknown origin)	2021	European journal of medicinal chemistry, Jan-15, Volume: 210ISSN: 1768-3254	PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases.
AID720188	Millipore: Percentage of residual kinase activity of HIPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720421	Millipore: Percentage of residual kinase activity of ZAP70 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1298653	Anifungal activity against Aspergillus fumigatus AF293 assessed as growth inhibition at 50 uM after 48 to 72 hrs by Neubauer chamber analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116ISSN: 1768-3254	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth.
AID720233	Millipore: Percentage of residual kinase activity of PRKX at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720092	Millipore: Percentage of residual kinase activity of CLK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720343	Millipore: Percentage of residual kinase activity of MAPKAPK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720256	Millipore: Percentage of residual kinase activity of RPS6KA6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720463	Millipore: Percentage of residual kinase activity of PDPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720332	Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720377	Millipore: Percentage of residual kinase activity of STK24 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720275	Millipore: Percentage of residual kinase activity of SRPK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720048	Millipore: Percentage of residual kinase activity of BLK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720353	Millipore: Percentage of residual kinase activity of MINK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720068	Millipore: Percentage of residual kinase activity of CDK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720128	Millipore: Percentage of residual kinase activity of EPHA3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720462	Millipore: Percentage of residual kinase activity of PDPK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720033	Millipore: Percentage of residual kinase activity of ABL2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720419	Millipore: Percentage of residual kinase activity of YES1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720420	Millipore: Percentage of residual kinase activity of ZAP70 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720054	Millipore: Percentage of residual kinase activity of BRSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720346	Millipore: Percentage of residual kinase activity of MARK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720032	Millipore: Percentage of residual kinase activity of ABL1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720261	Millipore: Percentage of residual kinase activity of MAPK11 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720127	Millipore: Percentage of residual kinase activity of EPHA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720459	Millipore: Percentage of residual kinase activity of PDGFRA at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720361	Millipore: Percentage of residual kinase activity of MAP3K9 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720047	Millipore: Percentage of residual kinase activity of BLK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720427	Millipore: Percentage of residual kinase activity of KIT at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720314	Millipore: Percentage of residual kinase activity of JAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720351	Millipore: Percentage of residual kinase activity of MELK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID471619	Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 10 ug/disk after 72 hrs at 37 degreeC by disc diffusion method	2009	Journal of natural products, Aug, Volume: 72, Issue:8 ISSN: 1520-6025	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp.
AID720330	Millipore: Percentage of residual kinase activity of STK10 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720126	Millipore: Percentage of residual kinase activity of EPHA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720020	Millipore: Percentage of residual kinase activity of ALK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720404	Millipore: Percentage of residual kinase activity of NTRK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720150	Millipore: Percentage of residual kinase activity of FGFR1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720369	Millipore: Percentage of residual kinase activity of RPS6KA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720034	Millipore: Percentage of residual kinase activity of ABL2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720056	Millipore: Percentage of residual kinase activity of CDK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720239	Millipore: Percentage of residual kinase activity of ROCK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID471623	Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 2.5 ug/disk after 72 hrs at 24 degreeC by disc diffusion method	2009	Journal of natural products, Aug, Volume: 72, Issue:8 ISSN: 1520-6025	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp.
AID74102	Specific activity against Glycogen synthase kinase-3 beta	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID720085	Millipore: Percentage of residual kinase activity of CSNK2A1 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720227	Millipore: Percentage of residual kinase activity of PIM3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720024	Millipore: Percentage of residual kinase activity of PRKAA1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 uM AMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720088	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720424	Millipore: Percentage of residual kinase activity of RAF1 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720160	Millipore: Percentage of residual kinase activity of FES at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720339	Millipore: Percentage of residual kinase activity of MAPK3 at 10uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720297	Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720389	Millipore: Percentage of residual kinase activity of NEK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720443	Millipore: Percentage of residual kinase activity of NLK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720084	Millipore: Percentage of residual kinase activity of CSNK1D at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720193	Millipore: Percentage of residual kinase activity of HCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID512484	Inhibition of GSK3-beta	2004	Trends in pharmacological sciences, Sep, Volume: 25, Issue:9 ISSN: 0165-6147	Pharmacological inhibitors of glycogen synthase kinase 3.
AID720371	Millipore: Percentage of residual kinase activity of SRPK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720217	Millipore: Percentage of residual kinase activity of PKN2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720271	Millipore: Percentage of residual kinase activity of SGK3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720037	Millipore: Percentage of residual kinase activity of AURKB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720109	Millipore: Percentage of residual kinase activity of DAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720441	Millipore: Percentage of residual kinase activity of NEK7 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720130	Millipore: Percentage of residual kinase activity of EPHA4 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720229	Millipore: Percentage of residual kinase activity of PLK1 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720390	Millipore: Percentage of residual kinase activity of NEK3 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720165	Millipore: Percentage of residual kinase activity of FLT3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720204	Millipore: Percentage of residual kinase activity of PRKCI at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720100	Millipore: Percentage of residual kinase activity of CAMK2G at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.5 mM CaCl2, 16 ug/mL calmodulin	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1730925	Neuroprotective activity against OA-induced neuronal injury in human SH-SY5Y cells assessed as reduction in cell death at 0.1 to 10 uM pre-incubated for 1 hrs followed by OA addition measured after 24 hrs by MTT assay	2021	Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3 ISSN: 1520-4804	Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3β.
AID1872911	Inhibition of rat brain PKC using peptide PANKTPPKSPGEPAK as substrate incubated for 20 mins in presence of phosphatidyl serine	2022	European journal of medicinal chemistry, Jun-05, Volume: 236ISSN: 1768-3254	Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.
AID720268	Millipore: Percentage of residual kinase activity of SGK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720252	Millipore: Percentage of residual kinase activity of RPS6KA3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720247	Millipore: Percentage of residual kinase activity of ROS1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720337	Millipore: Percentage of residual kinase activity of LYN at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720067	Millipore: Percentage of residual kinase activity of CDK6 at 1uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720214	Millipore: Percentage of residual kinase activity of MAPKAPK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720338	Millipore: Percentage of residual kinase activity of MAPK3 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID164471	Specific activity against Protein kinase A (PKA) from bovine heart	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID720394	Millipore: Percentage of residual kinase activity of TSSK1B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720360	Millipore: Percentage of residual kinase activity of MAP3K9 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720368	Millipore: Percentage of residual kinase activity of RPS6KA4 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720431	Millipore: Percentage of residual kinase activity of EEF2K at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720258	Millipore: Percentage of residual kinase activity of MAPK14 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720260	Millipore: Percentage of residual kinase activity of MAPK11 at 1uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720139	Millipore: Percentage of residual kinase activity of EPHB2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720208	Millipore: Percentage of residual kinase activity of PRKD2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720203	Millipore: Percentage of residual kinase activity of PRKCQ at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720334	Millipore: Percentage of residual kinase activity of LCK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID282724	Inhibition of EGF tyrosine kinase at 10 uM	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 ISSN: 0022-2623	SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
AID720444	Millipore: Percentage of residual kinase activity of PAK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720308	Millipore: Percentage of residual kinase activity of IRAK4 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720040	Millipore: Percentage of residual kinase activity of AURKC at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720235	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720291	Millipore: Percentage of residual kinase activity of TAOK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 200 mM NaCl, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720246	Millipore: Percentage of residual kinase activity of ROS1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720396	Millipore: Percentage of residual kinase activity of TSSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720474	Millipore: Percentage of residual kinase activity of PRKCB at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID55524	Specific activity against Cyclin dependent kinase 1-cyclin B	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID720296	Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720053	Millipore: Percentage of residual kinase activity of BRSK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720082	Millipore: Percentage of residual kinase activity of CSNK1G3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720313	Millipore: Percentage of residual kinase activity of ITK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720317	Millipore: Percentage of residual kinase activity of JAK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID282722	Inhibition of Abl kinase at 10 uM	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 ISSN: 0022-2623	SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
AID720183	Millipore: Percentage of residual kinase activity of GSK3B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720043	Millipore: Percentage of residual kinase activity of PTK6 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720342	Millipore: Percentage of residual kinase activity of MAPKAPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720162	Millipore: Percentage of residual kinase activity of FGR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1818124	Induction of apoptosis in human SH-SY5Y cells assessed as live cells at 10 uM preincubated for 2 hrs followed by coincubation with Abeta42 and measured after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb=94.8%)	2021	European journal of medicinal chemistry, Dec-15, Volume: 226ISSN: 1768-3254	Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease.
AID720356	Millipore: Percentage of residual kinase activity of MAP2K7 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol, 0.1 mM Na3VO4	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID49337	Specific activity against Casein kinase II (CK II)	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID720451	Millipore: Percentage of residual kinase activity of PAK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720456	Millipore: Percentage of residual kinase activity of PASK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720379	Millipore: Percentage of residual kinase activity of MERTK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720149	Millipore: Percentage of residual kinase activity of FGFR1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720304	Millipore: Percentage of residual kinase activity of INSR at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720198	Millipore: Percentage of residual kinase activity of IGF1R at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720166	Millipore: Percentage of residual kinase activity of FLT3 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720312	Millipore: Percentage of residual kinase activity of ITK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1692494	Inhibition of SARS-CoV2 3C-like protease expressed in Escherichia coli BL21 (DE3) cells using Mca-AVLQSGFR-K(Dnp)K as substrate by fluorescence method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21 ISSN: 1520-4804	COVID-19: Drug Targets and Potential Treatments.
AID720475	Millipore: Percentage of residual kinase activity of PRKCB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720111	Millipore: Percentage of residual kinase activity of DCLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720266	Millipore: Percentage of residual kinase activity of SGK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720121	Millipore: Percentage of residual kinase activity of EGFR at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720350	Millipore: Percentage of residual kinase activity of MELK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720269	Millipore: Percentage of residual kinase activity of SGK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720220	Millipore: Percentage of residual kinase activity of PHKG2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720365	Millipore: Percentage of residual kinase activity of CDC42BPB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720070	Millipore: Percentage of residual kinase activity of CDK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720083	Millipore: Percentage of residual kinase activity of CSNK1D at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720436	Millipore: Percentage of residual kinase activity of RPS6KB1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720039	Millipore: Percentage of residual kinase activity of AURKC at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720213	Millipore: Percentage of residual kinase activity of PRKG1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720473	Millipore: Percentage of residual kinase activity of PRKCA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 20 mM HEPES pH 7.4, 0.03% Triton X-100, 0.1 mM CaCl2, 0.1 mg/mL phosphatidylserine, 10 ug/mL diacylglycerol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720460	Millipore: Percentage of residual kinase activity of PDGFRB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720065	Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1298652	Anifungal activity against Aspergillus fumigatus CM237 assessed as growth inhibition at 50 uM after 48 to 72 hrs by Neubauer chamber analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116ISSN: 1768-3254	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth.
AID720152	Millipore: Percentage of residual kinase activity of FGFR2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720264	Millipore: Percentage of residual kinase activity of MAPK13 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720180	Millipore: Percentage of residual kinase activity of GRK7 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720311	Millipore: Percentage of residual kinase activity of INSRR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720142	Millipore: Percentage of residual kinase activity of EPHB3 at 10uM relative to control. Control inhibitor: PP2 at 30.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1298654	Anifungal activity against Aspergillus fumigatus CBS144 assessed as growth inhibition at 50 uM after 48 to 72 hrs by Neubauer chamber analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116ISSN: 1768-3254	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth.
AID720345	Millipore: Percentage of residual kinase activity of MAPKAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Na-?-glycerophosphate pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720374	Millipore: Percentage of residual kinase activity of STK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720191	Millipore: Percentage of residual kinase activity of GSG2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720347	Millipore: Percentage of residual kinase activity of MARK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1261877	Toxicity in C57BL/6J mouse amphetamine-induced hypermotility model assessed as reduction of spontaneous locomotor activity at 30 mg/kg, ip	2015	Journal of medicinal chemistry, Nov-25, Volume: 58, Issue:22 ISSN: 1520-4804	Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
AID720367	Millipore: Percentage of residual kinase activity of RPS6KA5 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720439	Millipore: Percentage of residual kinase activity of NEK6 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720279	Millipore: Percentage of residual kinase activity of STK33 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1175336	Inhibition of GSK3beta in human HepG2 cells assessed as decrease in ratio of phosphorylated GS/GS at 2 uM after 12 hrs by Western blot analysis	2014	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24 ISSN: 1464-3405	Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
AID720407	Millipore: Percentage of residual kinase activity of TXK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720399	Millipore: Percentage of residual kinase activity of TEC at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720157	Millipore: Percentage of residual kinase activity of FER at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720087	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1175329	Increase in glucose incorporation in human HepG2 cells at 2 uM after 12 hrs by glucose assay	2014	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24 ISSN: 1464-3405	Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
AID720340	Millipore: Percentage of residual kinase activity of MAPK1 at 1uM relative to control. Control inhibitor: ERK Inhibitor II at 30.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720061	Millipore: Percentage of residual kinase activity of CDK3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720238	Millipore: Percentage of residual kinase activity of ROCK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720465	Millipore: Percentage of residual kinase activity of PRKACA at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720425	Millipore: Percentage of residual kinase activity of RAF1 at 10uM relative to control. Control inhibitor: SB203580 at 100.0uM. Buffer: 25 mM Tris pH 7.5, 0.02 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720073	Millipore: Percentage of residual kinase activity of CHEK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720286	Millipore: Percentage of residual kinase activity of TAOK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720202	Millipore: Percentage of residual kinase activity of PRKCQ at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720300	Millipore: Percentage of residual kinase activity of IKBKB at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720216	Millipore: Percentage of residual kinase activity of PKN2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720321	Millipore: Percentage of residual kinase activity of MAPK9 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720470	Millipore: Percentage of residual kinase activity of AKT3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720319	Millipore: Percentage of residual kinase activity of MAPK8 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ? -mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720058	Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1298647	Anifungal activity against Aspergillus nidulans MAD4097 deficient in sltA assessed as reduction in colonial diameter at 10 uM after 72 hrs by Neubauer chamber analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116ISSN: 1768-3254	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth.
AID720212	Millipore: Percentage of residual kinase activity of PRKG1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 uM cGMP	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720250	Millipore: Percentage of residual kinase activity of RPS6KA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720378	Millipore: Percentage of residual kinase activity of MERTK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: mM MOPS pH 7.0, 0.2 mM EDTA, 30 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720289	Millipore: Percentage of residual kinase activity of TAOK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720075	Millipore: Percentage of residual kinase activity of CHEK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720230	Millipore: Percentage of residual kinase activity of PLK3 at 1uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720042	Millipore: Percentage of residual kinase activity of AXL at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720231	Millipore: Percentage of residual kinase activity of PLK3 at 10uM relative to control. Control inhibitor: Wortmannin at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID471622	Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 5 ug/disk after 72 hrs at 37 degreeC by disc diffusion method	2009	Journal of natural products, Aug, Volume: 72, Issue:8 ISSN: 1520-6025	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp.
AID720270	Millipore: Percentage of residual kinase activity of SGK3 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720146	Millipore: Percentage of residual kinase activity of ERBB4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720156	Millipore: Percentage of residual kinase activity of FGFR4 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720028	Millipore: Percentage of residual kinase activity of NUAK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720423	Millipore: Percentage of residual kinase activity of DAPK3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720120	Millipore: Percentage of residual kinase activity of DYRK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720454	Millipore: Percentage of residual kinase activity of MARK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720090	Millipore: Percentage of residual kinase activity of CLK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720391	Millipore: Percentage of residual kinase activity of NEK3 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720051	Millipore: Percentage of residual kinase activity of BRSK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720305	Millipore: Percentage of residual kinase activity of INSR at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM Na3VO4, 5 mM Na-?-glycerophosphate	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720466	Millipore: Percentage of residual kinase activity of AKT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720408	Millipore: Percentage of residual kinase activity of ULK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720254	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720018	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720284	Millipore: Percentage of residual kinase activity of MAP3K7 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1298644	Inhibition of human recombinant GSK3beta expressed in Escherichia coli using GS-1 as substrate incubated for 20 mins by gamma[32P]ATP-based scintillation counting analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116ISSN: 1768-3254	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth.
AID720060	Millipore: Percentage of residual kinase activity of CDK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720249	Millipore: Percentage of residual kinase activity of TYRO3 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720123	Millipore: Percentage of residual kinase activity of EPHA1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720437	Millipore: Percentage of residual kinase activity of RPS6KB1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720163	Millipore: Percentage of residual kinase activity of FLT1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720322	Millipore: Percentage of residual kinase activity of MAPK10 at 1uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID73980	Inhibitory activity against recombinant rabbit Glycogen synthase kinase-3 beta	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID720409	Millipore: Percentage of residual kinase activity of ULK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720287	Millipore: Percentage of residual kinase activity of TAOK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720094	Millipore: Percentage of residual kinase activity of CSK at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol, 10 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720298	Millipore: Percentage of residual kinase activity of CHUK at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720272	Millipore: Percentage of residual kinase activity of SIK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720187	Millipore: Percentage of residual kinase activity of HIPK2 at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720131	Millipore: Percentage of residual kinase activity of EPHA5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2.5 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720413	Millipore: Percentage of residual kinase activity of VRK2 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720038	Millipore: Percentage of residual kinase activity of AURKB at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 mM NaCl, 0.1% v/v Triton-X-100	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720197	Millipore: Percentage of residual kinase activity of IGF1R at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720240	Millipore: Percentage of residual kinase activity of ROCK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720452	Millipore: Percentage of residual kinase activity of PAK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720177	Millipore: Percentage of residual kinase activity of GRK6 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720181	Millipore: Percentage of residual kinase activity of GSK3A at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID282726	Inhibition of MAPK at 10 uM	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 ISSN: 0022-2623	SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
AID720392	Millipore: Percentage of residual kinase activity of TLK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720248	Millipore: Percentage of residual kinase activity of TYRO3 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA, 1 mM MnCl2	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720301	Millipore: Percentage of residual kinase activity of IKBKB at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720323	Millipore: Percentage of residual kinase activity of MAPK10 at 10uM relative to control. Control inhibitor: JAK Inhibitor I at 30.0uM. Buffer: 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1% ?-mercaptoethanol	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720349	Millipore: Percentage of residual kinase activity of MAP2K1 at 10uM relative to control. Control inhibitor: Phosphoric acid* at 0.3uM. Buffer: 50 mM Tris pH 7.5, 0.2 mM EGTA, 0.1% ?-mercaptoethanol, 0.01% Brij-35	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID471617	Inhibition of GSK3-beta expressed in H10075 yeast assessed as growth inhibition at 20 ug/disk after 72 hrs at 25 degreeC by disc diffusion method	2009	Journal of natural products, Aug, Volume: 72, Issue:8 ISSN: 1520-6025	Yeast glycogen synthase kinase-3beta pathway inhibitors from an organic extract of Streptomyces sp.
AID49336	Inhibition of Casein kinase II (CK II) from purified bovine brain	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6 ISSN: 0022-2623	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
AID720063	Millipore: Percentage of residual kinase activity of CDK5 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720170	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720457	Millipore: Percentage of residual kinase activity of PASK at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720382	Millipore: Percentage of residual kinase activity of MKNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720397	Millipore: Percentage of residual kinase activity of TSSK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720169	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720306	Millipore: Percentage of residual kinase activity of IRAK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720406	Millipore: Percentage of residual kinase activity of TXK at 1uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720221	Millipore: Percentage of residual kinase activity of PHKG2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID720192	Millipore: Percentage of residual kinase activity of GSG2 at 10uM relative to control. Control inhibitor: Staurosporine at 100.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	2013	The Biochemical journal, Apr-15, Volume: 451, Issue:2 ISSN: 1470-8728	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
AID1345633	Human glycogen synthase kinase 3 beta (GSK subfamily)	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 ISSN: 1464-3405	Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.

Research

Studies (123)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (27.64)	29.6817
2010's	69 (56.10)	24.3611
2020's	20 (16.26)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (0.79%)	5.53%
Reviews	5 (3.97%)	6.00%
Case Studies	1 (0.79%)	4.05%
Observational	1 (0.79%)	0.25%
Other	118 (93.65%)	84.16%

Substance	Classes	Roles	Relationship Strength
np 031112	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	low
3-phenylpropionic acid	benzenes; monocarboxylic acid	antifungal agent; human metabolite; plant metabolite	low
benzene	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent	low
phenylacetic acid	benzenes; monocarboxylic acid; phenylacetic acids	allergen; Aspergillus metabolite; auxin; EC 6.4.1.1 (pyruvate carboxylase) inhibitor; Escherichia coli metabolite; human metabolite; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite; toxin	low
gallopamil	benzenes; organic amino compound		low
mandelic acid	2-hydroxy monocarboxylic acid; benzenes	antibacterial agent; human xenobiotic metabolite	low
4-phenyl-3-furoxancarbonitrile	1,2,5-oxadiazole; benzenes; N-oxide; nitrile	geroprotector; nitric oxide donor; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent	low
bencyclane	benzenes		low
benzamidine	benzenes; carboxamidine	serine protease inhibitor	low
benzyl isothiocyanate	benzenes; isothiocyanate	antibacterial drug	low
benzylhydrochlorothiazide	benzenes; benzothiadiazine; organochlorine compound; secondary amino compound; sulfonamide		low
carbetapentane	benzenes		low
carbidopa	benzenes; monocarboxylic acid		low
cetraxate	benzenes; monocarboxylic acid		low
chlorpropham	benzenes; carbamate ester; monochlorobenzenes	herbicide; plant growth retardant	low
cimaterol	benzenes; nitrile		low
clofilium	benzenes; organic amino compound		low
diphenidol	benzenes; piperidines; tertiary alcohol	antiemetic	low
cycloadiphenine	benzenes		low
fenipentol	benzenes		low
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester	benzenes		low
lidocaine	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic	low
isocarboxazid	benzenes		low
labetalol	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound		low
methadone	benzenes; diarylmethane; ketone; tertiary amino compound		low
3-Hydroxy-alpha-methyl-DL-tyrosine	benzenes; monocarboxylic acid		low
metolachlor	aromatic amide; benzenes; ether; organochlorine compound		low
nafoxidine	benzenes; naphthalenes; ring assembly		low
nicardipine	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound		low
phenprobamate	benzenes		low
sulfabenzamide	benzenes; sulfonamide antibiotic; sulfonamide	antibacterial drug; antimicrobial drug	low
sulfacytine	benzenes; sulfonamide		low
sulfamonomethoxine	benzenes; sulfonamide		low
sulfaquinoxaline	benzenes; sulfonamide		low
2-phenylcyclopropan-1-amine	benzenes; cyclopropanes; primary amine		low
tyropanoate	benzenes; monocarboxylic acid		low
tolazoline hydrochloride	benzenes		low
phenylethyl alcohol	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite	low
mebanazine	benzenes		low
phencyclidine	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug	low
caramiphen	benzenes		low
acetyl sulfisoxazole	benzenes; sulfonamide		low
2-phenylbutyric acid	benzenes; monocarboxylic acid	human xenobiotic metabolite	low
diphenyl	aromatic fungicide; benzenes; biphenyls	antifungal agrochemical; antimicrobial food preservative	low
styrene glycol	benzenes		low
sulfaethidole	benzenes; sulfonamide		low
iophenoxic acid	benzenes; monocarboxylic acid		low
benzotrichloride	benzenes; organochlorine compound; volatile organic compound	carcinogenic agent	low
benzal chloride	benzenes		low
benzoyl chloride	acyl chloride; benzenes	carcinogenic agent	low
benzonitrile	benzenes; nitrile		low
methylphenylsulfide	aryl sulfide; benzenes		low
methyl phenylacetate	benzenes		low
ethyl phenylacetate	benzenes		low
phenyl isocyanate	benzenes; isocyanates	allergen; hapten	low
3-phenylpropanal	aldehyde; benzenes	flavouring agent; plant metabolite	low
1,4-diethylbenzene	benzenes		low
benzyl cyanide	benzenes; nitrile	animal metabolite; pheromone	low
pivalylbenzhydrazine	benzenes		low
mexacarbate	benzenes		low
carbutamide	benzenes; sulfonamide		low
methaphenilene	benzenes		low
biphenylacetylene	arylacetylene; benzenes	fluorochrome	low
beclamide	benzenes		low
mepiperphenidol	benzenes; organic amino compound		low
glybuthiazol	benzenes; sulfonamide		low
phenylacetylene	benzenes		low
sulfanilylurea	benzenes; sulfonamide		low
metahexamide	benzenes; sulfonamide		low
nitrosobenzene	benzenes; nitroso compound	xenobiotic metabolite	low
triphenylphosphine	benzenes; tertiary phosphine	NMR chemical shift reference compound; reducing agent	low
2-cyanophenol	benzenes; nitrile		low
bensulide	benzenes		low
1-phenylcyclohex-1-ene	benzenes		low
diphenyl disulfide	benzenes		low
2-phenylpropanol	benzenes		low
methyl phenyl sulfoxide	benzenes; sulfoxide		low
2,6-dimethoxybenzoic acid	benzenes; carbonyl compound		low
phenylphosphonic acid	benzenes		low
pyrazon	benzenes; organochlorine compound; primary amino compound; pyridazinone	environmental contaminant; herbicide; xenobiotic	low
3-phenylpropylamine	benzenes; phenylalkylamine; primary amino compound		low
aminorex	benzenes		low
5-phenylvaleric acid	benzenes; monocarboxylic acid		low
bitoscanate	benzenes		low
3-phenylbutyric acid	benzenes; monocarboxylic acid	antibacterial agent; bacterial xenobiotic metabolite	low
teclozan	benzenes		low
dioxacarb	benzenes		low
fenestrel	benzenes		low
propham	benzenes; carbamate ester	herbicide; plant growth retardant	low
cyanophenphos	benzenes; nitrile		low
N'-methyl-N,N-diphenylurea	benzenes		low
dibenzo-18-crown-6	benzenes; crown ether	phase-transfer catalyst	low
clobutinol	benzenes; organic amino compound		low
phenyl acetate	benzenes; phenyl acetates		low
ripazepam	benzenes		low
u 40481	benzenes; formamidines	marine xenobiotic metabolite	low
iprodione	benzenes; dichlorophenyl dicarboximide fungicide; imidazole fungicide; imidazolidine-2,4-dione; ureas	antifungal agrochemical; nematicide	low
clorsulon	benzenes; sulfonamide		low
ibutilide	benzenes; organic amino compound		low
prosulfocarb	benzenes; monothiocarbamic ester	environmental contaminant; herbicide; xenobiotic	low
Isopropyl phenylacetate	benzenes		low
4-methyl-1-phenylpentan-2-ol	benzenes		low
magnesium salicylate	benzenes; carbonyl compound		low
plerixafor	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant	low
tribuzone	benzenes		low
phenylpropiolic acid	acetylenic compound; alpha,beta-unsaturated monocarboxylic acid; benzenes		low
2-Oxo-4-phenylbutyric acid	benzenes		low
emopamil	benzenes; organic amino compound		low
bathophenanthroline	benzenes; phenanthrolines	chelator	low
2-aminobenzenesulfonamide	benzenes; sulfonamide		low
3-phenylpropyl isothiocyanate	benzenes		low
4-chloro-5-sulfamoylanthranilic acid	benzenes; sulfonamide		low
phenylheptatriyne	benzenes		low
methyl mandelate	benzenes		low
benzylphosphonic acid	benzenes		low
9,10-bis(phenylethynyl)anthracene	anthracenes; arylacetylene; benzenes	fluorochrome	low
4-phenylbutylamine	benzenes; phenylalkylamine; primary amino compound		low
3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid	benzenes; monocarboxylic acid		low
sdds	benzenes; sulfonamide		low
1-hydroxy-1-phenyl-2-propanone	benzenes; methyl ketone; secondary alpha-hydroxy ketone		low
silomat	benzenes; organic amino compound		low
phenylisopropyladenosine	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent	low
alpha-Cyclohexylmandelic acid	benzenes		low
1-amino-1-phenylmethyl phosphonic acid	benzenes; phosphonic acids; primary amino compound		low
alpha-methylphenylalanine	benzenes; monocarboxylic acid		low
piscidic acid	benzenes; monocarboxylic acid		low
mitiglinide	benzenes; monocarboxylic acid		low
n-(4-(7-diethylamino-4-methylcoumarin-3-yl)phenyl)maleimide	benzenes; coumarins; maleimides; tertiary amino compound	fluorescent dye	low
4-phenylbutyl isothiocyanate	benzenes; organic amino compound		low
n-acetylphenelzine	benzenes		low
forasartan	benzenes; pyridines; tetrazoles; triazoles	angiotensin receptor antagonist; antihypertensive agent	low
desethyloxybutynin	benzenes		low
varespladib	aromatic ether; benzenes; dicarboxylic acid monoamide; indoles; monocarboxylic acid; primary carboxamide	anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor	low
3,5-dihydroxyphenylpropionic acid	benzenes; monocarboxylic acid		low
fukiic acid	benzenes; monocarboxylic acid		low
monodesmethylcitalopram	benzenes; organic amino compound		low
cyclodrine	benzenes		low
didesmethylcitalopram	benzenes; organic amino compound		low
carlina oxide	benzenes		low
4-butyl-4-(hydroxymethyl)-1,2-diphenylpyrazolidine-3,5-dione	benzenes		low
2-[(3-oxo-1-cyclohexenyl)amino]benzonitrile	benzenes; nitrile		low
benzyl d-glucopyranoside	benzenes; beta-D-glucoside	plant metabolite	low
cafenstrole	benzenes; sulfone; triazoles	agrochemical; antimitotic; herbicide	low
(5-Phenyl-1,2,4-triazol-3-yl)urea	benzenes		low
pifithrin mu	benzenes		low
2-(2-phenylethyl)chromone	benzenes; chromones	plant metabolite	low
bms 214662	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	low
N-bis(N-methylanilino)phosphoryl-N-methylaniline	benzenes		low
3-[di(propan-2-yl)phosphorylmethyl]benzonitrile	benzenes; nitrile		low
4,5-diphenyl-1,2,3-triazole	benzenes; ring assembly; triazoles		low
N-benzylquinazolin-4-amine	benzenes; quinazolines; secondary amino compound		low
2-acetyl-6-amino-8-(2-phenylethyl)-1,3,8,8a-tetrahydroisoquinoline-5,7,7-tricarbonitrile	benzenes		low
thiobenzamide	benzenes		low
4-(benzylsulfanyl)thieno[2,3-d]pyrimidine	aryl sulfide; benzenes; thienopyrimidine		low
4-[(4-chloro-5-dithiazolylidene)amino]benzonitrile	benzenes; nitrile		low
N-methyl-N-phenylthiourea	benzenes		low
3,6-dibenzyl-1,2-dihydro-1,2,4,5-tetraazine	benzenes		low
1-cyclohexyl-3-(2-phenylethyl)urea	benzenes		low
5-ethyl-1-(phenylmethyl)-1,3,5-triazinane-2-thione	benzenes		low
4-amino-N-(4-ethoxyphenyl)benzenesulfonamide	benzenes; sulfonamide		low
N-[5-(phenylmethyl)-1,3,4-thiadiazol-2-yl]carbamic acid methyl ester	benzenes		low
1,3-bis(2-phenylethyl)thiourea	benzenes		low
8-methyl-2-phenyl-1,2,4-triazaspiro[4.5]decane-3-thione	benzenes		low
3-(4-ethyl-5-methyl-3-thiophenyl)-4-(phenylmethyl)-1H-1,2,4-triazole-5-thione	benzenes		low
4-(phenylmethyl)-3-(5-propyl-3-thiophenyl)-1H-1,2,4-triazole-5-thione	benzenes		low
6-(2-phenylethyl)-3-(phenylmethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole	benzenes; triazolothiadiazole		low
4-(2-furanylmethyl)-3-(phenylmethyl)-1H-1,2,4-triazole-5-thione	benzenes		low
4-(1H-imidazol-1-ylmethyl)benzonitrile	benzenes; nitrile		low
N-(3-cyano-5-methyl-4-phenyl-2-thiophenyl)-3,5-dimethyl-4-isoxazolecarboxamide	benzenes		low
1-amino-3-[3-(2-sulfanylidene-3H-1,3,4-oxadiazol-5-yl)phenyl]thiourea	benzenes		low
N-(3-phenylpropyl)methanesulfonamide	benzenes		low
1-ethyl-3-[[[(phenylmethyl)amino]-sulfanylidenemethyl]amino]thiourea	benzenes		low
N-[[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)amino]-sulfanylidenemethyl]-5-methyl-3-phenyl-4-isoxazolecarboxamide	benzenes		low
amn082	benzenes; diamine; diarylmethane; secondary amino compound	metabotropic glutamate receptor agonist; neuroprotective agent	low
2-(2-furanyl)-3,5-dimethyl-4-oxido-6-phenylpyrazin-1-ium 1-oxide	benzenes		low
N-(3,4-dihydro-2H-pyrrol-5-yl)-5-phenyl-1,3,4-oxadiazol-2-amine	benzenes		low
4-butyl-3-(phenylmethyl)-1H-1,2,4-triazole-5-thione	benzenes		low
N1-phenethylhydrazine-1-carbothioamide	benzenes		low
1-hydroxy-5,5-dimethyl-2-phenyltetrahydro-4H-imidazole-4-thione	benzenes		low
2-[1-[2-oxo-2-[(4-thiophen-2-ylphenyl)methylamino]ethyl]cyclohexyl]acetic acid	benzenes		low
5-[4-(2-furylcarbonyl)piperazino]-5-oxo-3-phenylpentanoic acid	benzenes; monocarboxylic acid		low
N-(cyclopropylmethyl)-N'-phenylurea	benzenes		low
2-[(4-chlorophenyl)methoxy]-6-methoxybenzonitrile	benzenes; nitrile		low
2-(4-pentylphenyl)acetic acid	benzenes		low
5-methyl-2-phenyl-5-(2-phenylethyl)-1,2,4-triazolidine-3-thione	benzenes		low
k 858	benzenes		low
4-[[[4-(2-furanylmethyl)-5-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]thio]methyl]benzonitrile	benzenes; nitrile		low
9-oxo-N-(1-phenylethyl)-3-bicyclo[3.3.1]nonanecarboxamide	benzenes		low
N1,N4-bis(1-phenylethyl)cyclohexane-1,4-dicarboxamide	benzenes		low
4-phenyl-3H-thiazole-2-thione	benzenes		low
sulfatolamide	benzenes; sulfonamide		low
ifetroban	benzenes; monocarboxylic acid		low
1-[(2-ethyl-4-hydroxy-4-methyl-1-oxopentyl)amino]-3-phenylthiourea	benzenes		low
2-[6-amino-5-cyano-4-(4-ethylphenyl)-2,4-dihydropyrano[2,3-c]pyrazol-3-yl]acetic acid methyl ester	benzenes; pyranopyrazole		low
3-phenyl-3-(1-tetrazolyl)propanoic acid	benzenes; monocarboxylic acid		low
3,5-dimethyl-N-(2-phenylethyl)-N-(phenylmethyl)-4-isoxazolesulfonamide	benzenes		low
4-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)-3-nitrobenzenesulfonamide	benzenes; sulfonamide		low
N'-[5-(phenylmethyl)-4,5-dihydrothiazol-2-yl]hexanehydrazide	benzenes		low
5-amino-2-(diethylamino)-N-(2-methoxyphenyl)benzenesulfonamide	benzenes; sulfonamide		low
4-(1-phenylethyl)-3-(5-propyl-3-thiophenyl)-1H-1,2,4-triazole-5-thione	benzenes		low
N-[[(3-cyano-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)amino]-sulfanylidenemethyl]-5-methyl-3-phenyl-4-isoxazolecarboxamide	benzenes		low
N-[2-(4-methoxyphenyl)ethyl]-2-nitro-4-(1-pyrrolidinylsulfonyl)aniline	benzenes; sulfonamide		low
1-(1-adamantyl)-3-[1-(phenylmethyl)-4-pyrazolyl]urea	benzenes		low
neticonazole	aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide	antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor	low
l796778	benzenes; C-nitro compound; L-lysine derivative; L-phenylalanine derivative; methyl ester; oligopeptide; secondary carboxamide; ureas	somatostatin receptor agonist	low
l803087	benzenes; fluoroindole; guanidines; L-arginine derivative; methyl ester; phenylindole; secondary carboxamide	somatostatin receptor agonist	low
ro 4-6790	benzenes; sulfonamide		low
bay 11-7085	benzenes; nitrile; sulfone	anti-inflammatory agent; antibacterial agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; ferroptosis inducer; NF-kappaB inhibitor	low
gluconasturtiin	aralkylglucosinolic acid; benzenes		low
DPI2	benzenes; morpholines; secondary carboxamide; tertiary amino compound; thiazolidinone	ferroptosis inducer	low
l 744832	benzenes; ether; isopropyl ester; secondary carboxamide; sulfone; thiol	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; geroprotector	low
glucotropeolin	aralkylglucosinolic acid; benzenes		low
5-(4-phenylbutoxy)psoralen	aromatic ether; benzenes; psoralens	geroprotector; immunosuppressive agent; potassium channel blocker	low
ro 25-6981	benzenes; phenols; piperidines; secondary alcohol; tertiary amino compound	anticonvulsant; antidepressant; neuroprotective agent; NMDA receptor antagonist	low
bm 567	benzenes; sulfonamide		low
varespladib methyl	aromatic ether; benzenes; indoles; methyl ester; primary carboxamide	anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor; prodrug	low
npi 2358	2,5-diketopiperazines; benzenes; imidazoles; olefinic compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; microtubule-destabilising agent	low
chlorobactene	benzenes; carotenoid phi-end group; carotenoid	bacterial metabolite	low
ws-5995 c	benzenes; naphthalenes; ring assembly		low
phevalin	benzenes; pyrazinone	bacterial metabolite; calpain inhibitor	low
ym 216391	1,3-oxazoles; 1,3-thiazoles; azamacrocycle; benzenes; heterodetic cyclic peptide	antineoplastic agent; bacterial metabolite	low
3-(4-nitrophenyl)-N-(4-phenylbutyl)-5-(phenylmethyl)-4,6-dihydro-3aH-pyrrolo[3,4-d]isoxazole-6a-carboxamide	benzenes; organic amino compound		low
SYC-435	benzenes; cyclic hydroxamic acid; pyridone	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor	low
trelagliptin	benzenes; nitrile		low
1-hydroxy-5-nitro-N-(2-phenylethyl)-4-spiro[benzimidazole-2,1'-cyclohexane]imine	benzenes		low
5-methyl-5-pentyl-2-phenyl-1,2,4-triazolidine-3-thione	benzenes		low
N-methyl-3-[5-(3-phenylpropyl)-1,3,4-oxadiazol-2-yl]-N-(3-thiophenylmethyl)propanamide	benzenes		low
(5S)-1-(4-cyclohexylbutyl)-5-phenyl-4,5-dihydroimidazol-2-amine	benzenes		low
phenylmercuric acetate	arylmercury compound; benzenes		low
sm 164	benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; radiosensitizing agent	low
5-Methyl-1-phenyl-3-hexanyl sulfamate	benzenes		low
1-(3-methoxyphenyl)-3-(4-phenylbutyl)urea	benzenes; organic amino compound		low
niraparib	benzenes; indazoles; piperidines; primary carboxamide	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	low
n-alpha-benzoyl-n5-(2-chloro-1-iminoethyl)-l-ornithine amide	benzenes		low
1,1,1,2,2-pentafluoro-7-phenylheptan-3-one	benzenes		low
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline	benzenes; sulfonamide		low
difenacoum	benzenes; naphthalenes; ring assembly		low
warfarin	benzenes; hydroxycoumarin; methyl ketone		low
bromfenacoum	benzenes; naphthalenes; ring assembly		low
flocoumafen	benzenes; naphthalenes; ring assembly		low
gsk2879552	benzenes; benzoic acids; cyclopropanes; monocarboxylic acid; piperidines; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor	low

Substance	Classes	Roles	Relationship Strength
nsc 664704	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector	low
paullone	indolobenzazepine; lactam	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor	low
sb 415286	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	low
alsterpaullone	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor	low
8-hydroxymanzamine a	alkaloid; beta-carbolines; isoquinolines	anti-HSV-2 agent; EC 2.7.11.26 (tau-protein kinase) inhibitor; metabolite	low
GSK3-XIII	aromatic amine; pyrazoles; quinazolines; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor	low
manzamine a	alkaloid; beta-carbolines; isoquinolines	animal metabolite; anti-HSV-1 agent; antimalarial; antineoplastic agent; EC 2.7.11.26 (tau-protein kinase) inhibitor; marine metabolite	low
1-azakenpaullone	lactam; organic heterotetracyclic compound; organobromine compound; organonitrogen heterocyclic compound	EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator	low
chir 99021	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor	low
ly2090314	diazepinoindole; imidazopyridine; maleimides; monofluorobenzenes; piperidinecarboxamide; ureas	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator	low
azd2858	aromatic amine; N-methylpiperazine; pyrazines; pyridines; secondary carboxamide; sulfonamide	antineoplastic agent; bone density conservation agent; EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator	low
np 031112	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	low
tak-632	(trifluoromethyl)benzenes; aromatic ether; benzothiazoles; cyclopropylcarboxamide; monofluorobenzenes; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; necroptosis inhibitor	low
chir 98014	aminopyrimidine; C-nitro compound; diaminopyridine; dichlorobenzene; imidazoles; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; hypoglycemic agent; tau aggregation inhibitor; Wnt signalling activator	low
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile	hydroxyindoles; morpholines; nitrile; pyridines; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; tau aggregation inhibitor	low
gallic acid	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite	low
5-(n,n-hexamethylene)amiloride	aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines	antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker	low
am 251	amidopiperidine; carbohydrazide; dichlorobenzene; organoiodine compound; pyrazoles	antidepressant; antineoplastic agent; apoptosis inducer; CB1 receptor antagonist	low
calmidazolium	imidazolium ion	apoptosis inducer; calmodulin antagonist	low
danthron	dihydroxyanthraquinone	apoptosis inducer; plant metabolite	low
disulfiram	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor	low
ebselen	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger	low
miltefosine	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor	low
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	low
methyl methanesulfonate	methanesulfonate ester	alkylating agent; apoptosis inducer; carcinogenic agent; genotoxin; mutagen	low
midazolam	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative	low
entinostat	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	low
niclosamide	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor	low
nortriptyline	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite	low
4-phenylbutyric acid	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug	low
oxophenylarsine	arsine oxides	antineoplastic agent; apoptosis inducer; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor	low
pj-34	phenanthridines; secondary carboxamide; tertiary amino compound	angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent	low
sb 202190	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
imatinib	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	low
vorinostat	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	low
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine	N-substituted diamine; pyridines; tertiary amino compound	apoptosis inducer; chelator; copper chelator	low
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole	aromatic primary alcohol; furans; indazoles	antineoplastic agent; apoptosis inducer; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent	low
allyl isothiocyanate	alkenyl isothiocyanate; isothiocyanate	antimicrobial agent; antineoplastic agent; apoptosis inducer; lachrymator; metabolite	low
tributyrin	butyrate ester; triglyceride	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug; protective agent	low
diethyl sulfate	alkyl sulfate	alkylating agent; apoptosis inducer; carcinogenic agent; mutagen	low
n-nitrosopiperidine	nitrosamine; piperidine	apoptosis inducer; carcinogenic agent; environmental contaminant; mutagen	low
ziram	dithiocarbamate salt; zinc molecular entity	antifungal agrochemical; apoptosis inducer	low
diazooxonorleucine	amino acid zwitterion; diazo compound; ketone; non-proteinogenic L-alpha-amino acid	analgesic; antibacterial agent; antimetabolite; antineoplastic agent; antiviral agent; apoptosis inducer; bacterial metabolite; EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor; EC 3.5.1.2 (glutaminase) inhibitor; EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor; EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor; EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor; EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor; EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor; EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor; glutamine antagonist	low
naphthazarin	hydroxy-1,4-naphthoquinone	acaricide; antibacterial agent; antineoplastic agent; apoptosis inducer; geroprotector; plant metabolite	low
iberin	isothiocyanate; sulfoxide	apoptosis inducer; plant metabolite; quorum sensing inhibitor	low
physcione	dihydroxyanthraquinone	anti-inflammatory agent; antibacterial agent; antifungal agent; antineoplastic agent; apoptosis inducer; hepatoprotective agent; metabolite	low
4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol	terpineol; tertiary alcohol	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiparasitic agent; apoptosis inducer; plant metabolite; volatile oil component	low
thallium acetate	acetate salt; thallium molecular entity	apoptosis inducer; neurotoxin	low
toyocamycin	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; nitrile; ribonucleoside	antimetabolite; antineoplastic agent; apoptosis inducer; bacterial metabolite	low
2-hydroxyacetanilide	acetamides; phenols	anti-inflammatory agent; antineoplastic agent; antirheumatic drug; apoptosis inducer; platelet aggregation inhibitor; xenobiotic metabolite	low
methyl isocyanate	isocyanates	allergen; apoptosis inducer	low
methoxyacetic acid	ether; monocarboxylic acid	antineoplastic agent; apoptosis inducer; human xenobiotic metabolite; mutagen	low
dibromoacetic acid	2-bromocarboxylic acid; monocarboxylic acid	apoptosis inducer; geroprotector; marine metabolite	low
diallyl trisulfide	organic trisulfide	anti-inflammatory agent; antilipemic drug; antineoplastic agent; antioxidant; antiprotozoal drug; apoptosis inducer; estrogen receptor antagonist; insecticide; platelet aggregation inhibitor; vasodilator agent	low
antimony trichloride	antimony molecular entity; inorganic chloride	apoptosis inducer; colorimetric reagent; Lewis acid	low
tetradecanoylphorbol acetate	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator	low
pyoluteorin	aromatic ketone; beta-hydroxy ketone; diol; organochlorine compound; organochlorine pesticide; polyketide; pyrroles; resorcinols	antibacterial agent; antifungal agent; apoptosis inducer; bacterial metabolite; marine metabolite	low
norsalsolinol	isoquinolinol	animal metabolite; apoptosis inducer; human metabolite; marine metabolite	low
1-methyl-4-phenylpyridinium	pyridinium ion	apoptosis inducer; herbicide; human xenobiotic metabolite; neurotoxin	low
midazolam hydrochloride	hydrochloride; imidazobenzodiazepine	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative	low
staurosporine	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector	low
irinotecan	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug	low
mevastatin	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite	low
epigallocatechin gallate	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite	low
salvin	abietane diterpenoid; carbotricyclic compound; catechols; monocarboxylic acid	angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; food preservative; HIV protease inhibitor; plant metabolite	low
tetraiodothyroacetic acid	2-halophenol; aromatic ether; iodophenol; monocarboxylic acid	apoptosis inducer; human metabolite; thyroid hormone	low
toxoflavin	carbonyl compound; pyrimidotriazine	antibacterial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; toxin; virulence factor; Wnt signalling inhibitor	low
lupulon	beta-bitter acid	angiogenesis inhibitor; antimicrobial agent; antineoplastic agent; apoptosis inducer	low
alantolactone	naphthofuran; olefinic compound; sesquiterpene lactone	antineoplastic agent; apoptosis inducer; plant metabolite	low
dehydrocostus lactone	gamma-lactone; guaiane sesquiterpenoid; organic heterotricyclic compound; sesquiterpene lactone	antimycobacterial drug; antineoplastic agent; apoptosis inducer; cyclooxygenase 2 inhibitor; metabolite; trypanocidal drug	low
isoalantolactone	eudesmane sesquiterpenoid; sesquiterpene lactone	antifungal agent; apoptosis inducer; plant metabolite	low
brazilin	catechols; organic heterotetracyclic compound; tertiary alcohol	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; apoptosis inducer; biological pigment; hepatoprotective agent; histological dye; NF-kappaB inhibitor; plant metabolite	low
tetrazolium violet	organic chloride salt	antineoplastic agent; apoptosis inducer; dye	low
irinotecan hydrochloride	hydrochloride	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug	low
ethyl protocatechuate	catechols; ethyl ester	antibacterial agent; antioxidant; apoptosis inducer; EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; plant metabolite	low
fluazinam	(trifluoromethyl)benzenes; aminopyridine; C-nitro compound; chloropyridine; monochlorobenzenes; secondary amino compound	allergen; antifungal agrochemical; apoptosis inducer; environmental contaminant; xenobiotic	low
eupatorin	dihydroxyflavone; polyphenol; trimethoxyflavone	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; Brassica napus metabolite; calcium channel blocker; P450 inhibitor; vasodilator agent	low
atromentin	dihydroxy-1,4-benzoquinones; polyphenol	antibacterial agent; anticoagulant; antineoplastic agent; apoptosis inducer; biological pigment; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; fungal metabolite	low
diosgenin	3beta-sterol; hexacyclic triterpenoid; sapogenin; spiroketal	antineoplastic agent; antiviral agent; apoptosis inducer; metabolite	low
sn 38	delta-lactone; phenols; pyranoindolizinoquinoline; tertiary alcohol	antineoplastic agent; apoptosis inducer; drug metabolite; EC 5.99.1.2 (DNA topoisomerase) inhibitor	low
deguelin	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite	low
cafestol	diterpenoid; furans; organic heteropentacyclic compound; primary alcohol; tertiary alcohol	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; hypoglycemic agent; plant metabolite	low
kahweol	diterpenoid; furans; organic heteropentacyclic compound; primary alcohol; tertiary alcohol	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; plant metabolite	low
5-(tetradecyloxy)-2-furancarboxylic acid	aromatic ether; furoic acid	antineoplastic agent; apoptosis inducer; EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; PPARalpha agonist	low
tabtoxinine beta-lactam	beta-lactam antibiotic; monobactam; non-proteinogenic L-alpha-amino acid; tertiary alpha-hydroxy ketone	apoptosis inducer; bacterial metabolite; EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor	low
dioscin	hexacyclic triterpenoid; spiroketal; spirostanyl glycoside; trisaccharide derivative	anti-inflammatory agent; antifungal agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 1.14.18.1 (tyrosinase) inhibitor; hepatoprotective agent; metabolite	low
ginsenoside rh2	12beta-hydroxy steroid; 20-hydroxy steroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	antineoplastic agent; apoptosis inducer; bone density conservation agent; cardioprotective agent; hepatoprotective agent; plant metabolite	low
imatinib mesylate	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	low
27-hydroxycholesterol	26-hydroxycholesterol	apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent	low
rubimaillin	benzochromene; methyl ester; phenols	acyl-CoA:cholesterol acyltransferase 2 inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; neuroprotective agent; NF-kappaB inhibitor; plant metabolite	low
cd 437	adamantanes; monocarboxylic acid; naphthoic acid; phenols	apoptosis inducer; retinoic acid receptor gamma agonist	low
tempol	aminoxyls; hydroxypiperidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; catalyst; hepatoprotective agent; nephroprotective agent; neuroprotective agent; radical scavenger	low
tipifarnib	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	low
actinodaphine	aporphine alkaloid; aromatic ether; organic heteropentacyclic compound; phenols; secondary amino compound	antibacterial agent; antifungal agent; antineoplastic agent; apoptosis inducer; plant metabolite; platelet aggregation inhibitor; topoisomerase inhibitor	low
pannarin	aldehyde; aromatic ether; depsidones; organic heterotricyclic compound; organochlorine compound; phenols	antimicrobial agent; antineoplastic agent; apoptosis inducer; lichen metabolite	low
sclareol	labdane diterpenoid	antifungal agent; antimicrobial agent; apoptosis inducer; fragrance; plant metabolite	low
anacardic acid	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite	low
pectolinarin	dimethoxyflavone; disaccharide derivative; glycosyloxyflavone; monohydroxyflavanone; rutinoside	anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; plant metabolite	low
withaferin a	27-hydroxy steroid; 4-hydroxy steroid; delta-lactone; enone; epoxy steroid; ergostanoid; primary alcohol; secondary alcohol; withanolide	antineoplastic agent; apoptosis inducer	low
noscapine	aromatic ether; benzylisoquinoline alkaloid; cyclic acetal; isobenzofuranone; organic heterobicyclic compound; organic heterotricyclic compound; tertiary amino compound	antineoplastic agent; antitussive; apoptosis inducer; plant metabolite	low
homoharringtonine	alkaloid ester; enol ether; organic heteropentacyclic compound; tertiary alcohol	anticoronaviral agent; antineoplastic agent; apoptosis inducer; protein synthesis inhibitor	low
elesclomol	carbohydrazide; thiocarbonyl compound	antineoplastic agent; apoptosis inducer	low
anthricin	furonaphthodioxole; gamma-lactone; lignan; methoxybenzenes	antineoplastic agent; apoptosis inducer; plant metabolite	low
nsc 23766	aminopyrimidine; aminoquinoline; primary amino compound; secondary amino compound; tertiary amino compound	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist	low
gant 61	aminal; dialkylarylamine; pyridines; substituted aniline; tertiary amino compound	antineoplastic agent; apoptosis inducer; glioma-associated oncogene inhibitor; Hedgehog signaling pathway inhibitor	low
peonidin	5-hydroxyanthocyanidin	antineoplastic agent; antioxidant; apoptosis inducer; metabolite	low
helveticoside	14beta-hydroxy steroid; 5beta-hydroxy steroid; cardenolide glycoside; digitoxoside; monosaccharide derivative; steroid aldehyde; steroid lactone	antineoplastic agent; apoptosis inducer; plant metabolite	low
ginsenoside rf	12beta-hydroxy steroid; 20-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	antineoplastic agent; apoptosis inducer; plant metabolite	low
notoginsenoside r1	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	antioxidant; apoptosis inducer; neuroprotective agent; phytoestrogen; plant metabolite	low
theasinensin a	biflavonoid; gallate ester; proanthocyanidin	anti-inflammatory agent; anticoronaviral agent; apoptosis inducer; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; melanin synthesis inhibitor; plant metabolite	low
solasodine	alkaloid antibiotic; azaspiro compound; hemiaminal ether; oxaspiro compound; sapogenin; steroid alkaloid	anticonvulsant; antifungal agent; antiinfective agent; antioxidant; antipyretic; antispermatogenic agent; apoptosis inducer; cardiotonic drug; central nervous system depressant; diuretic; immunomodulator; plant metabolite; teratogenic agent	low
devazepide	1,4-benzodiazepinone; indolecarboxamide	antineoplastic agent; apoptosis inducer; cholecystokinin antagonist; gastrointestinal drug	low
carubicin	aminoglycoside antibiotic; anthracycline antibiotic; p-quinones; tertiary alpha-hydroxy ketone; tetracenequinones	antineoplastic agent; apoptosis inducer	low
epothilone b	epothilone; epoxide	antineoplastic agent; apoptosis inducer; microtubule-stabilising agent	low
bms 214662	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	low
aclarubicin	aminoglycoside; anthracycline; methyl ester; phenols; polyketide; tetracenequinones; trisaccharide derivative; zwitterion	antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor	low
aphidicolin	tetracyclic diterpenoid	antimicrobial agent; antimitotic; antineoplastic agent; antiviral drug; apoptosis inducer; Aspergillus metabolite; DNA synthesis inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; fungal metabolite	low
licocoumarone	1-benzofurans; aromatic ether; resorcinols	antibacterial agent; apoptosis inducer; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite	low
piperyline	benzodioxoles; N-acylpyrrolidine; pyrrolidine alkaloid; tertiary carboxamide	antifungal agent; apoptosis inducer; plant metabolite	low
rhapontin	rhaponticin	angiogenesis inhibitor; anti-allergic agent; anti-inflammatory agent; antilipemic drug; antineoplastic agent; apoptosis inducer; EC 2.3.1.85 (fatty acid synthase) inhibitor; hypoglycemic agent; neuroprotective agent; plant metabolite	low
xanthohumol	aromatic ether; chalcones; polyphenol	anti-HIV-1 agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor; metabolite	low
p-hydroxycinnamaldehyde	cinnamaldehydes	apoptosis inducer; EC 1.14.13.39 (nitric oxide synthase) inhibitor; plant metabolite	low
calmidazolium	organic chloride salt	apoptosis inducer; calmodulin antagonist	low
amygdalin	amygdalin	antineoplastic agent; apoptosis inducer; plant metabolite	low
3,3',4,5'-tetrahydroxystilbene	catechols; polyphenol; resorcinols; stilbenol	antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor	low
4-iodo-6-phenylpyrimidine	biaryl; organoiodine compound; pyrimidines	antineoplastic agent; apoptosis inducer; macrophage migration inhibitory factor inhibitor	low
oncrasin-1	arenecarbaldehyde; indoles; monochlorobenzenes	antineoplastic agent; apoptosis inducer	low
cct018159	benzodioxine; pyrazoles; resorcinols	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor	low
sulindac	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent	low
aurapten	coumarins; monoterpenoid	antihypertensive agent; antineoplastic agent; antioxidant; apoptosis inducer; dopaminergic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; gamma-secretase modulator; gastrointestinal drug; hepatoprotective agent; matrix metalloproteinase inhibitor; neuroprotective agent; plant metabolite; PPARalpha agonist; vulnerary	low
10058-F4	olefinic compound; thiazolidinone	antineoplastic agent; apoptosis inducer	low
u 0126	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent	low
bms 387032	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
vx-745	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
bigelovin	acetate ester; cyclic ketone; gamma-lactone; organic heterotricyclic compound; sesquiterpene lactone	antineoplastic agent; apoptosis inducer; immunomodulator; plant metabolite	low
sc 560	aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug	low
fraxetin	aromatic ether; hydroxycoumarin	anti-inflammatory agent; antibacterial agent; antimicrobial agent; antioxidant; apoptosis inducer; apoptosis inhibitor; Arabidopsis thaliana metabolite; hepatoprotective agent; hypoglycemic agent	low
luteolin	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist	low
herbacetin	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antilipemic drug; antineoplastic agent; apoptosis inducer; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; plant metabolite	low
oleuropein	beta-D-glucoside; catechols; diester; methyl ester; pyrans; secoiridoid glycoside	anti-inflammatory agent; antihypertensive agent; antineoplastic agent; antioxidant; apoptosis inducer; NF-kappaB inhibitor; nutraceutical; plant metabolite; radical scavenger	low
baicalein	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger	low
diosmetin	3'-hydroxyflavonoid; monomethoxyflavone; trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; bone density conservation agent; cardioprotective agent; plant metabolite; tropomyosin-related kinase B receptor agonist; vasodilator agent	low
hispidulin	monomethoxyflavone; trihydroxyflavone	anti-inflammatory agent; anticonvulsant; antineoplastic agent; antioxidant; apoptosis inducer; plant metabolite	low
pterostilbene	diether; methoxybenzenes; stilbenol	anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; hypoglycemic agent; neuroprotective agent; neurotransmitter; plant metabolite; radical scavenger	low
wedelolactone	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite	low
rottlerin	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite	low
plaunotol	diterpenoid; primary alcohol	anti-ulcer drug; antibacterial agent; antineoplastic agent; apoptosis inducer; nephroprotective agent; plant metabolite; vulnerary	low
tocotrienol, beta	tocotrienol; vitamin E	antineoplastic agent; apoptosis inducer; plant metabolite	low
gamma-tocotrienol	tocotrienol; vitamin E	antineoplastic agent; antioxidant; apoptosis inducer; hepatoprotective agent; plant metabolite; radiation protective agent	low
tocotrienol, delta	tocotrienol; vitamin E	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bone density conservation agent; NF-kappaB inhibitor; plant metabolite; radiation protective agent; Saccharomyces cerevisiae metabolite	low
9,11-linoleic acid	octadeca-9,11-dienoic acid	anti-inflammatory agent; antiatherogenic agent; antineoplastic agent; apoptosis inducer; bacterial xenobiotic metabolite; human metabolite	low
2,4-decadienal	polyunsaturated fatty aldehyde	apoptosis inducer; nematicide	low
natamycin	antibiotic antifungal drug; dicarboxylic acid monoester; epoxide; macrolide antibiotic; monosaccharide derivative; polyene antibiotic	antifungal agrochemical; antimicrobial food preservative; apoptosis inducer; bacterial metabolite; ophthalmology drug	low
t-2 toxin	acetate ester; organic heterotetracyclic compound; trichothecene	apoptosis inducer; cardiotoxic agent; DNA synthesis inhibitor; environmental contaminant; fungal metabolite; mycotoxin; neurotoxin	low
alvocidib	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
herbimycin	1,4-benzoquinones; lactam; macrocycle	antimicrobial agent; apoptosis inducer; herbicide; Hsp90 inhibitor; tyrosine kinase inhibitor	low
ro 41-5253	aromatic ether; benzoic acids; sulfone; thiochromane	apoptosis inducer; retinoic acid receptor alpha antagonist	low
casticin	dihydroxyflavone; tetramethoxyflavone	apoptosis inducer; plant metabolite	low
3,3'-di-o-methylquercetin	3'-methoxyflavones; dimethoxyflavone; trihydroxyflavone	antibacterial agent; antineoplastic agent; apoptosis inducer; plant metabolite	low
oridonin	cyclic hemiketal; enone; ent-kaurane diterpenoid; organic heteropentacyclic compound; secondary alcohol	angiogenesis inhibitor; anti-asthmatic agent; antibacterial agent; antineoplastic agent; apoptosis inducer; plant metabolite	low
pd 166866	biaryl; dimethoxybenzene; primary arylamine; pyridopyrimidine; ureas	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
ag-490	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor	low
mitoguazone	guanidines; hydrazone	antineoplastic agent; apoptosis inducer; EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor	low
ermanin	dihydroxyflavone; dimethoxyflavone	anti-inflammatory agent; antimycobacterial drug; antineoplastic agent; apoptosis inducer; plant metabolite	low
sulindac sulfide	aryl sulfide; monocarboxylic acid; organofluorine compound	antineoplastic agent; apoptosis inducer; non-steroidal anti-inflammatory drug	low
bay 11-7082	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor	low
bay 11-7085	benzenes; nitrile; sulfone	anti-inflammatory agent; antibacterial agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; ferroptosis inducer; NF-kappaB inhibitor	low
flavokawain b	chalcones; dimethoxybenzene; phenols	anti-inflammatory agent; antileishmanial agent; antineoplastic agent; apoptosis inducer; metabolite	low
pipercallosidine	alkaloid; benzodioxoles; enamide; secondary carboxamide	apoptosis inducer; metabolite; plant metabolite	low
jaceosidin	dimethoxyflavone; trihydroxyflavone	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; metabolite	low
cisplatin	diamminedichloroplatinum	antineoplastic agent; apoptosis inducer; cross-linking reagent; ferroptosis inducer; genotoxin; mutagen; nephrotoxin; photosensitizing agent	low
sulindac sulfone	monocarboxylic acid; organofluorine compound; sulfone	apoptosis inducer; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor	low
lespenefril	alpha-L-rhamnoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative; polyphenol	anti-inflammatory agent; antidepressant; antineoplastic agent; apoptosis inducer; bone density conservation agent; hypoglycemic agent; immunomodulator; plant metabolite	low
baohuoside i	glycosyloxyflavone	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; plant metabolite	low
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	enone; pyridines	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor	low
coronardine	alkaloid ester; methyl ester; monoterpenoid indole alkaloid; organic heteropentacyclic compound	antileishmanial agent; antineoplastic agent; apoptosis inducer; plant metabolite	low
bafilomycin a1	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin	low
columbianadin	alpha,beta-unsaturated carboxylic ester; furanocoumarin	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; hepatoprotective agent; plant metabolite; rat metabolite	low
germacrone	germacrane sesquiterpenoid; olefinic compound	androgen antagonist; anti-inflammatory agent; antifeedant; antifungal agent; antimicrobial agent; antineoplastic agent; antioxidant; antitussive; antiviral agent; apoptosis inducer; autophagy inducer; hepatoprotective agent; insecticide; neuroprotective agent; plant metabolite; volatile oil component	low
manumycin	enamide; epoxide; organic heterobicyclic compound; polyketide; secondary carboxamide; tertiary alcohol	antiatherosclerotic agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; marine metabolite	low
thermozymocidin	alpha-amino fatty acid; hydroxy monocarboxylic acid; non-proteinogenic alpha-amino acid; sphingoid	antifungal agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor; fungal metabolite; immunosuppressive agent	low
salvianolic acid B	1-benzofurans; catechols; dicarboxylic acid; enoate ester; polyphenol	anti-inflammatory agent; antidepressant; antineoplastic agent; antioxidant; apoptosis inducer; autophagy inhibitor; cardioprotective agent; hepatoprotective agent; hypoglycemic agent; neuroprotective agent; osteogenesis regulator; plant metabolite	low
tanespimycin	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor	low
soblidotin	tetrapeptide	antineoplastic agent; apoptosis inducer; microtubule-destabilising agent	low
on 01910	N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine	antineoplastic agent; apoptosis inducer; EC 2.7.11.21 (polo kinase) inhibitor; microtubule-destabilising agent	low
alpha-solanine	glycoalkaloid; organic heterohexacyclic compound; steroid saponin; trisaccharide derivative	antineoplastic agent; apoptosis inducer; phytotoxin; plant metabolite	low
2-hydroxy-9-cis-octadecenoic acid	2-hydroxy fatty acid; hydroxy monounsaturated fatty acid; long-chain fatty acid	antihypertensive agent; antineoplastic agent; apoptosis inducer	low
dolastatin 10	1,3-thiazoles; tetrapeptide	animal metabolite; antineoplastic agent; apoptosis inducer; marine metabolite; microtubule-destabilising agent	low
jasplakinolide	cyclodepsipeptide; phenols	actin polymerisation inducer; animal metabolite; antifungal agent; antineoplastic agent; apoptosis inducer; marine metabolite; neuroprotective agent	low
mocetinostat	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent	low
scio-469	aromatic amide; aromatic ketone; chloroindole; dicarboxylic acid diamide; indolecarboxamide; monofluorobenzenes; N-acylpiperazine; N-alkylpiperazine	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
cp 724714	2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; hepatotoxic agent	low
hmr 1275	hydrochloride	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
zm 447439	aromatic ether; benzamides; morpholines; polyether; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; Aurora kinase inhibitor	low
ginsenoside f2	12beta-hydroxy steroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	antineoplastic agent; apoptosis inducer; plant metabolite	low
ginsenoside rg3	ginsenoside; glycoside; tetracyclic triterpenoid	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; plant metabolite	low
jte 607	hydrochloride	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; CPSF3 inhibitor; prodrug	low
npi 2358	2,5-diketopiperazines; benzenes; imidazoles; olefinic compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; microtubule-destabilising agent	low
NNC 55-0396 (free base)	benzimidazoles; cyclopropanecarboxylate ester; organofluorine compound; tertiary amino compound; tetralins	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; neuroprotective agent; potassium channel blocker; T-type calcium channel blocker	low
osu 03012	antibiotic antifungal drug; aromatic amide; glycine derivative; organofluorine compound; phenanthrenes; pyrazoles	antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	low
avenanthramide b	amidobenzoic acid; cinnamamides; monohydroxybenzoic acid; monomethoxybenzene; phenols; secondary carboxamide	antineoplastic agent; apoptosis inducer; phytoalexin	low
HT-2 toxin	acetate ester; organic heterotetracyclic compound; trichothecene	apoptosis inducer; fungal metabolite	low
delphinidin 3-sambubioside	anthocyanidin 3-O-beta-D-sambubioside	apoptosis inducer; metabolite	low
bl1521	enamide; hydroxamic acid; monocarboxylic acid amide	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	low
binimetinib	benzimidazoles; bromobenzenes; hydroxamic acid ester; monofluorobenzenes; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
aee 788	6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist; trypanocidal drug	low
saracatinib	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent	low
crenolanib	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
triptohypol C	benzenediols; monocarboxylic acid; pentacyclic triterpenoid	apoptosis inducer; plant metabolite	low
PB28	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist	low
ym 155	organic bromide salt	antineoplastic agent; apoptosis inducer; survivin suppressant	low
abt-737	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor	low
brivanib	aromatic ether; diether; fluoroindole; pyrrolotriazine; secondary alcohol	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; drug metabolite; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	low
rx-3117	organofluorine compound; primary allylic alcohol; triol	antimetabolite; antineoplastic agent; apoptosis inducer; DNA synthesis inhibitor; prodrug	low
laurinterol	organobromine compound; phenols; sesquiterpenoid	antibacterial agent; apoptosis inducer; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; metabolite	low
MI-63	azaspiro compound; monochlorobenzenes; monofluorobenzenes; morpholines; oxindoles; pyrrolidines; secondary carboxamide	apoptosis inducer	low
ki11502	aromatic ether; benzamides; quinolines; thioureas	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
idelalisib	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	low
ginsenoside rd	beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	anti-inflammatory drug; apoptosis inducer; immunosuppressive agent; neuroprotective agent; plant metabolite; vulnerary	low
amrubicinol	diastereoisomeric mixture; quinone; secondary alcohol; tetracenes	antineoplastic agent; apoptosis inducer; topoisomerase II inhibitor	low
cytotrienin a	cyclopropanecarboxylate ester; ether; hydroquinones; lactam; macrocycle; secondary alcohol	antibacterial agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; metabolite	low
forapin	peptidyl amide; polypeptide	animal metabolite; antineoplastic agent; apoptosis inducer; EC 2.7.11.13 (protein kinase C) inhibitor; hepatoprotective agent; neuroprotective agent; venom	low
pevonedistat	cyclopentanols; indanes; pyrrolopyrimidine; secondary amino compound; sulfamidate	antineoplastic agent; apoptosis inducer	low
tg101209	N-alkylpiperazine; N-arylpiperazine; pyrimidines; secondary amino compound; sulfonamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	low
nsc 23766	hydrochloride	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist	low
sm 164	benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; radiosensitizing agent	low
scalaradial	acetate ester; carbotetracyclic compound; dialdehyde; enal; scalarane sesterterpenoid	animal metabolite; anti-inflammatory agent; apoptosis inducer; EC 3.1.1.4 (phospholipase A2) inhibitor; marine metabolite; TRP channel blocker	low
nnc 55-0396	hydrochloride	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; neuroprotective agent; potassium channel blocker; T-type calcium channel blocker	low
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine	1,2-diacyl-sn-glycero-3-phosphocholine; aldehyde	apoptosis inducer	low
borrelidin	aliphatic nitrile; diol; macrolide; monocarboxylic acid; secondary alcohol	antifungal agent; antimalarial; antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite	low
olaparib	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	low
lcl161	1,3-thiazoles; aromatic ketone; L-alanine derivative; monofluorobenzenes; N-acylpyrrolidine	antineoplastic agent; apoptosis inducer	low
delanzomib	C-terminal boronic acid peptide; phenylpyridine; secondary alcohol; threonine derivative	antineoplastic agent; apoptosis inducer; proteasome inhibitor	low
sch772984	biaryl; indazoles; N-acylpiperazine; N-alkylpyrrolidine; N-arylpiperazine; pyridines; pyrimidines; pyrrolidinecarboxamide; secondary carboxamide; tertiary amino compound; tertiary carboxamide	analgesic; antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
niraparib	2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent	low
navitoclax	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor	low
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	low
poziotinib	acrylamides; aromatic ether; dichlorobenzene; diether; monofluorobenzenes; N-acylpiperidine; quinazolines; secondary amino compound; substituted aniline	antineoplastic agent; apoptosis inducer; epidermal growth factor receptor antagonist	low
asp3026	aromatic amine; diamino-1,3,5-triazine; monomethoxybenzene; N-methylpiperazine; piperidines; secondary amino compound; sulfone	antimalarial; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 6.1.1.6 (lysine--tRNA ligase) inhibitor	low
entrectinib	benzamides; difluorobenzene; indazoles; N-methylpiperazine; oxanes; secondary amino compound; secondary carboxamide	antibacterial agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
TAK-580	1,3-thiazolecarboxamide; aminopyrimidine; chloropyridine; organofluorine compound; pyrimidinecarboxamide; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor	low
ixazomib	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor	low
cx 5461	diazepine; naphthyridine derivative; organic heterotetracyclic compound; pyrazines; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.7.6 (RNA polymerase) inhibitor	low
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	benzyl alcohols; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; apoptosis inducer; mTOR inhibitor	low
GDC-0623	hydroxamic acid ester; imidazopyridine; monofluorobenzenes; organoiodine compound; primary alcohol; secondary amino compound; substituted aniline	antineoplastic agent; apoptosis inducer; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	low
cblc137	aromatic ketone; carbazoles; methyl ketone; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; NF-kappaB inhibitor; p53 activator	low
jadomycin b	glycoside; jadomycin; organic heteropentacyclic compound	antibacterial agent; antineoplastic agent; apoptosis inducer; Aurora kinase inhibitor; bacterial metabolite	low
jq1 compound	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer	low
gilteritinib	aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
abt-199	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor	low
pracinostat	benzimidazole; hydroxamic acid; olefinic compound; tertiary amino compound	antimalarial; antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	low
physalin f	enone; epoxy steroid; lactone; physalin	antileishmanial agent; antimalarial; antineoplastic agent; apoptosis inducer; immunosuppressive agent	low
n-(2-(5-methoxy-2-oxo-2,3-dihydro-1h-indol-3-yl)ethyl)acetamide	acetamides; hydroxyindoles; tryptamines	antineoplastic agent; apoptosis inducer; plant metabolite	low
lfm a13	aromatic amide; dibromobenzene; enamide; enol; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 2.7.11.21 (polo kinase) inhibitor; geroprotector; platelet aggregation inhibitor	low
AZD3463	aminopiperidine; aminopyrimidine; indoles; monomethoxybenzene; organochlorine compound; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
MK-8353	aromatic ether; dihydropyridine; indazoles; methyl sulfide; N-alkylpyrrolidine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
acp-196	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	low
gsk343	aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor	low
ly3009120	aminotoluene; aromatic amine; biaryl; monofluorobenzenes; phenylureas; pyridopyrimidine; secondary amino compound	antineoplastic agent; apoptosis inducer; autophagy inducer; B-Raf inhibitor; necroptosis inhibitor	low
as 1842856	organofluorine compound; primary amino compound; quinolinemonocarboxylic acid; quinolone; secondary amino compound; tertiary amino compound	anti-obesity agent; antineoplastic agent; apoptosis inducer; autophagy inhibitor; forkhead box protein O1 inhibitor; hypoglycemic agent	low
sr9243	bromobenzenes; sulfonamide; sulfone	antineoplastic agent; apoptosis inducer; liver X receptor inverse agonist	low
ldc4297	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
duramycin	heterodetic cyclic peptide; macrocycle	antimicrobial agent; apoptosis inducer; bacterial metabolite	low
cigb-300	heterodetic cyclic peptide; polypeptide	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	low
BDA-366	anthraquinone; epoxide; secondary alcohol; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer	low
THZ531	aminopyrimidine; enamide; indoles; N-acylpiperidine; organochlorine compound; secondary amino compound; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
can 508	aromatic amine; monoazo compound; phenols; pyrazoles	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
tirapazamine	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer	low
undecylprodigiosin	alkaloid; aromatic ether; tripyrrole	antibacterial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; biological pigment; immunosuppressive agent; radiosensitizing agent	low
tilimycin	phenols; pyrrolobenzodiazepine	alkylating agent; apoptosis inducer; bacterial metabolite; toxin	low
protocatechuic acid	catechols; dihydroxybenzoic acid	antineoplastic agent; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; human xenobiotic metabolite; plant metabolite	low
aminolevulinic acid	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite	low
perillic acid	alpha,beta-unsaturated monocarboxylic acid; cyclohexenecarboxylic acid	antineoplastic agent; human metabolite; mouse metabolite	low
pk 11195	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent	low
pd 173074	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	low
aminopropionitrile	aminopropionitrile	antineoplastic agent; antirheumatic drug; collagen cross-linking inhibitor; plant metabolite	low
7,8-dihydroxyflavone	dihydroxyflavone	antidepressant; antineoplastic agent; antioxidant; plant metabolite; tropomyosin-related kinase B receptor agonist	low
ro 48-8071	aromatic ether; aromatic ketone; bromobenzenes; monofluorobenzenes; olefinic compound; tertiary amino compound	antineoplastic agent; EC 5.4.99.7 (lanosterol synthase) inhibitor	low
rtki cpd	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector	low
alfuzosin	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent	low
am 580	amidobenzoic acid; tetralins	antineoplastic agent; retinoic acid receptor alpha/beta agonist	low
aminoglutethimide	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	low
amsacrine	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor	low
anastrozole	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	low
azathioprine	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug	low
azelaic acid	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	antibacterial agent; antineoplastic agent; dermatologic drug; plant metabolite	low
berberine	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker	low
buformin	biguanides	antineoplastic agent; antiviral agent; geroprotector; hypoglycemic agent; radiosensitizing agent	low
busulfan	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent	low
camostat	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor	low
carmustine	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent	low
cgs 15943	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant	low
chelerythrine	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	low
chlorambucil	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent	low
ci 994	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor	low
ciglitazone	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug	low
cl 387785	bromobenzenes; quinazolines; secondary carboxamide; ynamide	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist	low
clioquinol	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator	low
clofibric acid	aromatic ether; monocarboxylic acid; monochlorobenzenes	anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist	low
dacarbazine	imidazoles; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; carcinogenic agent; prodrug	low
dequalinium	quinolinium ion	antifungal agent; antineoplastic agent; antiseptic drug; mitochondrial NADH:ubiquinone reductase inhibitor	low
3,3'-diindolylmethane	indoles	antineoplastic agent; P450 inhibitor	low
doxazosin	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent	low
ellipticine	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite	low
embelin	dihydroxy-1,4-benzoquinones	antimicrobial agent; antineoplastic agent; hepatitis C protease inhibitor; plant metabolite	low
emodin	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor	low
etanidazole	C-nitro compound; imidazoles; monocarboxylic acid amide	alkylating agent; antineoplastic agent; prodrug; radiosensitizing agent	low
etidronate	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator	low
fluorouracil	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic	low
flutamide	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent	low
beta-thujaplicin	cyclic ketone; enol; monoterpenoid	antibacterial agent; antifungal agent; antineoplastic agent; antiplasmodial drug; plant metabolite	low
hydroxyurea	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent	low
ifosfamide	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic	low
indole-3-carbinol	indolyl alcohol	antineoplastic agent; plant metabolite	low
beta-lapachone	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite	low
leflunomide	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor	low
letrozole	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	low
lomustine	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent	low
6-anilino-5,8-quinolinedione	aminoquinoline; aromatic amine; p-quinones; quinolone	antineoplastic agent; EC 4.6.1.2 (guanylate cyclase) inhibitor	low
meclofenamic acid	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug	low
vitamin k 3	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical	low
methoxsalen	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite	low
nocodazole	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator	low
mitoxantrone	dihydroxyanthraquinone	analgesic; antineoplastic agent	low
n(1), n(12)-diethylspermine	polyazaalkane; secondary amino compound; substituted spermine; tetramine	antineoplastic agent	low
nilutamide	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent	low
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor	low
oxyphenbutazone	phenols; pyrazolidines	antimicrobial agent; antineoplastic agent; antipyretic; drug metabolite; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic metabolite	low
pd 158780	aromatic amine; bromobenzenes; diamine; pyridopyrimidine; secondary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
phloretin	dihydrochalcones	antineoplastic agent; plant metabolite	low
pipobroman	N-acylpiperazine; organobromine compound; tertiary carboxamide	alkylating agent; antineoplastic agent	low
procarbazine	benzamides; hydrazines	antineoplastic agent	low
salicylsalicylic acid	benzoate ester; benzoic acids; phenols; salicylates	antineoplastic agent; antirheumatic drug; EC 3.5.2.6 (beta-lactamase) inhibitor; hypoglycemic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug	low
semustine	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent	low
streptonigrin	pyridines; quinolone	antimicrobial agent; antineoplastic agent	low
SU6656	oxindoles; sulfonamide	antineoplastic agent; Aurora kinase inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	low
sulforaphane	isothiocyanate; sulfoxide	antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite	low
suramin	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug	low
temozolomide	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug	low
terazosin	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent	low
2,2'-thiodiethanol	aliphatic sulfide; diol	antineoplastic agent; antioxidant; metabolite; solvent	low
tilorone	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist	low
troglitazone	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent	low
mitomycin	mitomycin	alkylating agent; antineoplastic agent	low
prednisolone	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic	low
floxuridine	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent	low
prednisone	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug	low
estrone	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite	low
azauridine	N-glycosyl-1,2,4-triazine	antimetabolite; antineoplastic agent; drug metabolite	low
mechlorethamine hydrochloride	hydrochloride	antineoplastic agent	low
vincristine	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator	low
methyltestosterone	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; enone	anabolic agent; androgen; antineoplastic agent	low
dromostanolone	17beta-hydroxy steroid; 3-oxo-5alpha-steroid; anabolic androgenic steroid	anabolic agent; antineoplastic agent	low
bromodeoxyuridine	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent	low
ethyl methanesulfonate	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; genotoxin; mutagen; teratogenic agent	low
triaziquone	1,4-benzoquinones; aziridines	alkylating agent; antineoplastic agent	low
tubercidin	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite	low
cytarabine	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent	low
trifluridine	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor	low
medroxyprogesterone acetate	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive	low
fluoxymesterone	11beta-hydroxy steroid; 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid; fluorinated steroid	anabolic agent; antineoplastic agent	low
rotenone	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin	low
acetopyrrothine	acetamides; dithiolopyrrolone antibiotic	angiogenesis inhibitor; antibacterial agent; antifungal agent; antineoplastic agent; bacterial metabolite; chelator; EC 2.7.7.6 (RNA polymerase) inhibitor; marine metabolite; protein synthesis inhibitor; toxin	low
phenformin	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent	low
dibenzoylmethane	aromatic ketone; beta-diketone	antimutagen; antineoplastic agent; metabolite	low
suramin sodium	organic sodium salt	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug	low
pyrazolanthrone	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector	low
azacitidine	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent	low
diazomethane	diazo compound	alkylating agent; antineoplastic agent; carcinogenic agent; poison	low
procarbazine hydrochloride	hydrochloride	antineoplastic agent	low
liriodenine	alkaloid antibiotic; cyclic ketone; organic heteropentacyclic compound; oxacycle; oxoaporphine alkaloid	antifungal agent; antimicrobial agent; antineoplastic agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; metabolite	low
lucanthone	thioxanthenes	adjuvant; antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; mutagen; photosensitizing agent; prodrug; schistosomicide drug	low
plumbagin	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite	low
aloe emodin	aromatic primary alcohol; dihydroxyanthraquinone	antineoplastic agent; plant metabolite	low
emetine	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor	low
thymoquinone	1,4-benzoquinones	adjuvant; anti-inflammatory agent; antidepressant; antineoplastic agent; antioxidant; cardioprotective agent; plant metabolite	low
podophyllotoxin	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator	low
dequalinium chloride	organic chloride salt	antifungal agent; antineoplastic agent; antiseptic drug; mitochondrial NADH:ubiquinone reductase inhibitor	low
formestane	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	low
chlorotrianisene	chloroalkene	antineoplastic agent; estrogen receptor modulator; xenoestrogen	low
megestrol acetate	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive	low
hadacidin	aldehyde; monocarboxylic acid; N-hydroxy-alpha-amino-acid	antimicrobial agent; antineoplastic agent; Penicillium metabolite; teratogenic agent	low
2-fluoroadenine	organofluorine compound; purines	antineoplastic agent	low
tetramethylpyrazine	alkaloid; pyrazines	antineoplastic agent; apoptosis inhibitor; bacterial metabolite; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent	low
guanazole	aromatic amine; triazoles	antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor	low
diallyl disulfide	organic disulfide	antifungal agent; antineoplastic agent; plant metabolite	low
phenethyl isothiocyanate	isothiocyanate	antineoplastic agent; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; metabolite	low
glaucine	aporphine alkaloid; organic heterotetracyclic compound; polyether; tertiary amino compound	antibacterial agent; antineoplastic agent; antitussive; muscle relaxant; NF-kappaB inhibitor; plant metabolite; platelet aggregation inhibitor; rat metabolite	low
acadesine	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor	low
doxifluridine	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug	low
megestrol	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive	low
mitomycin a	ether; mitomycin	alkylating agent; antimicrobial agent; antineoplastic agent; toxin	low
cladribine	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent	low
tabersonine	alkaloid ester; methyl ester; monoterpenoid indole alkaloid; organic heteropentacyclic compound	antineoplastic agent; metabolite	low
vidarabine	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic	low
cyclophosphamide	hydrate	alkylating agent; antineoplastic agent; carcinogenic agent; immunosuppressive agent	low
helenalin	cyclic ketone; gamma-lactone; organic heterotricyclic compound; secondary alcohol; sesquiterpene lactone	anti-inflammatory agent; antineoplastic agent; metabolite; plant metabolite	low
etidronate disodium	organic sodium salt	antineoplastic agent; bone density conservation agent; chelator	low
camptothecin	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite	low
isopentenyladenosine	N-ribosyl-N(6)-isopentenyladenine; nucleoside analogue	antineoplastic agent; plant growth regulator; plant metabolite	low
nsc-145,668	hydrochloride	antimetabolite; antineoplastic agent	low
ancitabine	diol; organic heterotricyclic compound	antimetabolite; antineoplastic agent; prodrug	low
clodronic acid	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent	low
streptozocin	N-acylglucosamine; N-nitrosoureas	antimicrobial agent; antineoplastic agent; DNA synthesis inhibitor; metabolite	low
daunorubicin	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite	low
fludarabine phosphate	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug	low
2,6-diaminopurine	2,6-diaminopurines; primary amino compound	antineoplastic agent	low
silybin	aromatic ether; benzodioxine; flavonolignan; polyphenol; secondary alpha-hydroxy ketone	antineoplastic agent; antioxidant; hepatoprotective agent; plant metabolite	low
glucaric acid	glucaric acid	antineoplastic agent	low
paclitaxel	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent	low
etoposide	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor	low
promegestone	20-oxo steroid; 3-oxo-Delta(4) steroid	antineoplastic agent; progesterone receptor agonist; progestin	low
perfosfamide	nitrogen mustard; organochlorine compound; peroxol; phosphorodiamide	alkylating agent; antineoplastic agent; drug allergen; immunosuppressive agent; metabolite	low
nimustine	aminopyrimidine; N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent	low
lonidamine	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector	low
vindesine	methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; primary carboxamide; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent	low
epirubicin	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor	low
diaziquone	1,4-benzoquinones; aziridines; carbamate ester; enamine	alkylating agent; antineoplastic agent	low
oltipraz	1,2-dithiole; pyrazines	angiogenesis modulating agent; antimutagen; antineoplastic agent; antioxidant; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; neurotoxin; protective agent; schistosomicide drug	low
fazarabine	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent	low
mitoxantrone hydrochloride	hydrochloride	antineoplastic agent	low
bisantrene	anthracenes; hydrazone; imidazolidines	antineoplastic agent	low
swainsonine	indolizidine alkaloid	antineoplastic agent; EC 3.2.1.114 (mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase) inhibitor; immunological adjuvant; plant metabolite	low
lovastatin	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug	low
cabergoline	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist	low
nitrogenase stabilizing-protective protein, bacteria	N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide	androgen antagonist; antineoplastic agent	low
bmy 25067	C-nitro compound; organic disulfide	antineoplastic agent	low
brequinar	biphenyls; monocarboxylic acid; monofluorobenzenes; quinolinemonocarboxylic acid	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor	low
imiquimod	imidazoquinoline	antineoplastic agent; interferon inducer	low
aromasil	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic	low
cidofovir anhydrous	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent	low
topotecan	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor	low
gemcitabine hydrochloride	hydrochloride; organofluorine compound	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral drug; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; immunosuppressive agent; radiosensitizing agent	low
gemcitabine	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic	low
capecitabine	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug	low
nelfinavir mesylate	methanesulfonate salt	antineoplastic agent; HIV protease inhibitor	low
nelfinavir	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor	low
betulinic acid	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite	low
baicalin	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug	low
ro 5-3335	1,4-benzodiazepinone; organochlorine compound; pyrroles	anti-HIV-1 agent; antineoplastic agent; HIV-1 Tat inhibitor; RUNX1 inhibitor	low
plerixafor	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant	low
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose	gallate ester; galloyl beta-D-glucose	anti-inflammatory agent; antineoplastic agent; geroprotector; hepatoprotective agent; plant metabolite; radiation protective agent; radical scavenger	low
pyrrolidine dithiocarbamate	dithiocarbamic acids; pyrrolidines	anticonvulsant; antineoplastic agent; geroprotector; neuroprotective agent; NF-kappaB inhibitor; radical scavenger	low
triptonide	butenolide; cyclic ketone; diterpene triepoxide; organic heteroheptacyclic compound	anti-inflammatory agent; antineoplastic agent; immunosuppressive agent	low
3'-deoxyadenosine 5'-triphosphate	purine ribonucleoside 5'-triphosphate	antifungal agent; antimetabolite; antineoplastic agent; antiviral agent	low
2-methoxyestradiol	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite	low
pinocembrin	(2S)-flavan-4-one; dihydroxyflavanone	antineoplastic agent; antioxidant; metabolite; neuroprotective agent; vasodilator agent	low
tangeretin	pentamethoxyflavone	antineoplastic agent; plant metabolite	low
ethinylestradiol-3-sulfate	17beta-hydroxy steroid; steroid sulfate	antineoplastic agent; estrogen	low
lonazolac	monocarboxylic acid; monochlorobenzenes; pyrazoles	antineoplastic agent; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	low
bromopyruvate	2-oxo monocarboxylic acid; organobromine compound; oxo carboxylic acid	alkylating agent; antineoplastic agent	low
enrofloxacin	cyclopropanes; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone	antibacterial agent; antimicrobial agent; antineoplastic agent	low
dexrazoxane	razoxane	antineoplastic agent; cardiovascular drug; chelator; immunosuppressive agent	low
masoprocol	nordihydroguaiaretic acid	antineoplastic agent; hypoglycemic agent; lipoxygenase inhibitor; metabolite	low
dw a 2114r	platinum coordination entity; pyrrolidines	antineoplastic agent	low
prednisolone phosphate	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; glucocorticoid; steroid phosphate; tertiary alpha-hydroxy ketone	anti-inflammatory agent; antineoplastic agent; glucocorticoid receptor agonist; prodrug	low
hesperetin	3'-hydroxyflavanones; 4'-methoxyflavanones; monomethoxyflavanone; trihydroxyflavanone	antineoplastic agent; antioxidant; plant metabolite	low
sesamin	benzodioxoles; furofuran; lignan	antineoplastic agent; neuroprotective agent; plant metabolite	low
betulin	diol; pentacyclic triterpenoid	analgesic; anti-inflammatory agent; antineoplastic agent; antiviral agent; metabolite	low
nobiletin	methoxyflavone	antineoplastic agent; plant metabolite	low
picropodophyllin	furonaphthodioxole; lignan; organic heterotetracyclic compound	antineoplastic agent; insulin-like growth factor receptor 1 antagonist; plant metabolite; tyrosine kinase inhibitor	low
kaurenoic acid	ent-kaurane diterpenoid	anti-HIV-1 agent; antineoplastic agent; plant metabolite	low
xanthomicrol	dihydroxyflavone; trimethoxyflavone	antineoplastic agent; plant metabolite	low
voacamine	alkaloid ester; methyl ester; monoterpenoid indole alkaloid; organic heteropentacyclic compound; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; plant metabolite	low
uvaretin	aromatic ether; dihydrochalcones; polyketide; resorcinol	antineoplastic agent; plant metabolite	low
fangchinoline	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite	low
maslinic acid	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite	low
5-(3-methyl-1-triazeno)imidazole-4-carboxamide	imidazoles; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent	low
hydroxyguanidine	guanidines; one-carbon compound	antineoplastic agent; antiviral agent	low
cryptolepine	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound	anti-inflammatory agent; antimalarial; antineoplastic agent; cysteine protease inhibitor; plant metabolite	low
bexarotene	benzoic acids; naphthalenes; retinoid	antineoplastic agent	low
3,4-dihydroxyphenylethanol	catechols; primary alcohol	antineoplastic agent; antioxidant; metabolite	low
terreic acid	arene epoxide; diketone; monohydroxy-1,4-benzoquinones; tertiary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; Aspergillus metabolite; EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; mycotoxin	low
4-methylumbelliferyl glucuronide	beta-D-glucosiduronic acid; coumarins; monosaccharide derivative	antineoplastic agent; chromogenic compound; hyaluronan synthesis inhibitor	low
9-hydroxyellipticine	organic heterotetracyclic compound; organonitrogen heterocyclic compound	antineoplastic agent	low
nimustine	hydrochloride	antineoplastic agent	low
beta-peltatin	furonaphthodioxole; gamma-lactone; lignan; organic heterotetracyclic compound; phenols	antineoplastic agent; plant metabolite	low
alpha-peltatin	furonaphthodioxole; gamma-lactone; lignan; organic heterotetracyclic compound; phenols	antineoplastic agent; metabolite	low
cryptopleurine	alkaloid antibiotic; alkaloid; aromatic ether; organic heteropentacyclic compound	antineoplastic agent; antiviral agent; protein synthesis inhibitor	low
sugiol	abietane diterpenoid; carbotricyclic compound; cyclic terpene ketone; meroterpenoid; phenols	antineoplastic agent; antioxidant; antiviral agent; plant metabolite; radical scavenger	low
1-methyltryptophan	non-proteinogenic alpha-amino acid; tryptophan derivative	antineoplastic agent; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor	low
alpha-glutamyltryptophan	dipeptide	angiogenesis modulating agent; antineoplastic agent; immunomodulator; metabolite	low
fulvestrant	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist	low
ici 164384	17beta-hydroxy steroid; 3-hydroxy steroid; tertiary carboxamide	anti-estrogen; antineoplastic agent; estrogen receptor antagonist	low
hc toxin	homodetic cyclic peptide; tetrapeptide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor; metabolite; phytotoxin	low
fingolimod	aminodiol; primary amino compound	antineoplastic agent; CB1 receptor antagonist; immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist	low
tamibarotene	dicarboxylic acid monoamide; retinoid; tetralins	antineoplastic agent; retinoic acid receptor alpha/beta agonist	low
ecteinascidin 743	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite	low
homoorientin	flavone C-glycoside; tetrahydroxyflavone	antineoplastic agent; radical scavenger	low
selenomethylselenocysteine	non-proteinogenic alpha-amino acid; selenocysteines	antineoplastic agent; human metabolite	low
tephrosin	aromatic ether; cyclic ketone; organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; pesticide	low
sc 58125	organofluorine compound; pyrazoles; sulfone	antineoplastic agent; cyclooxygenase 2 inhibitor	low
marimastat	hydroxamic acid; secondary carboxamide	antineoplastic agent; matrix metalloproteinase inhibitor	low
1'-acetoxychavicol acetate	acetate ester; phenylpropanoid	antineoplastic agent; NF-kappaB inhibitor; plant metabolite	low
clofarabine	adenosines; organofluorine compound	antimetabolite; antineoplastic agent	low
trapoxin a	epoxide; homodetic cyclic peptide; ketone	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor; fungal metabolite	low
celastrol	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite	low
4'-demethylepipodophyllotoxin	furonaphthodioxole; organic heterotetracyclic compound; phenols	antineoplastic agent	low
aminolevulinic acid hydrochloride	hydrochloride	antineoplastic agent; dermatologic drug; photosensitizing agent; prodrug	low
gefitinib	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	low
cgp 42112a	benzyl ester; oligopeptide; pyridinecarboxamide	angiotensin receptor agonist; anti-inflammatory agent; antineoplastic agent; neuroprotective agent; vasodilator agent	low
vadimezan	monocarboxylic acid; xanthones	antineoplastic agent	low
4-carbamoylimidazolium 5-olate	hydroxyimidazole; monocarboxylic acid amide	antineoplastic agent	low
nsc 224070	1,4-benzoquinones; aziridines; enamine; primary alcohol; secondary amino compound	alkylating agent; antineoplastic agent	low
psorospermin	epoxide; organic heterotetracyclic compound; xanthones	antineoplastic agent; plant metabolite	low
ay 25545	acetate ester; aromatic ether; C-glycosyl compound; naphthoisochromene; olefinic compound; phenols; tertiary amine	antimicrobial agent; antineoplastic agent; bacterial metabolite	low
methotrexate	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent	low
3,7-dihydroxytropolone	alpha-hydroxy ketone; cyclic ketone; enol; triol	antineoplastic agent; bacterial metabolite	low
delphinidin	5-hydroxyanthocyanidin	antineoplastic agent; biological pigment; plant metabolite	low
tamsulosin	5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide	alpha-adrenergic antagonist; antineoplastic agent	low
saintopin	tetracenequinones	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; fungal metabolite; intercalator	low
6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene	monoterpenoid; organobromine compound; organochlorine compound	algal metabolite; antineoplastic agent; marine metabolite	low
ilomastat	hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid	anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent	low
abiraterone	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; pyridines	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor	low
yakuchinone-a	ketone; monomethoxybenzene; phenols	antineoplastic agent; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; EC 1.14.13.39 (nitric oxide synthase) inhibitor; metabolite	low
pomalidomide	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator	low
selenomethylselenocysteine	amino acid zwitterion; L-selenocysteine derivative; non-proteinogenic L-alpha-amino acid; Se-methylselenocysteine	antineoplastic agent	low
10-propargyl-10-deazaaminopterin	N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor	low
docetaxel	hydrate; secondary alpha-hydroxy ketone	antineoplastic agent	low
docetaxel anhydrous	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent	low
lonafarnib	4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	low
aclacinomycin	aminoglycoside; anthracycline; deoxy hexoside; methyl ester; monosaccharide derivative; phenols; polyketide; tertiary alcohol; tetracenequinones; zwitterion	antimicrobial agent; antineoplastic agent; metabolite	low
6-azauridine-5'-monophosphate	N-glycosyl-1,2,4-triazine; nucleoside monophosphate analogue	antineoplastic agent; EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor	low
ptk 787	succinate salt	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	low
vatalanib	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	low
cyc 682	nitrile; nucleoside analogue; secondary carboxamide	antimetabolite; antineoplastic agent; DNA synthesis inhibitor; prodrug	low
canertinib	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	low
methyl 5-aminolevulinate hydrochloride	hydrochloride	antineoplastic agent; dermatologic drug; photosensitizing agent; prodrug	low
methyl 5-aminolevulinate	delta-amino acid ester	antineoplastic agent; dermatologic drug; photosensitizing agent; prodrug	low
aklavinone	anthracycline; methyl ester; tertiary alcohol; tetracenequinones	antineoplastic agent	low
i-677	L-serine derivative; non-proteinogenic L-alpha-amino acid	antimetabolite; antimicrobial agent; antineoplastic agent; metabolite	low
anonaine	aporphine alkaloid; organic heteropentacyclic compound; oxacycle	antineoplastic agent; antiplasmodial drug; trypanocidal drug	low
4'-demethyldesoxypodophyllotoxin	furonaphthodioxole; gamma-lactone; lignan; methoxybenzenes; phenols	antineoplastic agent; antioxidant; immunosuppressive agent; plant metabolite	low
salvigenin	monohydroxyflavone; trimethoxyflavone	antilipemic drug; antineoplastic agent; apoptosis inhibitor; autophagy inducer; hypoglycemic agent; immunomodulator; neuroprotective agent; plant metabolite	low
deferrioxamine e	cyclic desferrioxamine; cyclic hydroxamic acid; macrocycle	antineoplastic agent; bacterial metabolite; marine metabolite; siderophore	low
ampelopsin	dihydromyricetin; secondary alpha-hydroxy ketone	antineoplastic agent; antioxidant; metabolite	low
methylselenic acid	one-carbon compound; organoselenium compound	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor; human xenobiotic metabolite	low
acetyl aleuritolic acid	acetate ester; monocarboxylic acid; pentacyclic triterpenoid	antineoplastic agent; plant metabolite	low
withanolide d	20-hydroxy steroid; 4-hydroxy steroid; delta-lactone; enone; epoxy steroid; ergostanoid; secondary alcohol; tertiary alcohol; withanolide	antineoplastic agent	low
myricanone	aromatic ether; cyclic ketone; diarylheptanoid; methoxybenzenes; phenols	antineoplastic agent; plant metabolite	low
cirsilineol	dihydroxyflavone; trimethoxyflavone	antineoplastic agent; plant metabolite	low
6-methylthiohexyl isothiocyanate	isothiocyanate; methyl sulfide	antineoplastic agent; Arabidopsis thaliana metabolite; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; neuroprotective agent	low
albicanol	carbobicyclic compound; homoallylic alcohol; primary alcohol; sesquiterpenoid	antifeedant; antifungal agent; antineoplastic agent; fungal metabolite; mammalian metabolite; marine metabolite; plant metabolite	low
5-o-methylembelin	enol ether; monohydroxy-1,4-benzoquinones	antileishmanial agent; antineoplastic agent; hepatitis C protease inhibitor; metabolite	low
asperphenamate	benzamides; carboxylic ester; L-phenylalanine derivative	antineoplastic agent	low
erlotinib	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor	low
erlotinib hydrochloride	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor	low
corynoline	benzophenanthridine alkaloid; cyclic acetal; isoquinolines; organic heterohexacyclic compound; secondary alcohol	antineoplastic agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hepatoprotective agent; metabolite	low
helioxanthin	benzodioxoles; furonaphthodioxole; lignan	anti-HBV agent; antineoplastic agent; plant metabolite	low
top 53	furonaphthodioxole; gamma-lactone; organic heterotetracyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor	low
5-heptadecylresorcinol	5-alkylresorcinol	antineoplastic agent; plant metabolite	low
minquartynoic acid	acetylenic fatty acid; hydroxy polyunsaturated fatty acid; long-chain fatty acid; straight-chain fatty acid; tetrayne	antimalarial; antineoplastic agent; antiviral agent	low
scutellarin	glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antineoplastic agent; proteasome inhibitor	low
ergolide	acetate ester; cyclic ketone; gamma-lactone; organic heterotricyclic compound; sesquiterpene lactone	anti-inflammatory agent; antineoplastic agent; metabolite; NF-kappaB inhibitor; plant metabolite	low
2,5-dihydroxybenzyl alcohol	aromatic primary alcohol; phenols	antineoplastic agent; antioxidant; apoptosis inhibitor; fungal metabolite	low
chrysosplenol c	trihydroxyflavone; trimethoxyflavone	antineoplastic agent; antiviral agent; plant metabolite	low
lanperisone	2-methyl-3-(pyrrolidin-1-yl)-1-[4-(trifluoromethyl)phenyl]propan-1-one	antineoplastic agent; calcium channel blocker; ferroptosis inducer; muscle relaxant; voltage-gated sodium channel blocker	low
(-)-gallocatechin gallate	catechin; gallate ester; polyphenol	antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human xenobiotic metabolite; plant metabolite	low
orantinib	monocarboxylic acid; oxindoles; pyrroles	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	low
lapatinib	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor	low
firocoxib	butenolide; cyclopropanes; enol ether; sulfone	antineoplastic agent; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	low
2-(4-morpholinoanilino)-6-cyclohexylaminopurine	morpholines; purines; secondary amino compound; tertiary amino compound	adenosine A3 receptor antagonist; antineoplastic agent; Aurora kinase inhibitor; cell dedifferentiation agent	low
sorafenib	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor	low
lenalidomide	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator	low
lasofoxifene	aromatic ether; N-alkylpyrrolidine; naphthols; tetralins	antineoplastic agent; bone density conservation agent; cardioprotective agent; estrogen receptor agonist; estrogen receptor antagonist	low
l 778,123	hydrochloride	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor; radiosensitizing agent	low
l 778,123	imidazoles; monochlorobenzenes; nitrile; piperazinone; tertiary amino compound	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor	low
n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide	chloroindole; organochlorine compound; sulfonamide	antineoplastic agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor	low
diflomotecan	epsilon-lactone; organic heteropentacyclic compound; organofluorine compound; organonitrogen heterocyclic compound; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor	low
demecolcine	alkaloid; secondary amino compound	antineoplastic agent; microtubule-destabilising agent	low
dromostanolone propionate	3-oxo-5alpha-steroid; steroid ester	antineoplastic agent	low
vincaleukoblastine	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite	low
vincristine sulfate	organic sulfate salt	antineoplastic agent; geroprotector	low
anisomycin	monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic	anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor	low
estramustine	17beta-hydroxy steroid; carbamate ester; organochlorine compound	alkylating agent; antineoplastic agent; radiation protective agent	low
acivicin	isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound	antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite	low
wortmannin	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent	low
rocaglamide	monocarboxylic acid amide; monomethoxybenzene; organic heterotricyclic compound	antileishmanial agent; antineoplastic agent; metabolite	low
acronine	acridone derivatives; alkaloid	antineoplastic agent; metabolite	low
taiwanin c	benzodioxoles; furonaphthodioxole; lignan	antineoplastic agent; plant metabolite; platelet aggregation inhibitor	low
o-(chloroacetylcarbamoyl)fumagillol	carbamate ester; organochlorine compound; semisynthetic derivative; sesquiterpenoid; spiro-epoxide	angiogenesis inhibitor; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; methionine aminopeptidase 2 inhibitor; retinoic acid receptor alpha antagonist	low
bortezomib	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor	low
carnosine	amino acid zwitterion; dipeptide	anticonvulsant; antineoplastic agent; antioxidant; Daphnia magna metabolite; geroprotector; human metabolite; mouse metabolite; neuroprotective agent	low
puromycin	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor	low
pentostatin	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor	low
canaline	amino acid zwitterion; non-proteinogenic L-alpha-amino acid	antimetabolite; antineoplastic agent; phytogenic insecticide; plant metabolite	low
hippeastrine	delta-lactone; indole alkaloid; organic heteropentacyclic compound; secondary alcohol	antineoplastic agent; metabolite	low
glaucarubinone	carboxylic ester; organic heteropentacyclic compound; quassinoid; secondary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone; tetrol	antimalarial; antineoplastic agent; geroprotector; plant metabolite	low
ginsenoside re	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; nephroprotective agent; neuroprotective agent; plant metabolite	low
ferruginol	abietane diterpenoid; carbotricyclic compound; meroterpenoid; phenols	antibacterial agent; antineoplastic agent; plant metabolite; protective agent	low
stevioside	beta-D-glucoside; bridged compound; diterpene glycoside; ent-kaurane diterpenoid; tetracyclic diterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; hypoglycemic agent; plant metabolite; sweetening agent	low
decursinol	cyclic ether; delta-lactone; organic heterotricyclic compound; secondary alcohol	analgesic; antineoplastic agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite	low
naringin	(2S)-flavan-4-one; 4'-hydroxyflavanones; dihydroxyflavanone; disaccharide derivative; neohesperidoside	anti-inflammatory agent; antineoplastic agent; metabolite	low
eugeniin	beta-D-glucoside; ellagitannin; gallate ester; lactone	anti-HSV-1 agent; antifungal agent; antineoplastic agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; metabolite	low
knipholone	aromatic ketone; dihydroxyanthraquinone; methoxybenzenes; methyl ketone; polyphenol; resorcinols	antineoplastic agent; antioxidant; antiplasmodial drug; leukotriene antagonist; metabolite	low
gingerol	beta-hydroxy ketone; guaiacols	antineoplastic agent; plant metabolite	low
mucronulatol	hydroxyisoflavans; methoxyisoflavan	antineoplastic agent; plant metabolite	low
syringaresinol	syringaresinol	antineoplastic agent	low
enkephalin, methionine	pentapeptide; peptide zwitterion	analgesic; antineoplastic agent; delta-opioid receptor agonist; human metabolite; mu-opioid receptor agonist	low
sodium arsenite	arsenic molecular entity; inorganic sodium salt	antibacterial agent; antifungal agent; antineoplastic agent; carcinogenic agent; herbicide; insecticide; rodenticide	low
surfactin c	cyclodepsipeptide; lipopeptide antibiotic; macrocyclic lactone	antibacterial agent; antifungal agent; antineoplastic agent; antiviral agent; metabolite; platelet aggregation inhibitor; surfactant	low
kerriamycin b	angucycline antibiotic	antineoplastic agent	low
tretinoin	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule	low
docosahexaenoate	docosahexaenoic acid; omega-3 fatty acid	algal metabolite; antineoplastic agent; Daphnia tenebrosa metabolite; human metabolite; mouse metabolite; nutraceutical	low
eicosapentaenoic acid	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical	low
mycophenolic acid	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic	low
formycin	formycin	antineoplastic agent	low
neocarzinostatin chromophore	cyclopentacyclononaoxirene; D-galactosaminide; dioxolane; monosaccharide derivative; naphthoate ester	antineoplastic agent	low
adenosine-5'-(n-ethylcarboxamide)	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent	low
n(1)-guanyl-1,7-diaminoheptane	guanidines; primary amino compound	antineoplastic agent; EC 2.5.1.46 (deoxyhypusine synthase) inhibitor	low
diethylstilbestrol	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen	low
epothilone a	epothilone; epoxide	antineoplastic agent; metabolite; microtubule-stabilising agent; tubulin modulator	low
8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine	6-aminopurines; acetylenic compound; methoxybenzenes; monochlorobenzenes; organofluorine compound	antineoplastic agent; Hsp90 inhibitor	low
alitretinoin	retinoic acid	antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist	low
afimoxifene	phenols; tertiary amino compound	antineoplastic agent; estrogen receptor antagonist; metabolite	low
teniposide	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor	low
steviol	bridged compound; ent-kaurane diterpenoid; monocarboxylic acid; tertiary allylic alcohol; tetracyclic diterpenoid	antineoplastic agent	low
tiazofurin	1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide	antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug	low
azaserine	carboxylic ester; diazo compound; L-serine derivative; non-proteinogenic L-alpha-amino acid	antifungal agent; antimetabolite; antimicrobial agent; antineoplastic agent; glutamine antagonist; immunosuppressive agent; metabolite	low
melphalan	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent	low
prinomastat	aromatic ether; hydroxamic acid; pyridines; sulfonamide; thiomorpholines	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; matrix metalloproteinase inhibitor	low
rubitecan	C-nitro compound; delta-lactone; pyranoindolizinoquinoline; semisynthetic derivative; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug	low
arsenic trioxide	arsenic oxide	antineoplastic agent; insecticide	low
isoliquiritigenin	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist	low
antofine	alkaloid antibiotic; alkaloid; aromatic ether; organic heteropentacyclic compound	angiogenesis inhibitor; anti-inflammatory agent; antimicrobial agent; antineoplastic agent; antiviral agent; phytotoxin; plant metabolite	low
vedelianin	cyclic ether; organic heterotricyclic compound; resorcinols; stilbenoid	antineoplastic agent; plant metabolite	low
s 1033	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	low
trilostane	17beta-hydroxy steroid; 3-hydroxy steroid; androstanoid; epoxy steroid; nitrile	abortifacient; antineoplastic agent; EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor	low
leuprolide acetate	acetate salt	antineoplastic agent; gonadotropin releasing hormone agonist	low
leuprolide	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist	low
mercaptopurine	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent	low
iFSP1	aromatic amine; nitrile; primary amino compound; pyridobenzimidazole; toluenes	antineoplastic agent; ferroptosis inducer; ferroptosis suppressor protein 1 inhibitor	low
curcumin	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger	low
xl147	aromatic amine; benzothiadiazole; quinoxaline derivative; sulfonamide	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	low
mcb-613	cyclic ketone; enone; pyridines	antineoplastic agent; steroid receptor coactivator stimulator	low
thioguanine anhydrous	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent	low
tamoxifen	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator	low
stattic	1-benzothiophenes; C-nitro compound; sulfone	antineoplastic agent; radiosensitizing agent; STAT3 inhibitor	low
krn 7000	glycophytoceramide; N-acyl-beta-D-galactosylphytosphingosine	allergen; antigen; antineoplastic agent; epitope; immunological adjuvant	low
monastrol	enoate ester; ethyl ester; phenols; racemate; thioureas	antileishmanial agent; antimitotic; antineoplastic agent; EC 3.5.1.5 (urease) inhibitor	low
toremifene	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator	low
beauvericin	cyclodepsipeptide	antibiotic insecticide; antifungal agent; antineoplastic agent; apoptosis inhibitor; fungal metabolite; ionophore; mycotoxin; P450 inhibitor	low
nelarabine	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug	low
manool	labdane diterpenoid; tertiary alcohol	antibacterial agent; antineoplastic agent; plant metabolite	low
amrubicin	anthracycline antibiotic; methyl ketone; primary amino compound; quinone; tetracenes	antineoplastic agent; prodrug; topoisomerase II inhibitor	low
ospemifene	aromatic ether; organochlorine compound; primary alcohol	anti-inflammatory agent; antineoplastic agent; estrogen receptor modulator	low
tandutinib	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
dasatinib	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	low
emetine dihydrochloride	hydrochloride	anticoronaviral agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; protein synthesis inhibitor	low
zd 6474	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor	low
l 663536	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist	low
ginkgetin	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	anti-HSV-1 agent; antineoplastic agent; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; metabolite	low
eupatilin	dihydroxyflavone; trimethoxyflavone	anti-inflammatory agent; anti-ulcer drug; antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; metabolite	low
quercetin	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger	low
biochanin a	4'-methoxyisoflavones; 7-hydroxyisoflavones	antineoplastic agent; EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; phytoestrogen; plant metabolite; tyrosine kinase inhibitor	low
vitexin	C-glycosyl compound; trihydroxyflavone	antineoplastic agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite; platelet aggregation inhibitor	low
apigenin	trihydroxyflavone	antineoplastic agent; metabolite	low
calcitriol	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical	low
hymecromone	hydroxycoumarin	antineoplastic agent; hyaluronic acid synthesis inhibitor	low
chrysoeriol	monomethoxyflavone; trihydroxyflavone	antineoplastic agent; antioxidant; metabolite	low
dexmedetomidine	trihydroxyflavone; trimethoxyflavone	antineoplastic agent; metabolite	low
bryostatin 1	acetate ester; bryostatins; cyclic hemiketal; enoate ester; methyl ester; organic heterotetracyclic compound; secondary alcohol	alpha-secretase activator; anti-HIV-1 agent; antineoplastic agent; marine metabolite; protein kinase C agonist	low
quercetin 3-o-glucopyranoside	beta-D-glucoside; monosaccharide derivative; quercetin O-glucoside; tetrahydroxyflavone	antineoplastic agent; antioxidant; antipruritic drug; bone density conservation agent; geroprotector; histamine antagonist; osteogenesis regulator; plant metabolite	low
9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2	prostaglandins J; secondary alcohol	antineoplastic agent; antiviral agent	low
genistein	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor	low
pyrvinium	quinolinium ion	anthelminthic drug; antineoplastic agent	low
cyclobenzaprine	9,11,13-octadecatrienoic acid	antineoplastic agent; plant metabolite	low
butein	chalcones; polyphenol	antineoplastic agent; antioxidant; EC 1.1.1.21 (aldehyde reductase) inhibitor; geroprotector; hypoglycemic agent; plant metabolite; radiosensitizing agent; tyrosine kinase inhibitor	low
cucurbitacin i	cucurbitacin; tertiary alpha-hydroxy ketone	antineoplastic agent; plant metabolite	low
daphnoretin	aromatic ether; hydroxycoumarin	antineoplastic agent; antiviral agent; metabolite	low
costunolide	germacranolide; heterobicyclic compound	anthelminthic drug; antiinfective agent; antineoplastic agent; antiparasitic agent; antiviral drug; metabolite	low
eupatolide	gamma-lactone; germacranolide; homoallylic alcohol; secondary alcohol	antineoplastic agent; plant metabolite	low
agathisflavone	biaryl; biflavonoid; hydroxyflavone	antineoplastic agent; antiviral agent; hepatoprotective agent; metabolite	low
chrysin	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite	low
hinokiflavone	aromatic ether; biflavonoid; hydroxyflavone	antineoplastic agent; metabolite; neuroprotective agent	low
gartanin	polyphenol; xanthones	antineoplastic agent; plant metabolite	low
mangostin	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite	low
norathyriol	polyphenol; xanthones	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor; plant metabolite	low
morin	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent	low
morusin	extended flavonoid; trihydroxyflavone	antineoplastic agent; plant metabolite	low
myricetin	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite	low
robustaflavone	biflavonoid; hydroxyflavone; ring assembly	anti-HBV agent; antineoplastic agent; antioxidant; metabolite	low
tricetin	pentahydroxyflavone	antineoplastic agent; metabolite	low
wogonin	dihydroxyflavone; monomethoxyflavone	angiogenesis inhibitor; antineoplastic agent; cyclooxygenase 2 inhibitor; plant metabolite	low
daidzein	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite	low
astringin	beta-D-glucoside; monosaccharide derivative; polyphenol; stilbenoid	antineoplastic agent; antioxidant; metabolite	low
irilone	hydroxyisoflavone; organic heterotricyclic compound; oxacycle	antineoplastic agent; immunomodulator; metabolite	low
caffeic acid phenethyl ester	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent	low
maytansine	alpha-amino acid ester; carbamate ester; epoxide; maytansinoid; organic heterotetracyclic compound; organochlorine compound	antimicrobial agent; antimitotic; antineoplastic agent; plant metabolite; tubulin modulator	low
tectochrysin	monohydroxyflavone; monomethoxyflavone	antidiarrhoeal drug; antineoplastic agent; plant metabolite	low
tranilast	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent	low
4'-hydroxychalcone	chalcones; phenols	anti-inflammatory agent; antineoplastic agent	low
isotretinoin	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent	low
camostat mesylate	methanesulfonate salt	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor	low
sirolimus	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor	low
3',4',7-trihydroxyisoflavone	7-hydroxyisoflavones	antineoplastic agent; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor; metabolite	low
fenretinide	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant	low
geldanamycin	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor	low
4-oxoretinol	cyclic ketone; enone; primary allylic alcohol; retinoid	antineoplastic agent	low
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid	benzoic acids; naphthalenes; retinoid	antineoplastic agent; retinoic acid receptor agonist; teratogenic agent	low
vinorelbine	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent	low
centaureidin	trihydroxyflavone; trimethoxyflavone	antineoplastic agent; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; plant metabolite	low
ethyl caffeate	alkyl caffeate ester; ethyl ester; hydroxycinnamic acid	anti-inflammatory agent; antineoplastic agent; metabolite	low
andrographolide	carbobicyclic compound; gamma-lactone; labdane diterpenoid; primary alcohol; secondary alcohol	anti-HIV agent; anti-inflammatory drug; antineoplastic agent; metabolite	low
isoginkgetin	aromatic ether; biflavonoid	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; plant metabolite	low
cudraflavone c	tetrahydroxyflavone	antibacterial agent; antineoplastic agent; plant metabolite	low
neobavaisoflavone	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; plant metabolite; platelet aggregation inhibitor	low
neoglycyrol	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; plant metabolite	low
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	dihydroxyflavone; monomethoxyflavone	antineoplastic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor	low
spiraeoside	beta-D-glucoside; flavonols; monosaccharide derivative; quercetin O-glucoside; tetrahydroxyflavone	antineoplastic agent; antioxidant; plant metabolite	low
rhamnazin	aromatic ether; dimethoxyflavone; phenols; trihydroxyflavone	antineoplastic agent; plant metabolite	low
bosutinib	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor	low
semaxinib	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	low
su 11248	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist	low
palbociclib	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
reumycin	carbonyl compound; pyrimidotriazine	antimicrobial agent; antineoplastic agent; bacterial metabolite	low
ergosterol-5,8-peroxide	3beta-sterol; ergostanoid; organic peroxide; phytosterols	antimycobacterial drug; antineoplastic agent; metabolite; trypanocidal drug	low
romidepsin	cyclodepsipeptide; heterocyclic antibiotic; organic disulfide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor	low
macluraxanthone b	phenols; xanthones	anti-HIV agent; antineoplastic agent; metabolite	low
tamsulosin hydrochloride	hydrochloride	alpha-adrenergic antagonist; antineoplastic agent	low
batimastat	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor	low
glyceryl behenate	1-monoglyceride; fatty acid ester	antineoplastic agent; plant metabolite	low
5,7,3'-trihydroxy-3,4'-dimethoxyflavone	dimethoxyflavone; trihydroxyflavone	antineoplastic agent; metabolite	low
pederin	cyclic ketal; diol; oxanes; polyketide; secondary alcohol; secondary carboxamide	antimitotic; antineoplastic agent; bacterial metabolite; vesicant	low
artocarpin lectin	monomethoxyflavone; trihydroxyflavone	antineoplastic agent; metabolite	low
bleomycin	bleomycin	antineoplastic agent; metabolite	low
beta-aminopropionitrile fumarate (2:1)	fumarate salt	antineoplastic agent; antirheumatic drug; collagen cross-linking inhibitor; plant metabolite	low
gamma-mangostin	phenols; xanthones	antineoplastic agent; plant metabolite; protein kinase inhibitor	low
demethoxycurcumin	beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antineoplastic agent; metabolite	low
cystothiazole a	1,3-thiazoles; biaryl; enoate ester; enol ether; methyl ester; organonitrogen heterocyclic antibiotic	antifungal agent; antineoplastic agent; bacterial metabolite	low
arglabin	epoxide; gamma-lactone; organic heterotetracyclic compound; sesquiterpene lactone	antineoplastic agent; metabolite	low
ma-1	carboxamidine; organochlorine compound; pyrimidone; pyrrolidines	antineoplastic agent; EC 2.4.2.4 (thymidine phosphorylase) inhibitor	low
apratoxin a	1,3-thiazoles; apratoxin	antineoplastic agent; metabolite	low
ascofuranone	dihydroxybenzaldehyde; meroterpenoid; monochlorobenzenes; olefinic compound; resorcinols; sesquiterpenoid; tetrahydrofuranone	angiogenesis inhibitor; antilipemic drug; antineoplastic agent; antiprotozoal drug; fungal metabolite	low
rhizoxin	1,3-oxazoles; epoxide; macrolide antibiotic	antimitotic; antineoplastic agent; metabolite	low
sibiromycin	aminoglycoside antibiotic; hemiaminal; phenols; pyrrolobenzodiazepine	antineoplastic agent; bacterial metabolite	low
bryostatin 2	bryostatins; cyclic hemiketal; enoate ester; methyl ester; organic heterotetracyclic compound; secondary alcohol	antineoplastic agent; marine metabolite; protein kinase C agonist	low
asukamycin	enamide; epoxide; organic heterobicyclic compound; polyketide; secondary carboxamide; tertiary alcohol	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; bacterial metabolite	low
everolimus	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor	low
13(S)-HODE	HODE	antineoplastic agent; human xenobiotic metabolite; mouse metabolite	low
ixabepilone	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent	low
axitinib	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist	low
l 744832	benzenes; ether; isopropyl ester; secondary carboxamide; sulfone; thiol	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; geroprotector	low
sophoraflavanone a	(2S)-flavan-4-one; 4'-hydroxyflavanones; trihydroxyflavanone	antibacterial agent; antineoplastic agent; metabolite	low
aureothin	4-pyranones; C-nitro compound; ketene acetal; olefinic compound; oxolanes	antibacterial agent; antifungal agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor	low
fostriecin	2-pyranones; olefinic compound; phosphate monoester; polyketide; primary allylic alcohol; secondary allylic alcohol; triol	antineoplastic agent; apoptosis inhibitor; bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; topoisomerase II inhibitor	low
artesunate	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer	low
ru 58668	17beta-hydroxy steroid; 3-hydroxy steroid; aromatic ether; organofluorine compound; sulfone	anti-estrogen; antineoplastic agent; estrogen receptor antagonist	low
beta-elemene	beta-elemene	antineoplastic agent	low
laulimalide	carboxylic ester; epoxide; macrolide; secondary alcohol; secondary allylic alcohol	animal metabolite; antimitotic; antineoplastic agent; marine metabolite; microtubule-stabilising agent	low
jwh-133	benzochromene; dibenzopyran; organic heterotricyclic compound	analgesic; anti-inflammatory agent; antineoplastic agent; apoptosis inhibitor; CB2 receptor agonist; opioid analgesic; vasodilator agent	low
belinostat	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor	low
panobinostat	cinnamamides; hydroxamic acid; methylindole; secondary amino compound	angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor	low
bml 210	dicarboxylic acid diamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor	low
bufalin	14beta-hydroxy steroid; 3beta-hydroxy steroid	animal metabolite; anti-inflammatory agent; antineoplastic agent; cardiotonic drug	low
rhosin	D-tryptophan derivative; hydrazone; quinoxaline derivative	antineoplastic agent; RhoA inhibitor; RhoC inhibitor	low
s-allylcysteine	L-alpha-amino acid zwitterion; S-hydrocarbyl-L-cysteine	antineoplastic agent; metabolite	low
plitidepsin	didemnin	anticoronaviral agent; antineoplastic agent; marine metabolite	low
abiraterone acetate	pyridines; sterol ester	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor; prodrug	low
lenvatinib	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist	low
nsc 716970	aromatic amine; aromatic ether; indolecarboxamide; organochlorine compound	antineoplastic agent	low
pd 0325901	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor	low
midostaurin	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	low
muromonab-cd3	alkaloid; macrocycle; organic heteropentacyclic compound; organonitrogen heterocyclic compound; oxacycle; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; IP3 receptor antagonist; marine metabolite	low
ginsenoside m1	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; hepatoprotective agent; plant metabolite	low
cabazitaxel	tetracyclic diterpenoid	antineoplastic agent; microtubule-stabilising agent	low
elisidepsin	cyclodepsipeptide	antineoplastic agent	low
fr 148083	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor	low
tln 4601	dibenzodiazepine; farnesane sesquiterpenoid; olefinic compound; secondary amine; triol	antineoplastic agent; antioxidant; cathepsin L (EC 3.4.22.15) inhibitor	low
tmc-95a	indoles; lactam; macrocycle; phenols; secondary alcohol; tertiary alcohol	antimicrobial agent; antineoplastic agent; bacterial metabolite; fungal metabolite; proteasome inhibitor	low
9-methoxycanthin-6-one	aromatic ether; indole alkaloid; organic heterotetracyclic compound	antineoplastic agent; antiplasmodial drug; metabolite	low
topopyrone c	naphthochromene; p-quinones; phenols	antimicrobial agent; antineoplastic agent; antiviral agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; Penicillium metabolite	low
pi103	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	low
5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride	hydrochloride; iminium salt	antineoplastic agent; EC 2.4.2.4 (thymidine phosphorylase) inhibitor	low
fty 720p	monoalkyl phosphate; primary alcohol; primary amino compound	antineoplastic agent; immunosuppressive agent; sphingosine-1-phosphate receptor agonist	low
hki 272	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor	low
es-285	amino alcohol; sphingoid	antineoplastic agent	low
nidulalin a	methyl ester; phenols; xanthones	antimicrobial agent; antineoplastic agent; Penicillium metabolite	low
hypothemycin	aromatic ether; diol; enone; epoxide; macrolide; phenols; polyketide; secondary alpha-hydroxy ketone	antifungal agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; fungal metabolite	low
rucaparib	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	low
pasireotide	homodetic cyclic peptide; peptide hormone	antineoplastic agent	low
rubraxanthone	aromatic ether; polyphenol; xanthones	antibacterial agent; antineoplastic agent; metabolite	low
sr 11302	alpha,beta-unsaturated monocarboxylic acid; retinoid; toluenes	antineoplastic agent; AP-1 antagonist	low
sch 51344	aromatic amine; aromatic ether; primary alcohol; pyrazoloquinoline; secondary amino compound	antineoplastic agent	low
4alpha-methylergosta-8,24(28)-dien-3,7,11-trione-26-oic acid	11-oxo steroid; 3-oxo steroid; 7-oxo steroid; ergostanoid; monocarboxylic acid; steroid acid	anti-inflammatory agent; antineoplastic agent; plant metabolite	low
cerberin	acetate ester; cardenolide glycoside; monosaccharide derivative	antineoplastic agent; metabolite	low
pateamine a	1,3-thiazoles; macrodiolide; olefinic compound; primary amino compound; tertiary amino compound	antineoplastic agent; antiviral agent; eukaryotic initiation factor 4F inhibitor; marine metabolite	low
6-hydroxytaxol	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent	low
masitinib	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor	low
ageladine a	alkaloid; aromatic amine; imidazopyridine; organobromine compound; pyrroles	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor; metabolite	low
ly-2157299	aromatic amide; methylpyridines; monocarboxylic acid amide; pyrrolopyrazole; quinolines	antineoplastic agent; TGFbeta receptor antagonist	low
pazopanib	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist	low
azd 6244	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
bibw 2992	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor	low
jte 013	chloropyridine; pyrazolopyridine	anti-asthmatic agent; anti-inflammatory agent; antineoplastic agent; osteogenesis regulator; pro-angiogenic agent; sphingosine-1-phosphate receptor 2 antagonist	low
holomycin	acetamides; dithiolopyrrolone antibiotic	antibacterial agent; antineoplastic agent; bacterial metabolite; chelator; EC 2.7.7.6 (RNA polymerase) inhibitor; marine metabolite	low
trilobacin	butenolide; polyketide; triol	antineoplastic agent; plant metabolite	low
manassantin b	benzodioxoles; dimethoxybenzene; lignan; oxolanes; secondary alcohol	antineoplastic agent; metabolite	low
pha 665752	dichlorobenzene; enamide; indolones; N-acylpyrrolidine; pyrrolecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide	antineoplastic agent; c-Met tyrosine kinase inhibitor	low
tmc-95b	indoles; lactam; macrocycle; phenols; secondary alcohol; tertiary alcohol	antimicrobial agent; antineoplastic agent; fungal metabolite; proteasome inhibitor	low
fr 901464	acetate ester; cyclic hemiketal; monocarboxylic acid amide; pyrans; spiro-epoxide	antimicrobial agent; antineoplastic agent; bacterial metabolite	low
vinflunine	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; semisynthetic derivative; vinca alkaloid	antineoplastic agent	low
homocamptothecin	epsilon-lactone; organic heteropentacyclic compound; organonitrogen heterocyclic compound; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor	low
3,5-dimethoxy-4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranoside	aromatic ether; benzyl alcohols; beta-D-glucoside; monosaccharide derivative; primary alcohol	antineoplastic agent; metabolite	low
jaspamide b	cyclodepsipeptide; organobromine compound	animal metabolite; antineoplastic agent; marine metabolite	low
ossamycin	cyclic hemiketal; macrolide antibiotic; organic heterotetracyclic compound; secondary alcohol; spiroketal; tertiary alcohol	antineoplastic agent; bacterial metabolite	low
nigranoic acid	dicarboxylic acid; tetracyclic triterpenoid	antineoplastic agent; HIV-1 reverse transcriptase inhibitor; metabolite	low
esculeoside a	azaspiro compound; oxaspiro compound; saponin; steroid alkaloid; steroid saponin	antineoplastic agent; metabolite	low
azadirone	acetate ester; cyclic terpene ketone; furans; limonoid; tetracyclic triterpenoid	antineoplastic agent; antiplasmodial drug; plant metabolite	low
iejimalide b	ether; formamides; macrolide	antineoplastic agent; marine metabolite	low
migrastatin	ether; macrolide antibiotic; piperidones; secondary alcohol	antineoplastic agent; metabolite	low
cembra-2,7,11-triene-4,6-diol	cembrane diterpenoid	antineoplastic agent	low
2,3,6,8-tetrahydroxy-1-(3-methylbut-2-enyl)-5-(2-methylbut-3-en-2-yl)-9h-xanthen-9-one	polyphenol; xanthones	anti-inflammatory agent; antineoplastic agent; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; metabolite	low
regorafenib	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor	low
at 7867	monochlorobenzenes; piperidines; pyrazoles	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	low
bielschowskysin	acetate ester; cyclic acetal; diterpenoid; gamma-lactone; organic heterohexacyclic compound	antimalarial; antineoplastic agent; metabolite	low
erastin	aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide	antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor	low
ascochlorin	cyclohexanones; dihydroxybenzaldehyde; meroterpenoid; monochlorobenzenes; olefinic compound; resorcinols; sesquiterpenoid	angiogenesis inhibitor; antifungal agent; antineoplastic agent; antiprotozoal drug; fungal metabolite	low
spiculoic acid a	carbobicyclic compound; cyclic ketone; oxo monocarboxylic acid; styrenes	antineoplastic agent; metabolite	low
N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide	D-valine derivative; hydroxamic acid	antineoplastic agent; autophagy inducer; EC 3.4.24.24 (gelatinase A) inhibitor; melanin synthesis inhibitor	low
at 7519	dichlorobenzene; piperidines; pyrazoles; secondary carboxamide	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
ym 216391	1,3-oxazoles; 1,3-thiazoles; azamacrocycle; benzenes; heterodetic cyclic peptide	antineoplastic agent; bacterial metabolite	low
marizomib	beta-lactone; gamma-lactam; organic heterobicyclic compound; organochlorine compound; salinosporamide	antineoplastic agent; proteasome inhibitor	low
er-086526	cyclic ketal; cyclic ketone; macrocycle; polycyclic ether; polyether; primary amino compound	antineoplastic agent; microtubule-destabilising agent	low
obolactone	2-pyranones; 4-pyranones	antineoplastic agent; plant metabolite	low
episilvestrol	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite	low
abt 869	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
azd 1152	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug	low
pf 00299804	enamide; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	low
carfilzomib	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor	low
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	aminopyridine; aromatic ether; dichlorobenzene; organofluorine compound; pyrazolylpiperidine; racemate	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
crizotinib	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
zstk474	benzimidazoles; morpholines; organofluorine compound; triamino-1,3,5-triazine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	low
trametinib	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	low
lyoniresinol	dimethoxybenzene; lignan; polyphenol; primary alcohol; tetralins	antineoplastic agent; metabolite	low
GDC-0879	indanes; ketoxime; primary alcohol; pyrazoles; pyridines	antineoplastic agent; B-Raf inhibitor	low
physalin b	enone; lactone; organic heteroheptacyclic compound; physalin	antimalarial; antimicrobial agent; antineoplastic agent	low
silvestrol	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite	low
at 13387	benzamides; isoindoles; N-alkylpiperazine; resorcinols; tertiary carboxamide	antineoplastic agent; Hsp90 inhibitor	low
dactolisib	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	low
bgt226	aromatic ether; imidazoquinoline; N-arylpiperazine; organofluorine compound; pyridines	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	low
2'-methoxykurarinone	4'-hydroxyflavanones; dihydroxyflavanone; dimethoxyflavanone	antineoplastic agent; metabolite	low
gedunin	acetate ester; enone; epoxide; furans; lactone; limonoid; organic heteropentacyclic compound; pentacyclic triterpenoid	antimalarial; antineoplastic agent; Hsp90 inhibitor; plant metabolite	low
monascin	alpha,beta-unsaturated ketone; gamma-lactone; organic heterotricyclic compound; polyketide	antilipemic drug; antineoplastic agent; fungal metabolite; PPARgamma agonist	low
monascorubrin	azaphilone; enone; gamma-lactone; polyketide; triketone	anti-inflammatory agent; antineoplastic agent; biological pigment; food colouring; fungal metabolite; Hsp90 inhibitor	low
5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4h-1-benzopyran-4-one	alkaloid; chromones; hydroxypiperidine; resorcinols; tertiary amino compound	anti-inflammatory agent; anti-ulcer drug; anticholesteremic drug; antileishmanial agent; antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; fungal metabolite; plant metabolite	low
SYC-435	benzenes; cyclic hydroxamic acid; pyridone	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor	low
ligstroside	beta-D-glucoside; diester; methyl ester; phenols; pyrans; secoiridoid glycoside	antineoplastic agent; plant metabolite	low
mogrol	hydroxy seco-steroid; tetracyclic triterpenoid	antineoplastic agent	low
simalikalactone D	cyclic ether; delta-lactone; enone; organic heteropentacyclic compound; quassinoid; secondary alcohol; secondary alpha-hydroxy ketone; triol	antimalarial; antineoplastic agent; antiviral agent; metabolite	low
4-methyl-5-pentylbenzene-1,3-diol	resorcinols	antineoplastic agent	low
mdv 3100	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent	low
azd 1152-hqpa	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor	low
adonixanthin	carotenone; cyclic ketone; secondary alcohol	algal metabolite; animal metabolite; antineoplastic agent; bacterial metabolite; marine metabolite; plant metabolite	low
schweinfurthin g	cyclic ether; organic heterotricyclic compound; resorcinols; stilbenoid	antineoplastic agent; metabolite	low
abarelix	polypeptide	antineoplastic agent; hormone antagonist	low
gastrin 17	gastrin	antineoplastic agent	low
gdc-0973	aromatic amine; difluorobenzene; N-acylazetidine; organoiodine compound; piperidines; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
buparlisib	aminopyridine; aminopyrimidine; morpholines; organofluorine compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	low
tubocapsanolide a	4-hydroxy steroid; delta-lactone; enone; epoxy steroid; ergostanoid; secondary alcohol; withanolide	antineoplastic agent; NF-kappaB inhibitor	low
ro5126766	aryloxypyrimidine; coumarins; organofluorine compound; pyridines; sulfamides	antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
gsk690693	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	low
cnf 2024	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor	low
ku 0063794	benzyl alcohols; monomethoxybenzene; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; mTOR inhibitor	low
respirantin	benzamides; cyclodepsipeptide; formamides; phenols	antimicrobial agent; antineoplastic agent; metabolite	low
berkeleydione	beta-diketone; cyclic terpene ketone; meroterpenoid; methyl ester; organic heterotetracyclic compound; terpene lactone; tertiary alcohol; tertiary alpha-hydroxy ketone	antineoplastic agent; cysteine protease inhibitor; Penicillium metabolite	low
lucidenic acid n	cyclic terpene ketone; dioxo monocarboxylic acid; secondary alcohol; tetracyclic triterpenoid	antineoplastic agent; EC 3.1.1.8 (cholinesterase) inhibitor; metabolite	low
bromophycolide a	diterpenoid; macrolide; organobromine compound; phenols; tertiary alcohol	anti-HIV agent; antibacterial agent; antifungal agent; antimalarial; antineoplastic agent; metabolite	low
meclofenamate sodium anhydrous	hydrate	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug	low
brequinar sodium	organic sodium salt	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor	low
plx 4720	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor	low
aspergillide b	bridged compound; cyclic ether; macrolide; secondary alcohol	antineoplastic agent; Aspergillus metabolite	low
tenovin-6	monocarboxylic acid amide; tertiary amino compound; thioureas	antineoplastic agent; p53 activator; Sir2 inhibitor	low
lde225	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist	low
gdc 0449	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent	low
bms 754807	pyrazoles; pyridines; pyrrolidines; pyrrolotriazine	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
marinopyrrole a	aromatic ketone; organochlorine compound; phenols; pyrroles	antibacterial agent; antimicrobial agent; antineoplastic agent; bacterial metabolite; marine metabolite	low
grassypeptolide	cyclodepsipeptide; macrocycle	antineoplastic agent; metabolite	low
pci 32765	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	low
ponatinib	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor	low
spiruchostatin b	macrocyclic lactone; organic disulfide; organic heterobicyclic compound; spiruchostatin	antineoplastic agent; bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor	low
AMG-208	aromatic ether; quinolines; triazolopyridazine	antineoplastic agent; c-Met tyrosine kinase inhibitor	low
papuamide b	cyclodepsipeptide; olefinic compound; secondary alcohol; tertiary alcohol	anti-HIV-1 agent; antineoplastic agent; marine metabolite	low
antroquinonol d	enol ether; enone; secondary alcohol	antineoplastic agent; fungal metabolite	low
quizartinib	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor	low
6-methoxyspirotryprostatin b	aromatic ether; azaspiro compound; indole alkaloid; indolones	antineoplastic agent; Aspergillus metabolite	low
PP121	aromatic amine; cyclopentanes; pyrazolopyrimidine; pyrrolopyridine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; tyrosine kinase inhibitor	low
niraparib	benzenes; indazoles; piperidines; primary carboxamide	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	low
lucitanib	aromatic ether; cyclopropanes; naphthalenecarboxamide; primary amino compound; quinolines	antineoplastic agent; fibroblast growth factor receptor antagonist; vascular endothelial growth factor receptor antagonist	low
chondramide c	chondramide; indoles; phenols	antineoplastic agent; bacterial metabolite	low
cetrorelix	oligopeptide	antineoplastic agent; GnRH antagonist	low
histrelin	oligopeptide	antineoplastic agent; gonadotropin releasing hormone agonist	low
cabozantinib	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor	low
salvileucalin b	bridged compound; diterpenoid; furans; gamma-lactone	antineoplastic agent; metabolite	low
incb-018424	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	low
pexidartinib	aminopyridine; organochlorine compound; organofluorine compound; pyrrolopyridine; secondary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
glasdegib	benzimidazoles; nitrile; phenylureas; piperidines	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist	low
gsk 2126458	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent	low
plx4032	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor	low
INDY	benzothiazoles; enone; organic hydroxy compound	antineoplastic agent; drug metabolite; EC 2.7.12.1 (dual-specificity kinase) inhibitor	low
7,8-dihydroxyflavanone	dihydroxyflavanone	antineoplastic agent; metabolite	low
dabrafenib	1,3-thiazoles; aminopyrimidine; organofluorine compound; sulfonamide	anticoronaviral agent; antineoplastic agent; B-Raf inhibitor	low
2,3-dihydro-3beta-O-sulfate withaferin A	27-hydroxy steroid; 4-hydroxy steroid; delta-lactone; epoxy steroid; ergostanoid; primary alcohol; steroid sulfate; withanolide	antineoplastic agent; metabolite; plant metabolite	low
leachianone a	4'-hydroxyflavanones; monomethoxyflavanone; trihydroxyflavanone	antimalarial; antineoplastic agent; metabolite	low
thiopental sodium	organochlorine compound; piperazines; pyrimidines	antineoplastic agent; tyrosine kinase inhibitor	low
EG00229	benzothiadiazole; dicarboxylic acid monoamide; L-arginine derivative; secondary carboxamide; sulfonamide; thiophenes	angiogenesis inhibitor; antineoplastic agent; neuropilin receptor antagonist	low
chondramide a	chondramide; indoles; phenols	antineoplastic agent; bacterial metabolite	low
englerin a	cinnamate ester; glycolate ester; guaiane sesquiterpenoid	antineoplastic agent; metabolite	low
lrrk2-in1	aromatic amine; aromatic ether; N-acylpiperidine; N-alkylpiperazine; pyrimidobenzodiazepine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	low
ML-210	C-nitro compound; diarylmethane; isoxazoles; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; tertiary carboxamide	antineoplastic agent; EC 1.11.1.9 (glutathione peroxidase) inhibitor; ferroptosis inducer; prodrug	low
eurycomanone	cyclic ether; delta-lactone; enone; organic heteropentacyclic compound; pentol; quassinoid; secondary alcohol; secondary alpha-hydroxy ketone; tertiary alcohol	antimalarial; antineoplastic agent; metabolite	low
alectinib	aromatic ketone; morpholines; nitrile; organic heterotetracyclic compound; piperidines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
ML240	aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound	antineoplastic agent	low
torin 1	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor	low
xl765	aromatic amine; aromatic ether; benzamides; quinoxaline derivative; sulfonamide	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	low
DMH1	aromatic ether; pyrazolopyrimidine; quinolines	antineoplastic agent; bone morphogenetic protein receptor antagonist; protein kinase inhibitor	low
torin 2	aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline	antineoplastic agent; mTOR inhibitor	low
oligomycin a	antibiotic antifungal agent; diketone; oligomycin; pentol	antineoplastic agent; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; nematicide	low
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea	aminopyrimidine; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; phenylureas	antineoplastic agent; fibroblast growth factor receptor antagonist	low
3alpha,12alpha-dihydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid	11-oxo steroid; 12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7-oxo steroid; monocarboxylic acid; secondary alpha-hydroxy ketone; steroid acid	antineoplastic agent; metabolite	low
3alpha-hydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid	11-oxo steroid; 3alpha-hydroxy steroid; 7-oxo steroid; monocarboxylic acid; steroid acid	antineoplastic agent; cholinergic antagonist; metabolite; serotonergic antagonist	low
gsk2656157	biaryl; indoles; methylpyridines; organofluorine compound; pyrrolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; PERK inhibitor	low
coumermycin	aromatic amide; coumarins; glycoside; heteroarenecarboxylate ester; pyrroles	antimicrobial agent; antineoplastic agent; bacterial metabolite; DNA synthesis inhibitor; Hsp90 inhibitor; topoisomerase IV inhibitor	low
calicheamicin gamma(1)i	calicheamicin; enediyne antibiotic; organoiodine compound	antineoplastic agent; metabolite	low
asperfuranone	2-benzofurans; cyclic ketone; diol; polyketide; secondary alcohol; tertiary alcohol; tertiary alpha-hydroxy ketone	antineoplastic agent; fungal metabolite	low
ceritinib	aminopyrimidine; aromatic ether; organochlorine compound; piperidines; secondary amino compound; sulfone	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
pelabresib	monochlorobenzenes; organic heterotricyclic compound; primary carboxamide	antineoplastic agent; bromodomain-containing protein 4 inhibitor	low
gsk2879552	benzenes; benzoic acids; cyclopropanes; monocarboxylic acid; piperidines; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor	low
ssr128129e	organic sodium salt	antineoplastic agent; fibroblast growth factor receptor antagonist	low
aspergillide a	bridged compound; cyclic ether; macrolide; secondary alcohol	antineoplastic agent; Aspergillus metabolite	low
capilliposide b	alpha-L-arabinopyranoside; bridged compound; cyclic ether; diol; hexacyclic triterpenoid; hexanoate ester; lactol; secondary alcohol; tetrasaccharide derivative; triterpenoid saponin	antineoplastic agent; plant metabolite	low
brasilicardin a	benzoate ester; carbotricyclic compound; diterpenoid; N-acetyl-D-glucosaminide; non-proteinogenic alpha-amino acid; phenols	antimicrobial agent; antineoplastic agent; bacterial metabolite; immunosuppressive agent	low
surfactin A	cyclodepsipeptide; lipopeptide antibiotic; macrocyclic lactone	antibacterial agent; antifungal agent; antineoplastic agent; antiviral agent; metabolite; surfactant	low
myriaporone 3	beta-hydroxy ketone; epoxide; lactol; oxanes; primary alcohol; secondary alcohol	antineoplastic agent; metabolite	low
GSK1059615	pyridines; quinolines; thiazolidinone	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	low
osimertinib	acrylamides; aminopyrimidine; biaryl; indoles; monomethoxybenzene; secondary amino compound; secondary carboxamide; substituted aniline; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	low
ivosidenib	cyanopyridine; monochlorobenzenes; organofluorine compound; pyrrolidin-2-ones; secondary carboxamide; tertiary carboxamide	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor	low
phleomycin d1	bi-1,3-thiazole; chelate-forming peptide; disaccharide derivative; glycopeptide; guanidines	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; bacterial metabolite	low
pf-06463922	aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
physalin d	5alpha-hydroxy steroid; 6beta-hydroxy steroid; cyclic ether; enone; lactone; organic heteroheptacyclic compound; physalin	antimalarial; antimycobacterial drug; antineoplastic agent	low
acarbose	chondramide; indoles; organochlorine compound; phenols	antineoplastic agent; bacterial metabolite	low
CCT251545	azaspiro compound; chloropyridine; pyrazoles	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; Wnt signalling inhibitor	low
hg-9-91-01	aminopyrimidine; dimethoxybenzene; N-alkylpiperazine; N-arylpiperazine; phenylureas; secondary amino compound	antineoplastic agent; salt-inducible kinase 2 inhibitor	low
chondramide d	chondramide; indoles; phenols	antineoplastic agent; bacterial metabolite	low
bassianolide	cyclodepsipeptide; cyclooctadepsipeptide	antineoplastic agent; fungal metabolite; insecticide	low
enasidenib	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor	low
ebc-46	diester; diterpenoid; organic heteropentacyclic compound; phorbol ester	antineoplastic agent; plant metabolite; protein kinase C agonist	low
levoleucovorin	5-formyltetrahydrofolic acid	antineoplastic agent; metabolite	low
rifampin	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor	low
azaguanine	nucleobase analogue; triazolopyrimidines	antimetabolite; antineoplastic agent; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor	low
pemetrexed	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor	low
pyrazofurin	C-glycosyl compound; pyrazoles	antimetabolite; antimicrobial agent; antineoplastic agent; EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor	low
MMP-9-IN-1	aromatic compound; organic sulfide; organofluorine compound; pyrimidone; secondary carboxamide	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor	low
hydrazinocurcumin	aromatic ether; olefinic compound; polyphenol; pyrazoles	angiogenesis modulating agent; antineoplastic agent; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	low
9-arabinofuranosylguanine	beta-D-arabinoside; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor	low
cerulomycin	aldoxime; aromatic ether; bipyridines; pyridine alkaloid	antineoplastic agent; bacterial metabolite; marine metabolite	low
ver 52296	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor	low
XL413	benzofuropyrimidine; organochlorine compound; pyrrolidines	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	low
pp242	aromatic amine; biaryl; hydroxyindoles; phenols; primary amino compound; pyrazolopyrimidine	antineoplastic agent; mTOR inhibitor	low
marineosin a	azaspiro compound; ether; macrocycle; oxaspiro compound; pyrroles	antineoplastic agent; metabolite	low
marineosin b	azaspiro compound; ether; macrocycle; oxaspiro compound; pyrroles	antineoplastic agent; metabolite	low
ARS-1620	quinazolines	antineoplastic agent; antiviral agent; inhibitor	low
sotorasib	acrylamides; methylpyridines; monofluorobenzenes; N-acylpiperazine; phenols; pyridopyrimidine; tertiary amino compound; tertiary carboxamide	antineoplastic agent	low
dihydrolipoic acid	thio-fatty acid	antioxidant; human metabolite; neuroprotective agent	low
creatine	glycine derivative; guanidines; zwitterion	geroprotector; human metabolite; mouse metabolite; neuroprotective agent; nutraceutical	low
niacinamide	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor	low
5,5-dimethyl-1-pyrroline-1-oxide	1-pyrroline nitrones	neuroprotective agent; spin trapping reagent	low
ethylisopropylamiloride	aromatic amine; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines; tertiary amino compound	anti-arrhythmia drug; neuroprotective agent; sodium channel blocker	low
5-methoxytryptamine	aromatic ether; primary amino compound; tryptamines	5-hydroxytryptamine 2A receptor agonist; 5-hydroxytryptamine 2B receptor agonist; 5-hydroxytryptamine 2C receptor agonist; antioxidant; cardioprotective agent; human metabolite; mouse metabolite; neuroprotective agent; radiation protective agent; serotonergic agonist	low
7-chlorokynurenic acid	organochlorine compound; quinolinemonocarboxylic acid	neuroprotective agent; NMDA receptor antagonist	low
cilostazol	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent	low
dantrolene	hydrazone; imidazolidine-2,4-dione	muscle relaxant; neuroprotective agent; ryanodine receptor antagonist	low
valproic acid	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent	low
etazolate	ethyl ester; hydrazone; pyrazolopyridine	alpha-secretase activator; antidepressant; antipsychotic agent; anxiolytic drug; GABA agent; neuroprotective agent; phosphodiesterase IV inhibitor	low
ethoxyquin	aromatic ether; quinolines	antifungal agrochemical; food antioxidant; genotoxin; geroprotector; herbicide; Hsp90 inhibitor; neuroprotective agent; UDP-glucuronosyltransferase activator	low
felbamate	carbamate ester	anticonvulsant; neuroprotective agent	low
fasudil	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent	low
kynurenic acid	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite	low
memantine	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist	low
palmidrol	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent	low
4-phenylbutyric acid, sodium salt	organic sodium salt	EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector; neuroprotective agent; orphan drug; prodrug	low
methylene blue	organic chloride salt	acid-base indicator; antidepressant; antimalarial; antimicrobial agent; antioxidant; cardioprotective agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 4.6.1.2 (guanylate cyclase) inhibitor; fluorochrome; histological dye; neuroprotective agent; physical tracer	low
cycloheximide	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor	low
methylprednisolone	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic	low
methylparaben	paraben	antifungal agent; antimicrobial food preservative; neuroprotective agent; plant metabolite	low
cytidine diphosphate choline	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite	low
pn 401	acetate ester; uridines	neuroprotective agent; orphan drug; prodrug	low
argon	monoatomic argon; noble gas atom; p-block element atom	food packaging gas; neuroprotective agent	low
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor	low
tenocyclidine	piperidines; tertiary amino compound; thiophenes	central nervous system stimulant; hallucinogen; neuroprotective agent; NMDA receptor antagonist	low
norvaline	2-aminopentanoic acid; L-alpha-amino acid zwitterion	bacterial metabolite; hypoglycemic agent; neuroprotective agent	low
rivastigmine	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent	low
loganin	beta-D-glucoside; cyclopentapyran; enoate ester; iridoid monoterpenoid; methyl ester; monosaccharide derivative; secondary alcohol	anti-inflammatory agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.4.23.46 (memapsin 2) inhibitor; neuroprotective agent; plant metabolite	low
7-ketocholesterol	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; 7-oxo steroid; cholestanoid	neuroprotective agent	low
phenylisopropyladenosine	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent	low
delta(9)-tetrahydrocannabinolic acid	benzochromene; diterpenoid; hydroxy monocarboxylic acid; phytocannabinoid; polyketide	anti-inflammatory agent; biomarker; metabolite; neuroprotective agent	low
galgravin	aryltetrahydrofuran; dimethoxybenzene; lignan; ring assembly	bone density conservation agent; neuroprotective agent; plant metabolite; platelet aggregation inhibitor	low
s-methylthiocitrulline	imidothiocarbamic ester; L-arginine derivative; L-ornithine derivative; non-proteinogenic L-alpha-amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; neuroprotective agent	low
ta 0910	oligopeptide	analgesic; neuroprotective agent; nootropic agent	low
3-(2,2,2-trimethylhydrazine)propionate	ammonium betaine	cardioprotective agent; EC 1.14.11.1 (gamma-butyrobetaine dioxygenase) inhibitor; neuroprotective agent	low
cyanidin	5-hydroxyanthocyanidin	antioxidant; metabolite; neuroprotective agent	low
lanthionine ketimine	1,4-thiazine; dicarboxylic acid; sulfur-containing amino acid	anti-inflammatory agent; human urinary metabolite; neuroprotective agent	low
schizandrin b	aromatic ether; cyclic acetal; organic heterotetracyclic compound; oxacycle; tannin	anti-asthmatic agent; anti-inflammatory agent; antilipemic drug; antioxidant; apoptosis inhibitor; hepatoprotective agent; nephroprotective agent; neuroprotective agent; plant metabolite	low
fasudil hydrochloride	hydrochloride	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; neuroprotective agent; nootropic agent; vasodilator agent	low
sb 203580	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent	low
dizocilpine	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist	low
memantine hydrochloride	hydrochloride	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist	low
methyl 3,4-dihydroxybenzoate	catechols; methyl ester	antioxidant; neuroprotective agent; plant metabolite	low
theanine	amino acid zwitterion; N(5)-alkyl-L-glutamine	geroprotector; neuroprotective agent; plant metabolite	low
neriifolin	cardenolide glycoside	cardiotonic drug; neuroprotective agent; toxin	low
ginsenoside rg1	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	neuroprotective agent; pro-angiogenic agent	low
5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol	carbotetracyclic compound; polyphenol	estrogen receptor agonist; estrogen receptor antagonist; geroprotector; neuroprotective agent	low
dimethyloxalylglycine	glycine derivative; methyl ester; secondary carboxamide	EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor; neuroprotective agent	low
glycerylphosphorylcholine	phosphocholines; sn-glycerol 3-phosphates	Escherichia coli metabolite; human metabolite; mouse metabolite; neuroprotective agent; parasympatholytic; Saccharomyces cerevisiae metabolite	low
huperzine a	organic heterotricyclic compound; primary amino compound; pyridone; sesquiterpene alkaloid	EC 3.1.1.7 (acetylcholinesterase) inhibitor; neuroprotective agent; nootropic agent; plant metabolite	low
n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide	pyrazines; sulfonamide; thiophenes	necroptosis inhibitor; neuroprotective agent	low
amn082	benzenes; diamine; diarylmethane; secondary amino compound	metabotropic glutamate receptor agonist; neuroprotective agent	low
rasagiline	indanes; secondary amine; terminal acetylenic compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; neuroprotective agent	low
ferrostatin-1	ethyl ester; primary arylamine; substituted aniline	antifungal agent; antioxidant; ferroptosis inhibitor; neuroprotective agent; radiation protective agent; radical scavenger	low
gossypin	7-hydroxyflavonol; glycosyloxyflavone; monosaccharide derivative; pentahydroxyflavone	neuroprotective agent; plant metabolite	low
acteoside	catechols; cinnamate ester; disaccharide derivative; glycoside; polyphenol	anti-inflammatory agent; antibacterial agent; antileishmanial agent; neuroprotective agent; plant metabolite	low
tocotrienol, alpha	tocotrienol; vitamin E	ferroptosis inhibitor; human metabolite; neuroprotective agent; plant metabolite	low
menatetrenone	menaquinone	anti-inflammatory agent; antioxidant; bone density conservation agent; human metabolite; neuroprotective agent	low
arachidonyl-2-chloroethylamide	fatty amide; organochlorine compound; secondary carboxamide; synthetic cannabinoid	CB1 receptor agonist; CB2 receptor agonist; neuroprotective agent	low
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone	morpholines; naphthyl ketone; organic heterotricyclic compound; synthetic cannabinoid	analgesic; apoptosis inhibitor; neuroprotective agent	low
cannabigerol	phytocannabinoid; resorcinols	anti-inflammatory agent; antibacterial agent; antioxidant; appetite enhancer; cannabinoid receptor agonist; neuroprotective agent; plant metabolite	low
tetrahydroxycurcumin	beta-diketone; catechols; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; neuroprotective agent; plant metabolite	low
dizocilpine maleate	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist	low
sdz eaa 494	monocarboxylic acid; olefinic compound; phosphonic acids; piperazinecarboxylic acid; tertiary amino compound	anticonvulsant; neuroprotective agent; NMDA receptor antagonist	low
ro 25-6981	benzenes; phenols; piperidines; secondary alcohol; tertiary amino compound	anticonvulsant; antidepressant; neuroprotective agent; NMDA receptor antagonist	low
bis(7)-tacrine	secondary amino compound	apoptosis inhibitor; EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; neuroprotective agent	low
ursodoxicoltaurine	bile acid taurine conjugate	anti-inflammatory agent; apoptosis inhibitor; bone density conservation agent; cardioprotective agent; human metabolite; neuroprotective agent	low
l 779976	benzimidazoles; indoles; piperidinecarboxamide; primary amino compound; secondary carboxamide	neuroprotective agent; somatostatin receptor agonist	low
ginsenoside rb1	ginsenoside; glycoside; tetracyclic triterpenoid	anti-inflammatory drug; anti-obesity agent; apoptosis inhibitor; neuroprotective agent; plant metabolite; radical scavenger	low
ly 379268	amino dicarboxylic acid; bridged compound; organic heterobicyclic compound	antipsychotic agent; anxiolytic drug; metabotropic glutamate receptor agonist; neuroprotective agent	low
glu-asp-arg	tripeptide	neuroprotective agent	low
n-arachidonoyl l-serine	N-(fatty acyl)-L-alpha-amino acid	cannabinoid receptor agonist; mammalian metabolite; neuroprotective agent; pro-angiogenic agent; vasodilator agent	low
n-benzylhexadecanamide	macamide; secondary carboxamide	EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; neuroprotective agent; plant metabolite	low
cytidine diphosphate choline	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite	low
n,n'-dibenzhydrylethane-1,2-diamine dihydrochloride	hydrochloride	geroprotector; metabotropic glutamate receptor agonist; neuroprotective agent	low
glycoursodeoxycholic acid	bile acid glycine conjugate; N-acylglycine	human blood serum metabolite; neuroprotective agent	low
ginsenoside rb3	12beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	antidepressant; antioxidant; cardioprotective agent; neuroprotective agent; NMDA receptor antagonist; plant metabolite	low
astragaloside IV	pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; antioxidant; EC 4.2.1.1 (carbonic anhydrase) inhibitor; neuroprotective agent; plant metabolite; pro-angiogenic agent	low
protectin d1	dihydroxydocosahexaenoic acid; protectin; secondary allylic alcohol	anti-inflammatory agent; apoptosis inhibitor; hepatoprotective agent; human xenobiotic metabolite; neuroprotective agent; PPARgamma agonist; specialised pro-resolving mediator	low
astressin	homodetic cyclic peptide; polypeptide	corticotropin-releasing factor receptor antagonist; neuroprotective agent	low
liraglutide	lipopeptide; polypeptide	glucagon-like peptide-1 receptor agonist; neuroprotective agent	low
albiflorin	benzoate ester; beta-D-glucoside; bridged compound; gamma-lactone; monoterpene glycoside; secondary alcohol	neuroprotective agent; plant metabolite	low
SL-327	(trifluoromethyl)benzenes; enamine; nitrile; organic sulfide; primary amino compound; substituted aniline	EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor; neuroprotective agent	low
apelin-13 peptide	oligopeptide	antihypertensive agent; autophagy inhibitor; biomarker; human metabolite; neuroprotective agent	low
p-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe	polypeptide	apoptosis inhibitor; human metabolite; neuroprotective agent	low
oleuropein aglycone	catechols; diester; lactol; methyl ester; pyrans; secoiridoid	anti-inflammatory agent; antioxidant; mTOR inhibitor; neuroprotective agent; plant metabolite; TRPA1 channel agonist	low
semaglutide	lipopeptide; polypeptide	anti-obesity agent; appetite depressant; glucagon-like peptide-1 receptor agonist; hypoglycemic agent; neuroprotective agent	low
maysin	disaccharide derivative; flavone C-glycoside; secondary alpha-hydroxy ketone; tetrahydroxyflavone	insecticide; neuroprotective agent; plant metabolite	low
((5z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4h-imidazol-4-one)	benzodioxoles; imidazolone; substituted aniline	autophagy inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.12.1 (dual-specificity kinase) inhibitor; neuroprotective agent; nootropic agent	low
apelin-12 peptide	oligopeptide	biomarker; human blood serum metabolite; human metabolite; neuroprotective agent	low
n(1)-methylnicotinamide	pyridinium ion	algal metabolite; anti-inflammatory agent; human urinary metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite	low
pqq cofactor	orthoquinones; pyrroloquinoline cofactor; tricarboxylic acid	anti-inflammatory agent; antioxidant; cofactor; water-soluble vitamin (role)	low
vanillin	benzaldehydes; monomethoxybenzene; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; flavouring agent; plant metabolite	low
tramiprosate	amino sulfonic acid; zwitterion	algal metabolite; anti-inflammatory agent; anticonvulsant; GABA agonist; nootropic agent	low
theophylline	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent	low
decanoic acid	medium-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; anti-inflammatory agent; antibacterial agent; human metabolite; plant metabolite; volatile oil component	low
dipyrone	amino sulfonic acid; pyrazoles	anti-inflammatory agent; antipyretic; antirheumatic drug; cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug; prodrug	low
oxatomide	benzimidazoles; diarylmethane; N-alkylpiperazine	anti-allergic agent; anti-inflammatory agent; geroprotector; H1-receptor antagonist; serotonergic antagonist	low
pentamidine	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic	low
sb 220025	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
colchicine	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen	low
visnagin	aromatic ether; furanochromone; polyketide	anti-inflammatory agent; antihypertensive agent; EC 1.1.1.37 (malate dehydrogenase) inhibitor; phytotoxin; plant metabolite; vasodilator agent	low
2-methyl-1,4-hydroquinone	hydroquinones	angiogenesis inhibitor; anti-inflammatory agent; Penicillium metabolite	low
methyl gallate	gallate ester	anti-inflammatory agent; antioxidant; plant metabolite	low
scoparone	aromatic ether; coumarins	anti-allergic agent; anti-inflammatory agent; antihypertensive agent; antilipemic drug; immunosuppressive agent; plant metabolite	low
chrysophanic acid	dihydroxyanthraquinone	anti-inflammatory agent; antiviral agent; plant metabolite	low
zingerone	methyl ketone; monomethoxybenzene; phenols	anti-inflammatory agent; antiemetic; antioxidant; flavouring agent; fragrance; plant metabolite; radiation protective agent	low
myrcene	monoterpene	anabolic agent; anti-inflammatory agent; flavouring agent; fragrance; plant metabolite; volatile oil component	low
castanospermine	indolizidine alkaloid	anti-HIV-1 agent; anti-inflammatory agent; EC 3.2.1.* (glycosidase) inhibitor; metabolite	low
7-hydroxydehydroepiandrosterone	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; 7alpha-hydroxy steroid; androstanoid	anti-inflammatory agent; antioxidant; estrogen; human xenobiotic metabolite; rat metabolite	low
goralatide	oligopeptide; tetrapeptide	anti-inflammatory agent; pro-angiogenic agent	low
sigmoidin a	4'-hydroxyflavanones; tetrahydroxyflavanone	anti-inflammatory agent; anti-obesity agent; antibacterial agent; metabolite; radical scavenger	low
pulsatilla saponin a	disaccharide derivative; hydroxy monocarboxylic acid; pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; plant metabolite	low
monotropein	beta-D-glucoside; cyclopentapyran; iridoid monoterpenoid; monocarboxylic acid; monosaccharide derivative	anti-inflammatory agent; metabolite	low
1,3,7,9-tetramethyluric acid	oxopurine; purine alkaloid	analgesic; anti-inflammatory agent; human xenobiotic metabolite; plant metabolite	low
decane-1,2-diol	glycol; volatile organic compound	anti-inflammatory agent; antioxidant; human metabolite	low
vestitol	aromatic ether; hydroxyisoflavans; methoxyisoflavan	anti-inflammatory agent; phytoalexin; plant metabolite	low
quillaic acid	aldehyde; hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; metabolite	low
u 69593	monocarboxylic acid amide; N-alkylpyrrolidine; organic heterobicyclic compound; oxaspiro compound	anti-inflammatory agent; diuretic; kappa-opioid receptor agonist	low
taraxasterol	pentacyclic triterpenoid; secondary alcohol	anti-inflammatory agent; metabolite	low
cubebin	benzodioxoles; cyclic acetal; lactol; lignan; secondary alcohol	analgesic; anti-inflammatory agent; antimicrobial agent; histamine antagonist; plant metabolite; trypanocidal drug	low
astilbin	3'-hydroxyflavanones; 4'-hydroxyflavanones; alpha-L-rhamnoside; flavanone glycoside; monosaccharide derivative; tetrahydroxyflavanone	anti-inflammatory agent; plant metabolite; radical scavenger	low
swertisin	dihydroxyflavone; flavone C-glycoside; monomethoxyflavone; monosaccharide derivative; polyphenol	adenosine A1 receptor antagonist; anti-inflammatory agent; antioxidant; hypoglycemic agent; plant metabolite	low
procyanidin b3	biflavonoid; hydroxyflavan; polyphenol; proanthocyanidin	anti-inflammatory agent; antioxidant; EC 2.3.1.48 (histone acetyltransferase) inhibitor; metabolite	low
rp 73401	aromatic ether; benzamides; chloropyridine; monocarboxylic acid amide	anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; phosphodiesterase IV inhibitor	low
butrin	4'-hydroxyflavanones; flavanone glycoside; monohydroxyflavanone	anti-inflammatory agent; plant metabolite	low
confertin	cyclic ketone; gamma-lactone; organic heterotricyclic compound; pseudoguaianolide	anti-inflammatory agent; metabolite; plant metabolite	low
procyanidin C1	hydroxyflavan; polyphenol; proanthocyanidin	anti-inflammatory agent; antioxidant; EC 1.17.3.2 (xanthine oxidase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; lipoxygenase inhibitor; metabolite	low
inuviscolide	gamma-lactone; organic heterotricyclic compound; sesquiterpene lactone; tertiary alcohol	anti-inflammatory agent; plant metabolite	low
aromaticin	cyclic ketone; gamma-lactone; organic heterotricyclic compound; sesquiterpene lactone	anti-inflammatory agent; metabolite; plant metabolite	low
absynthin	organic heteroheptacyclic compound; sesquiterpene lactone; triterpenoid	anti-inflammatory agent; plant metabolite	low
agnuside	benzoate ester; beta-D-glucoside; cyclopentapyran; iridoid monoterpenoid; monosaccharide derivative; phenols; terpene glycoside	anti-inflammatory agent; cyclooxygenase 2 inhibitor; plant metabolite; pro-angiogenic agent	low
genipin	iridoid monoterpenoid	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cross-linking reagent; hepatotoxic agent; uncoupling protein inhibitor	low
isonaringin	(2S)-flavan-4-one; 4'-hydroxyflavanones; dihydroxyflavanone; disaccharide derivative; rutinoside	anti-inflammatory agent; antioxidant; metabolite	low
cleomiscosin a	aromatic ether; delta-lactone; organic heterotricyclic compound; phenols; primary alcohol	anti-inflammatory agent; metabolite	low
ferulic acid	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite	low
rosuvastatin	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic	low
mln 4760	dichlorobenzene; L-histidine derivative; L-leucine derivative	anti-inflammatory agent; EC 3.4.17.23 (angiotensin-converting enzyme 2) inhibitor	low
histidyl-proline diketopiperazine	dipeptide; homodetic cyclic peptide; imidazoles; pyrrolopyrazine	anti-inflammatory agent; dopamine uptake inhibitor; human blood serum metabolite	low
23-hydroxytormentic acid	hydroxy monocarboxylic acid; pentacyclic triterpenoid; tetrol	anti-inflammatory agent; plant metabolite	low
riboflavin	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite	low
lisofylline	1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione	anti-inflammatory agent; immunomodulator	low
likviriton	beta-D-glucoside; flavanone glycoside; monohydroxyflavanone; monosaccharide derivative	anti-inflammatory agent; anticoronaviral agent; plant metabolite	low
dipyrone	organic sodium salt	anti-inflammatory agent; antipyretic; antirheumatic drug; cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug; prodrug	low
piperlactam s	alkaloid; aromatic ether; gamma-lactam; organic heterotetracyclic compound; phenols	anti-inflammatory agent; antioxidant; plant metabolite	low
2'-hydroxychalcone	chalcones; phenols	anti-inflammatory agent	low
sirtinol	aldimine; benzamides; naphthols	anti-inflammatory agent; EC 3.5.1.98 (histone deacetylase) inhibitor; Sir2 inhibitor	low
7-deacetylgedunin	cyclic terpene ketone; delta-lactone; enone; epoxide; furans; limonoid; pentacyclic triterpenoid	anti-inflammatory agent; antimalarial; metabolite; plant metabolite	low
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine	adenosines; dicarboxylic acid monoamide; monocarboxylic acid	adenosine A2A receptor agonist; anti-inflammatory agent	low
fraxin	aromatic ether; beta-D-glucoside; hydroxycoumarin	anti-inflammatory agent; hepatoprotective agent; plant metabolite	low
2'-hydroxyformononetin	4'-methoxyisoflavones; 7-hydroxyisoflavones	anti-inflammatory agent	low
naringenin chalcone	chalcones; polyphenol	anti-allergic agent; anti-inflammatory agent; metabolite	low
isobutrin	beta-D-glucoside; chalcones; monosaccharide derivative; phenols	anti-inflammatory agent; hepatoprotective agent; plant metabolite	low
diosmin	dihydroxyflavanone; disaccharide derivative; glycosyloxyflavone; monomethoxyflavone; rutinoside	anti-inflammatory agent; antioxidant	low
fisetin	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite	low
mangiferin	C-glycosyl compound; xanthones	anti-inflammatory agent; antioxidant; hypoglycemic agent; plant metabolite	low
kuwanon g	resorcinols; tetrahydroxyflavone	anti-inflammatory agent; plant metabolite	low
rhamnetin	monomethoxyflavone; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; metabolite	low
coumestrol	coumestans; delta-lactone; polyphenol	anti-inflammatory agent; antioxidant; plant metabolite	low
orobol	7-hydroxyisoflavones	anti-inflammatory agent; fungal metabolite; plant metabolite; radical scavenger	low
prunetin	7-methoxyisoflavones; hydroxyisoflavone	anti-inflammatory agent; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor; metabolite	low
tectorigenin	7-hydroxyisoflavones; methoxyisoflavone	anti-inflammatory agent; plant metabolite	low
savinin	benzodioxoles; gamma-lactone; lignan	anti-inflammatory agent; anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; plant metabolite; T-cell proliferation inhibitor	low
ethyl linoleate	long-chain fatty acid ethyl ester	anti-inflammatory agent; plant metabolite	low
rosuvastatin calcium	N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine; organic calcium salt	anti-inflammatory agent; cardioprotective agent; CETP inhibitor	low
leukotriene b5	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	anti-inflammatory agent; human xenobiotic metabolite; rat metabolite	low
6,7,4'-trihydroxyisoflavone	7-hydroxyisoflavones	anti-inflammatory agent; antimutagen; EC 1.14.18.1 (tyrosinase) inhibitor; metabolite; PPARalpha agonist; PPARgamma agonist	low
as 605240	quinoxaline derivative; thiazolidinediones	anti-inflammatory agent; antirheumatic drug; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	low
kaempferol 3-o-rhamnoside	glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	anti-inflammatory agent; antibacterial agent; plant metabolite	low
sappanchalcone	catechols; chalcones; monomethoxybenzene	anti-allergic agent; anti-inflammatory agent; antioxidant; metabolite	low
4-methylesculetin	hydroxycoumarin	anti-inflammatory agent; antioxidant; hyaluronan synthesis inhibitor	low
muromonab-cd3	extended flavonoid; pyranochromane; trihydroxyflavone	anti-inflammatory agent; plant metabolite	low
ombuine	dimethoxyflavone; flavonols; trihydroxyflavone	anti-inflammatory agent; plant metabolite	low
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside	beta-D-glucoside; resorcinols; stilbenoid	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; cyclooxygenase 2 inhibitor; platelet aggregation inhibitor	low
dehydrodiconiferyl alcohol	1-benzofurans; guaiacols; guaiacyl lignin; primary alcohol	anti-inflammatory agent; plant metabolite	low
5,4'-dihydroxy-7,3'-dimethoxyflavone	dihydroxyflavone; dimethoxyflavone	anti-allergic agent; anti-inflammatory agent; antibacterial agent; antioxidant; melanin synthesis inhibitor; plant metabolite	low
zerumbone	cyclic ketone; sesquiterpenoid	anti-inflammatory agent; glioma-associated oncogene inhibitor; plant metabolite	low
ochnaflavone	aromatic ether; biflavonoid; hydroxyflavone	anti-inflammatory agent; antiatherogenic agent; antibacterial agent; EC 3.1.1.4 (phospholipase A2) inhibitor; leukotriene antagonist; plant metabolite	low
4-hydroxycordoin	aromatic ether; chalcones; polyphenol	anti-inflammatory agent; antibacterial agent; plant metabolite	low
eupomatenoid 6	benzofurans; phenols	anti-inflammatory agent; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; NF-kappaB inhibitor; plant metabolite	low
meso-zeaxanthin	carotenol	anti-inflammatory agent; antioxidant; human xenobiotic metabolite; marine metabolite	low
trilobatin	aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative	anti-inflammatory agent; antioxidant; plant metabolite; sweetening agent	low
beraprost	enyne; monocarboxylic acid; organic heterotricyclic compound; secondary alcohol; secondary allylic alcohol	anti-inflammatory agent; antihypertensive agent; platelet aggregation inhibitor; prostaglandin receptor agonist; vasodilator agent	low
capsiate	carboxylic ester; monomethoxybenzene; phenols	angiogenesis inhibitor; anti-allergic agent; anti-inflammatory agent; antioxidant; capsaicin receptor agonist; hypoglycemic agent; plant metabolite	low
pinellic acid	TriHOME	adjuvant; anti-inflammatory agent	low
arachidonoylserotonin	N-acylserotonin; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; capsaicin receptor antagonist; EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; human metabolite; signalling molecule	low
demethylzeylasteral	arenecarbaldehyde; benzenediols; carbopolycyclic compound; cyclic ketone; enone; oxo monocarboxylic acid	anti-inflammatory agent; EC 2.4.1.17 (glucuronosyltransferase) inhibitor; immunosuppressive agent; nephroprotective agent; plant metabolite	low
myrsinoic acid b	1-benzofurans; monocarboxylic acid	anti-inflammatory agent; EC 4.4.1.11 (methionine gamma-lyase) inhibitor; metabolite	low
5s,12r,18r-trihydroxy-6z,8e,10e,14z,16e-eicosapentaenoic acid	hydroxy polyunsaturated fatty acid; long-chain fatty acid; nonclassic icosanoid; resolvin; triol	anti-inflammatory agent; human xenobiotic metabolite	low
procyanidin b1	biflavonoid; hydroxyflavan; polyphenol; proanthocyanidin	anti-inflammatory agent; EC 3.4.21.5 (thrombin) inhibitor; metabolite	low
cenicriviroc	aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide	anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist	low
resolvin d2	hydroxy polyunsaturated fatty acid; resolvin; secondary allylic alcohol; triol	anti-inflammatory agent; anti-obesity agent; estrogen receptor agonist; human xenobiotic metabolite; rat metabolite	low
kalopanax saponin b	carboxylic ester; pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; plant metabolite	low
hu 308	aromatic ether; bridged compound; carbobicyclic compound; primary allylic alcohol; synthetic cannabinoid	anti-inflammatory agent; antihypertensive agent; apoptosis inhibitor; bone density conservation agent; CB2 receptor agonist	low
bay 60-6583	aminopyridine; aromatic ether; aryl sulfide; cyanopyridine; cyclopropanes; monocarboxylic acid amide	adenosine A2B receptor agonist; anti-inflammatory agent; cardioprotective agent	low
viridiflorol	carbotricyclic compound; sesquiterpenoid; tertiary alcohol	anti-inflammatory agent; antifeedant; antimycobacterial drug; plant metabolite; volatile oil component	low
azadiradione	acetate ester; cyclic terpene ketone; furans; limonoid; tetracyclic triterpenoid	anti-inflammatory agent; antimycobacterial drug; plant metabolite	low
resolvin e2	diol; hydroxy polyunsaturated fatty acid; resolvin; secondary allylic alcohol	anti-inflammatory agent; human xenobiotic metabolite; rat metabolite	low
alpha-msh	peptide hormone	anti-inflammatory agent	low
antrocamphin a	methoxybenzenes	anti-inflammatory agent; metabolite	low
cauloside D	carboxylic ester; pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; plant metabolite	low
ph 797804	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
beraprost sodium	organic sodium salt	anti-inflammatory agent; antihypertensive agent; platelet aggregation inhibitor; prostaglandin receptor agonist; vasodilator agent	low
methylprednisolone suleptanate	organic sodium salt	anti-asthmatic drug; anti-inflammatory agent; glucocorticoid receptor agonist; prodrug	low
madecassoside	carboxylic ester; pentacyclic triterpenoid; trisaccharide derivative; triterpenoid saponin	anti-inflammatory agent; antioxidant; antirheumatic drug; plant metabolite; vulnerary	low
epi-maslinic acid	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; metabolite	low
baricitinib	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent	low
resolvin d1	hydroxy polyunsaturated fatty acid; resolvin; triol	anti-inflammatory agent	low
kurarinol	4'-hydroxyflavanones; monomethoxyflavanone; trihydroxyflavanone	anti-inflammatory agent; antioxidant; plant metabolite	low
picrinine	alkaloid ester; indole alkaloid; methyl ester; organic heteropentacyclic compound; polycyclic ether	analgesic; anti-asthmatic agent; anti-inflammatory agent; antitussive; plant metabolite	low
epoxyazadiradione	acetate ester; cyclic terpene ketone; epoxide; furans; limonoid; pentacyclic triterpenoid	anti-inflammatory agent; insecticide; plant metabolite	low
resolvin D4	hydroxy polyunsaturated fatty acid; resolvin; secondary allylic alcohol; triol	anti-inflammatory agent; human xenobiotic metabolite	low
resolvin d3	hydroxy polyunsaturated fatty acid; resolvin; secondary allylic alcohol; triol	anti-inflammatory agent; human xenobiotic metabolite	low
9-PAHSA	FAHFA; long-chain fatty acid	anti-inflammatory agent; human metabolite; hypoglycemic agent	low
praliciguat	aminopyrimidine; isoxazoles; monofluorobenzenes; organofluorine compound; pyrazoles; secondary amino compound; tertiary alcohol	anti-inflammatory agent; antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent	low
AZ3451	benzimidazoles; benzodioxoles; nitrile; organobromine compound; secondary carboxamide	anti-inflammatory agent; autophagy inducer; PAR2 negative allosteric modulator	low

Substance	Classes	Roles	Relationship Strength
np 031112	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	low
bms 214662	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	low
bay 11-7085	benzenes; nitrile; sulfone	anti-inflammatory agent; antibacterial agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; ferroptosis inducer; NF-kappaB inhibitor	low
npi 2358	2,5-diketopiperazines; benzenes; imidazoles; olefinic compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; microtubule-destabilising agent	low
sm 164	benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; radiosensitizing agent	low
plerixafor	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant	low
l 744832	benzenes; ether; isopropyl ester; secondary carboxamide; sulfone; thiol	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; geroprotector	low
ym 216391	1,3-oxazoles; 1,3-thiazoles; azamacrocycle; benzenes; heterodetic cyclic peptide	antineoplastic agent; bacterial metabolite	low
SYC-435	benzenes; cyclic hydroxamic acid; pyridone	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor	low
niraparib	benzenes; indazoles; piperidines; primary carboxamide	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	low
gsk2879552	benzenes; benzoic acids; cyclopropanes; monocarboxylic acid; piperidines; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor	low
phenylisopropyladenosine	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent	low
amn082	benzenes; diamine; diarylmethane; secondary amino compound	metabotropic glutamate receptor agonist; neuroprotective agent	low
ro 25-6981	benzenes; phenols; piperidines; secondary alcohol; tertiary amino compound	anticonvulsant; antidepressant; neuroprotective agent; NMDA receptor antagonist	low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's	post-2020
thioctic acid	1	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector	2022	2022	2.0	low	0	0	1
catechin	1	hydroxyflavan		2021	2021	3.0	low	0	0	1
5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate	1	catechin		2021	2021	3.0	medium	0	0	1
pd 173074	2	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist	2012	2013	11.5	low	0	2	0
tyrphostin ag 1024	1	alkylbenzene		2013	2013	11.0	low	0	1	0
ag 1295	1	quinoxaline derivative	geroprotector	2013	2013	11.0	low	0	1	0
ag-1296	1	quinoxaline derivative		2013	2013	11.0	low	0	1	0
rtki cpd	1	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector	2013	2013	11.0	low	0	1	0
tyrphostin a1	1	methoxybenzenes	geroprotector	2013	2013	11.0	low	0	1	0
theophylline	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent	2021	2021	3.0	low	0	0	1
bisindolylmaleimide i	2			2004	2013	15.5	low	1	1	0
bisindolylmaleimide iv	1	indoles; maleimides		2013	2013	11.0	low	0	1	0
bohemine	1	purines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2013	2013	11.0	low	0	1	0
bronopol	1	nitro compound		2021	2021	3.0	low	0	0	1
caffeine	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic	2021	2021	3.0	low	0	0	1
N-[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]carbamic acid (phenylmethyl) ester	1	leucine derivative		2021	2021	3.0	medium	0	0	1
carmofur	3	organohalogen compound; pyrimidines		2020	2022	3.0	low	0	1	2
chelerythrine	1	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2013	2013	11.0	low	0	1	0
disulfiram	3	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor	2020	2022	3.0	low	0	1	2
ebselen	3	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger	2020	2022	3.0	low	0	1	2
fluconazole	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic	2022	2022	2.0	low	0	0	1
gö6983	1	indoles; maleimides		2013	2013	11.0	low	0	1	0
go 6976	1	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor	2013	2013	11.0	low	0	1	0
fasudil	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent	2013	2013	11.0	low	0	1	0
hexachlorophene	1	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug	2021	2021	3.0	low	0	0	1
hydroxychloroquine	1	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug	2021	2021	3.0	low	0	0	1
indirubin-3'-monoxime	2			2004	2013	15.5	low	1	1	0
whi p154	1			2013	2013	11.0	low	0	1	0
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone	1	naphthalenes		2013	2013	11.0	low	0	1	0
nsc 664704	3	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector	2004	2021	11.3	low	1	1	1
beta-lapachone	1	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite	2021	2021	3.0	low	0	0	1
ly 303511	1	N-arylpiperazine		2013	2013	11.0	low	0	1	0
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector	2013	2013	11.0	low	0	1	0
vitamin k 3	1	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical	2021	2021	3.0	low	0	0	1
niclosamide	1	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor	2021	2021	3.0	low	0	0	1
pd 158780	1	aromatic amine; bromobenzenes; diamine; pyridopyrimidine; secondary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	0	1	0
pd 169316	1	imidazoles		2013	2013	11.0	low	0	1	0
pd 98059	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	2013	2013	11.0	low	0	1	0
pioglitazone	1	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic	2018	2018	6.0	low	0	1	0
1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine	1	pyrazoles; ring assembly		2013	2013	11.0	low	0	1	0
protoporphyrin ix	1			2021	2021	3.0	low	0	0	1
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one	1	indoles		2021	2021	3.0	low	0	0	1
ro 31-8220	1	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor	2004	2004	20.0	low	1	0	0
sb 220025	1	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	0	1	0
sb 202190	1	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	2013	2013	11.0	low	0	1	0
alkannin	1	naphthoquinone		2021	2021	3.0	medium	0	0	1
sk&f 86002	1	imidazoles		2013	2013	11.0	low	0	1	0
2,4-thiazolidinedione	1	thiazolidenedione		2005	2005	19.0	low	1	0	0
triclosan	1	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic	2021	2021	3.0	low	0	0	1
cycloheximide	1	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor	2009	2009	15.0	low	1	0	0
pyromellitic acid	1	benzoic acids; tetracarboxylic acid		2021	2021	3.0	low	0	0	1
maleic anhydride	1	cyclic dicarboxylic anhydride; furans	allergen	2005	2005	19.0	low	1	0	0
chloranil	1	1,4-benzoquinones; organochlorine compound	EC 2.7.1.33 (pantothenate kinase) inhibitor; metabolite	2021	2021	3.0	low	0	0	1
pyrazolanthrone	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector	2013	2013	11.0	low	0	1	0
hydantoins	1	imidazolidine-2,4-dione		2005	2005	19.0	low	1	0	0
indirubin	1			2017	2017	7.0	low	0	1	0
plumbagin	1	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite	2021	2021	3.0	low	0	0	1
dithiol	1			2021	2021	3.0	low	0	0	1
dihydroergotamine	1	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent	2021	2021	3.0	low	0	0	1
abietic acid	1	abietane diterpenoid; monocarboxylic acid	plant metabolite	2021	2021	3.0	low	0	0	1
maleimide	1	dicarboximide; maleimides	EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor	2005	2005	19.0	low	1	0	0
succinimide	1	dicarboximide; pyrrolidinone		2005	2005	19.0	low	1	0	0
4-(dimethylamino)benzoic acid	1			2021	2021	3.0	low	0	0	1
agaric acid	1			2021	2021	3.0	low	0	0	1
phenethyl isothiocyanate	1	isothiocyanate	antineoplastic agent; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; metabolite	2021	2021	3.0	low	0	0	1
1,2-benzisothiazoline-3-one	2	organic heterobicyclic compound; organonitrogen heterocyclic compound	disinfectant; drug allergen; environmental contaminant; platelet aggregation inhibitor; sensitiser; xenobiotic	2021	2022	2.5	low	0	0	2
ribavirin	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	2020	2020	4.0	low	0	1	0
staurosporine	3	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector	2004	2013	15.3	low	2	1	0
zinc ethylphenyldithiocarbamate	1			2021	2021	3.0	high	0	0	1
baicalin	1	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug	2021	2021	3.0	low	0	0	1
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose	1	gallate ester; galloyl beta-D-glucose	anti-inflammatory agent; antineoplastic agent; geroprotector; hepatoprotective agent; plant metabolite; radiation protective agent; radical scavenger	2021	2021	3.0	low	0	0	1
triciribine	1	nucleoside analogue	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	2013	2013	11.0	low	0	1	0
4-cyclopentene-1,3-dione	1			2005	2005	19.0	medium	1	0	0
n-methylmaleimide	1			2005	2005	19.0	low	1	0	0
vanitiolide	1	methoxybenzenes; phenols		2021	2021	3.0	low	0	0	1
LSM-4272	2	beta-carbolines		2013	2021	7.0	medium	0	1	1
n-benzylmaleimide	1			2005	2005	19.0	low	1	0	0
4-phenyl-1,2,4-triazoline-3,5-dione	1			2005	2005	19.0	low	1	0	0
lopinavir	1	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor	2021	2021	3.0	low	0	0	1
zpck	1			2021	2021	3.0	low	0	0	1
tingenone	1			2021	2021	3.0	low	0	0	1
homoorientin	1	flavone C-glycoside; tetrahydroxyflavone	antineoplastic agent; radical scavenger	2022	2022	2.0	low	0	0	1
tanshinone	1	abietane diterpenoid	anticoronaviral agent	2021	2021	3.0	low	0	0	1
celastrol	1	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite	2021	2021	3.0	low	0	0	1
pomalidomide	1	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator	2021	2021	3.0	low	0	0	1
moxifloxacin	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug	2021	2021	3.0	low	0	0	1
birb 796	1	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator	2021	2021	3.0	low	0	0	1
schizandrin b	1	aromatic ether; cyclic acetal; organic heterotetracyclic compound; oxacycle; tannin	anti-asthmatic agent; anti-inflammatory agent; antilipemic drug; antioxidant; apoptosis inhibitor; hepatoprotective agent; nephroprotective agent; neuroprotective agent; plant metabolite	2022	2022	2.0	medium	0	0	1
celastrol methyl ester	1	carboxylic ester		2021	2021	3.0	low	0	0	1
miltirone	1	abietane diterpenoid		2021	2021	3.0	low	0	0	1
cryptotanshinone	1	abietane diterpenoid	anticoronaviral agent	2021	2021	3.0	low	0	0	1
tanshinone ii a	1	abietane diterpenoid		2021	2021	3.0	low	0	0	1
2-phenyl-1,2-benzisothiazol-3-(2h)-one	2			2021	2022	2.5	low	0	0	2
rubschisandrin	1	tannin		2022	2022	2.0	high	0	0	1
sb 203580	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent	2013	2013	11.0	low	0	1	0
sb 216763	5	indoles; maleimides		2004	2021	9.2	low	1	3	1
carboxyebselen	2			2021	2022	2.5	high	0	0	2
darunavir	1	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor	2021	2021	3.0	low	0	0	1
sorafenib	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor	2021	2021	3.0	low	0	0	1
1-methylpropyl-2-imidazolyl disulfide	2	imidazoles		2020	2021	3.5	low	0	1	1
nsc 95397	1	1,4-naphthoquinones		2021	2021	3.0	low	0	0	1
nsc 663284	1	quinolone		2021	2021	3.0	low	0	0	1
bortezomib	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor	2022	2022	2.0	low	0	0	1
lithium chloride	2	inorganic chloride; lithium salt	antimanic drug; geroprotector	2015	2021	6.0	low	0	1	1
2H-pyrazolo[4,3-b]quinoxalin-3-amine	1	quinoxaline derivative		2013	2013	11.0	medium	0	1	0
abacavir	1	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor	2021	2021	3.0	low	0	0	1
ferruginol	1	abietane diterpenoid; carbotricyclic compound; meroterpenoid; phenols	antibacterial agent; antineoplastic agent; plant metabolite; protective agent	2021	2021	3.0	low	0	0	1
isopimaric acid	1	carbotricyclic compound; diterpenoid; monocarboxylic acid		2021	2021	3.0	low	0	0	1
acetylleucyl-leucyl-norleucinal	1	aldehyde; tripeptide	cysteine protease inhibitor	2021	2021	3.0	low	0	0	1
gw 3965	1	diarylmethane		2021	2021	3.0	low	0	0	1
hts 466284	1	pyrazoles; pyridines; quinolines	TGFbeta receptor antagonist	2013	2013	11.0	low	0	1	0
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea	3			2004	2017	12.7	low	1	2	0
y 27632	1	aromatic amide		2013	2013	11.0	low	0	1	0
7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine	2			2004	2013	15.5	high	1	1	0
6-bromoindirubin-3'-oxime	3			2004	2017	12.7	low	1	2	0
h 89	1	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide		2013	2013	11.0	low	0	1	0
purvalanol a	1	purvalanol		2013	2013	11.0	low	0	1	0
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	1	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor	2021	2021	3.0	low	0	0	1
tenofovir	1	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor	2021	2021	3.0	low	0	0	1
shikonin	1	hydroxy-1,4-naphthoquinone		2020	2020	4.0	low	0	1	0
2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione	1	aminotoluene		2013	2013	11.0	medium	0	1	0
favipiravir	1	hydroxypyrazine; organofluorine compound; primary carboxamide	anticoronaviral agent; antiviral drug; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor	2020	2020	4.0	low	0	1	0
evp 4593	1			2013	2013	11.0	low	0	1	0
1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide	1	indolecarboxamide	anticoronaviral agent	2021	2021	3.0	high	0	0	1
hirsutanone	1	diarylheptanoid		2020	2020	4.0	low	0	1	0
dimethyl fumarate	1	diester; enoate ester; methyl ester	antipsoriatic; immunomodulator	2022	2022	2.0	low	0	0	1
cgp 60474	1	substituted aniline		2004	2004	20.0	low	1	0	0
3-(4-pyridyl)-1h-indole	1	indoles		2013	2013	11.0	medium	0	1	0
r 59949	1	diarylmethane		2013	2013	11.0	low	0	1	0
3,4-methylenedioxy-beta-nitrostyrene	1			2013	2013	11.0	low	0	1	0
1-(4-Methoxyphenyl)-2-nitroethylene	1	methoxybenzenes		2021	2021	3.0	low	0	0	1
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol	1	substituted aniline		2013	2013	11.0	low	0	1	0
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide	1	naphthalenecarboxamide		2013	2013	11.0	low	0	1	0
curcumin	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger	2021	2021	3.0	low	0	0	1
2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	1	dimethoxybenzene		2013	2013	11.0	medium	0	1	0
rhodanine	1	thiazolidinone		2005	2005	19.0	low	1	0	0
Src Inhibitor-1	1	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	0	1	0
chlorogenic acid	1	cinnamate ester; tannin	food component; plant metabolite	2021	2021	3.0	low	0	0	1
tg 003	1			2013	2013	11.0	low	0	1	0
N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline	1	benzimidazoles		2013	2013	11.0	medium	0	1	0
cgp 74514a	1			2013	2013	11.0	low	0	1	0
5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine	1	sulfonic acid derivative	anticoronaviral agent	2021	2021	3.0	medium	0	0	1
S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate	1	acetylenic compound; furans; organofluorine compound; thioester; triazoles		2021	2021	3.0	high	0	0	1
1,4-dimethoxy-10H-acridine-9-thione	1	acridines		2013	2013	11.0	medium	0	1	0
telaprevir	1	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic	2021	2021	3.0	low	0	0	1
sf 2370	1	bridged compound; gamma-lactam; methyl ester; organic heterooctacyclic compound	antimicrobial agent; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; tropomyosin-related kinase B receptor antagonist	2013	2013	11.0	low	0	1	0
dasatinib	5	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	2012	2021	8.6	low	0	4	1
N-(4-Butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-pyridin-3-ylethyl]furan-2-carboxamide	1	aromatic amide; furans	anticoronaviral agent	2021	2021	3.0	medium	0	0	1
gtp 14564	1	pyrazoles; ring assembly		2013	2013	11.0	medium	0	1	0
sb 218078	1	indolocarbazole		2013	2013	11.0	low	0	1	0
sto 609	1	naphthoic acid		2013	2013	11.0	low	0	1	0
8-(Trifluoromethyl)-9H-purin-6-amine	1	6-aminopurines	anticoronaviral agent	2021	2021	3.0	medium	0	0	1
7-butyl-6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine	1	pyrroles		2013	2013	11.0	medium	0	1	0
l 663536	1	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist	2021	2021	3.0	low	0	0	1
suramin sodium	1	organosulfate oxoanion		2021	2021	3.0	low	0	0	1
sb 415286	1	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	2004	2004	20.0	low	1	0	0
sitagliptin	1	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic	2021	2021	3.0	low	0	0	1
alsterpaullone	3	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor	2004	2021	11.3	low	1	1	1
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-ylemine	1	pyrazolopyrimidine	tyrosine kinase inhibitor	2013	2013	11.0	low	0	1	0
ginkgetin	1	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	anti-HSV-1 agent; antineoplastic agent; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; metabolite	2021	2021	3.0	low	0	0	1
ku 55933	1			2013	2013	11.0	low	0	1	0
quercetin	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger	2021	2021	3.0	low	0	0	1
apigenin	1	trihydroxyflavone	antineoplastic agent; metabolite	2021	2021	3.0	low	0	0	1
luteolin	1	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist	2021	2021	3.0	low	0	0	1
amentoflavone	1	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite	2021	2021	3.0	low	0	0	1
baicalein	1	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger	2021	2021	3.0	low	0	0	1
sciadopitysin	1	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	bone density conservation agent; platelet aggregation inhibitor	2021	2021	3.0	low	0	0	1
scutellarein	1	tetrahydroxyflavone	metabolite	2021	2021	3.0	low	0	0	1
sirolimus	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor	2013	2013	11.0	low	0	1	0
as 604850	1			2013	2013	11.0	low	0	1	0
alvocidib	1	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	2004	2004	20.0	low	1	0	0
su 9516	2			2004	2013	15.5	low	1	1	0
benzyloxycarbonyl-phe-ala-fluormethylketone	1			2021	2021	3.0	high	0	0	1
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide	1	pyrimidines		2013	2013	11.0	low	0	1	0
kn 93	1	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector	2013	2013	11.0	low	0	1	0
kn 62	1	piperazines		2013	2013	11.0	low	0	1	0
su 6656	1			2013	2013	11.0	low	0	1	0
bilobetin	1	flavonoid oligomer		2021	2021	3.0	low	0	0	1
ag-490	1	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor	2013	2013	11.0	low	0	1	0
ag 112	1			2013	2013	11.0	low	0	1	0
semaxinib	1	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	0	1	0
su 11248	5	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist	2012	2021	8.6	low	0	4	1
su 11652	1	olefinic compound; organochlorine compound; oxindoles; pyrrolecarboxamide; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor	2013	2013	11.0	low	0	1	0
6-(4-methoxyphenyl)-3-(3-thiophenyl)pyrazolo[1,5-a]pyrimidine	1	pyrimidines		2013	2013	11.0	high	0	1	0
jnj-7706621	1	sulfonamide		2013	2013	11.0	low	0	1	0
bay 11-7082	1	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor	2013	2013	11.0	low	0	1	0
indinavir sulfate	1	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor	2021	2021	3.0	low	0	0	1
cinanserin	1	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor	2021	2021	3.0	low	0	0	1
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one	1	organic heterotetracyclic compound; organofluorine compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	2013	2013	11.0	low	0	1	0
N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide	1	benzyl ester; isoxazoles; pyrrolidin-2-ones; tripeptide	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor	2021	2021	3.0	medium	0	0	1
ml 3403	1			2013	2013	11.0	high	0	1	0
d 4476	1	imidazoles		2013	2013	11.0	low	0	1	0
GSK3-XIII	1	aromatic amine; pyrazoles; quinazolines; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor	2013	2013	11.0	low	0	1	0
herbimycin	1			2013	2013	11.0	medium	0	1	0
su 4312	1			2013	2013	11.0	low	0	1	0
Ethyl (E,4S)-4-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-phenylpropanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	1	dipeptide	anticoronaviral agent	2021	2021	3.0	high	0	0	1
manzamine a	1	alkaloid; beta-carbolines; isoquinolines	animal metabolite; anti-HSV-1 agent; antimalarial; antineoplastic agent; EC 2.7.11.26 (tau-protein kinase) inhibitor; marine metabolite	2012	2012	12.0	low	0	1	0
1-azakenpaullone	1	lactam; organic heterotetracyclic compound; organobromine compound; organonitrogen heterocyclic compound	EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator	2004	2004	20.0	medium	1	0	0
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole	2	aryl sulfide		2004	2013	15.5	high	1	1	0
b 43	1	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector	2013	2013	11.0	low	0	1	0
aminopurvalanol a	1	monochlorobenzenes; purvalanol	protein kinase inhibitor	2013	2013	11.0	medium	0	1	0
cgk 733	1	diarylmethane		2013	2013	11.0	low	0	1	0
cgp 53353	1	phthalimides		2013	2013	11.0	low	0	1	0
mdl 201053	1			2021	2021	3.0	low	0	0	1
cvt 313	1			2013	2013	11.0	low	0	1	0
5-Chloro-3-pyridinyl 2-furoate	1	carboxylic ester	anticoronaviral agent	2021	2021	3.0	low	0	0	1
tws 119	3	pyrroles		2004	2021	11.3	medium	1	1	1
c 1368	1			2013	2013	11.0	medium	0	1	0
pq 401	1	quinolines		2013	2013	11.0	low	0	1	0
jnj 10198409	1			2013	2013	11.0	medium	0	1	0
6-methylsulfinylhexyl isothiocyanate	1	sulfoxide		2022	2022	2.0	low	0	0	1
midostaurin	1	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor	2013	2013	11.0	low	0	1	0
sb-505124	1	benzodioxole; imidazoles; methylpyridines	TGFbeta receptor antagonist	2013	2013	11.0	low	0	1	0
ic 86621	1	aromatic ketone		2013	2013	11.0	medium	0	1	0
nu 7026	1	organic heterotricyclic compound; organooxygen compound		2013	2013	11.0	low	0	1	0
pi103	1	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	2013	2013	11.0	low	0	1	0
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide	1	aromatic amide; thiophenes		2013	2013	11.0	low	0	1	0
sp 100030	1			2021	2021	3.0	low	0	0	1
tivozanib	1	aromatic ether		2013	2013	11.0	low	0	1	0
gw0742	1	monocarboxylic acid		2021	2021	3.0	low	0	0	1
chir 99021	2	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor	2004	2021	11.5	low	1	0	1
benzyloxycarbonyl-isoleucyl-glutamyl(o-tert-butyl)-alanyl-leucinal	1			2021	2021	3.0	low	0	0	1
sepantronium	1	organic cation		2021	2021	3.0	low	0	0	1
azd2858	2	aromatic amine; N-methylpiperazine; pyrazines; pyridines; secondary carboxamide; sulfonamide	antineoplastic agent; bone density conservation agent; EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator	2021	2021	3.0	high	0	0	2
bibw 2992	5	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor	2012	2021	8.6	low	0	4	1
nu 6140	1			2013	2013	11.0	low	0	1	0
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	1	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic	2021	2021	3.0	low	0	0	1
triptohypol C	1	benzenediols; monocarboxylic acid; pentacyclic triterpenoid	apoptosis inducer; plant metabolite	2021	2021	3.0	medium	0	0	1
PDGF receptor tyrosine kinase inhibitor III	1	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; quinazolines; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	high	0	1	0
2-(4-chlorophenyl)-1,2-benzothiazol-3-one	1	benzothiazoles		2021	2021	3.0	medium	0	0	1
np 031112	6	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	2015	2021	5.7	low	0	4	2
4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide	1	biphenyls		2013	2013	11.0	high	0	1	0
Dihydrotanshinone I	1	abietane diterpenoid	anticoronaviral agent	2021	2021	3.0	low	0	0	1
nvp-aew541	1			2017	2017	7.0	low	0	1	0
fr 180204	1	pyrazoles; ring assembly		2013	2013	11.0	low	0	1	0
dorsomorphin	1	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor	2013	2013	11.0	low	0	1	0
ki11502	1	aromatic ether; benzamides; quinolines; thioureas	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2013	2013	11.0	medium	0	1	0
mk-0893	1			2021	2021	3.0	medium	0	0	1
gw 2580	1			2013	2013	11.0	low	0	1	0
crizotinib	1	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2017	2017	7.0	low	0	1	0
cgp 57380	1	pyrazolopyrimidine		2013	2013	11.0	low	0	1	0
Benzotriazol-1-yl 1H-indole-5-carboxylate	1	indolyl carboxylic acid	anticoronaviral agent	2021	2021	3.0	medium	0	0	1
tannins	1	tannin		2021	2021	3.0	low	0	0	1
oritavancin	1	disaccharide derivative; glycopeptide; semisynthetic derivative	antibacterial drug; antimicrobial agent	2021	2021	3.0	low	0	0	1
5-Bromopyridin-3-yl furan-2-carboxylate	1	carboxylic ester	anticoronaviral agent	2021	2021	3.0	high	0	0	1
(5-Chloropyridin-3-yl) 1H-indole-5-carboxylate	1	indolyl carboxylic acid	anticoronaviral agent	2021	2021	3.0	medium	0	0	1
5-Chloropyridin-3-yl 1H-indole-2-carboxylate	1	indolyl carboxylic acid	anticoronaviral agent	2021	2021	3.0	medium	0	0	1
phenylmercuric acetate	1	arylmercury compound; benzenes		2021	2021	3.0	low	0	0	1
thimerosal	1	alkylmercury compound	antifungal drug; antiseptic drug; disinfectant; drug allergen	2021	2021	3.0	low	0	0	1
sid 26681509	1	carbohydrazide; L-tryptophan derivative; secondary carboxamide; tert-butyl ester; thioester	antiplasmodial drug; cathepsin L (EC 3.4.22.15) inhibitor	2020	2020	4.0	high	0	1	0
(e)-3-(2,3,4,5-tetrabromophenyl)acrylic acid	1			2013	2013	11.0	medium	0	1	0
ponatinib	3	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor	2014	2021	6.7	low	0	2	1
cabozantinib	1	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor	2017	2017	7.0	low	0	1	0
(5-Chloropyridin-3-yl) 1H-indole-4-carboxylate	1	indolyl carboxylic acid	anticoronaviral agent	2021	2021	3.0	medium	0	0	1
Benzyl N-[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(1,3-thiazol-2-yl)propan-2-yl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]carbamate	1	dipeptide	anticoronaviral agent	2021	2021	3.0	high	0	0	1
amg-837	1			2021	2021	3.0	low	0	0	1
N-[(1R)-2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide	1	aromatic amide; furans		2021	2021	3.0	medium	0	0	1
azd4547	1	benzamides; N-arylpiperazine; pyrazoles	fibroblast growth factor receptor antagonist	2017	2017	7.0	low	0	1	0
palinurin	2			2012	2013	11.5	high	0	2	0
bictegravir	1	monocarboxylic acid amide; organic heterotetracyclic compound; secondary carboxamide; trifluorobenzene	HIV-1 integrase inhibitor	2021	2021	3.0	low	0	0	1
akt-i-1,2 compound	1			2013	2013	11.0	low	0	1	0
sildenafil	1	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent	2021	2021	3.0	low	0	0	1
penciclovir	1	2-aminopurines; propane-1,3-diols	antiviral drug	2020	2020	4.0	low	0	1	0
hymenialdisine	2			2004	2017	13.5	low	1	1	0
isogranulatimide	1			2013	2013	11.0	low	0	1	0
6-bromoindirubin-3'-acetoxime	1			2013	2013	11.0	high	0	1	0
amg531	1			2021	2021	3.0	low	0	0	1
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile	1	hydroxyindoles; morpholines; nitrile; pyridines; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; tau aggregation inhibitor	2017	2017	7.0	medium	0	1	0
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide	1	aldehyde; indolecarboxamide; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor	2021	2021	3.0	low	0	0	1
3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide	1	aldehyde; indolecarboxamide; monofluorobenzenes; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor	2021	2021	3.0	medium	0	0	1

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	2000's	2010's	post-2020
phosphoserine	1	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite	2007	2007	17.0	low	0	1	0	0
butyric acid	1	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite	2018	2018	6.0	low	1	0	1	0
chlorine	1	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite	2018	2018	6.0	low	1	0	1	0
formaldehyde	1	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2018	2018	6.0	low	1	0	1	0
histamine	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter	2016	2016	8.0	low	0	0	1	0
inositol	1	cyclitol; hexol		2007	2007	17.0	low	0	1	0	0
urea	2	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2010	2011	13.5	low	0	1	1	0
sk&f-38393	1	benzazepine; catechols; secondary amino compound		2016	2016	8.0	low	0	0	1	0
1-anilino-8-naphthalenesulfonate	1	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe	2005	2005	19.0	low	0	1	0	0
bisindolylmaleimide i	1			2007	2007	17.0	low	0	1	0	0
amphetamine	2	primary amine		2011	2013	12.0	low	0	0	2	0
diclofenac	2	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	2012	2018	9.0	low	1	0	2	0
valproic acid	2	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent	2005	2014	14.5	low	0	1	1	0
letrozole	1	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	2018	2018	6.0	low	1	0	1	0
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	3	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector	2005	2017	13.0	low	0	1	2	0
o(6)-benzylguanine	1			2018	2018	6.0	low	1	0	1	0
oxidopamine	2	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin	2004	2016	14.0	low	0	1	1	0
pd 98059	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	2005	2005	19.0	low	0	1	0	0
propofol	1	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative	2017	2017	7.0	low	0	0	1	0
rolipram	1	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor	2012	2012	12.0	low	0	0	1	0
sevoflurane	1	ether; organofluorine compound	central nervous system depressant; inhalation anaesthetic; platelet aggregation inhibitor	2018	2018	6.0	low	0	0	1	0
thalidomide	1	phthalimides; piperidones		2018	2018	6.0	low	1	0	1	0
zinc chloride	1	inorganic chloride; zinc molecular entity	astringent; disinfectant; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; Lewis acid	2018	2018	6.0	low	1	0	1	0
serine	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2011	2011	13.0	low	0	0	1	0
sucrose	1	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent	2018	2018	6.0	low	1	0	1	0
bromodeoxyuridine	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent	2017	2017	7.0	low	0	0	1	0
levodopa	1	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug	2016	2016	8.0	low	0	0	1	0
tyrosine	2	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical	2006	2011	15.5	low	0	1	1	0
boranes	1	boranes; mononuclear parent hydride		2018	2018	6.0	low	1	0	1	0
furaldehyde	1	aldehyde; furans	Maillard reaction product; metabolite	2018	2018	6.0	low	1	0	1	0
pyrazolanthrone	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector	2007	2007	17.0	low	0	1	0	0
2-naphthol	1	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger	2016	2016	8.0	low	0	0	1	0
thiazoles	2	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene		2010	2011	13.5	low	0	1	1	0
kainic acid	2	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist	2014	2015	9.5	low	0	0	2	0
oleanolic acid	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite	2017	2017	7.0	low	0	0	1	0
malondialdehyde	1	dialdehyde	biomarker	2007	2007	17.0	low	0	1	0	0
trinitrobenzenesulfonic acid	1	arenesulfonic acid; C-nitro compound	epitope; explosive; reagent	2018	2018	6.0	low	0	0	1	0
titanium	1	titanium group element atom		2018	2018	6.0	low	1	0	1	0
chromium	1	chromium group element atom; metal allergen	micronutrient	2018	2018	6.0	low	1	0	1	0
erbium	1	f-block element atom; lanthanoid atom		2018	2018	6.0	low	1	0	1	0
ytterbium	1	f-block element atom; lanthanoid atom		2018	2018	6.0	low	1	0	1	0
yttrium	1	d-block element atom; rare earth metal atom; scandium group element atom		2018	2018	6.0	low	1	0	1	0
mercuric chloride	1	mercury coordination entity	sensitiser	2012	2012	12.0	low	0	0	1	0
fluorides	1	halide anion; monoatomic fluorine		2018	2018	6.0	low	1	0	1	0
chromium	1	chromium cation; monoatomic hexacation		2018	2018	6.0	low	1	0	1	0
remifentanil	2	alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester	intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative	2013	2013	11.0	low	0	0	2	0
glucose, (beta-d)-isomer	1	D-glucopyranose	epitope; mouse metabolite	2007	2007	17.0	low	0	1	0	0
25-hydroxycholesterol	1	25-hydroxy steroid; oxysterol	human metabolite	2017	2017	7.0	low	0	0	1	0
pyrrolidine dithiocarbamate	1	dithiocarbamic acids; pyrrolidines	anticonvulsant; antineoplastic agent; geroprotector; neuroprotective agent; NF-kappaB inhibitor; radical scavenger	2015	2015	9.0	low	0	0	1	0
triazoles	1	1,2,3-triazole		2017	2017	7.0	low	0	0	1	0
fluorodeoxyglucose f18	1	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose		2018	2018	6.0	low	1	0	1	0
glycidyl nitrate	3			2005	2007	18.0	low	0	3	0	0
yttrium radioisotopes	1			2018	2018	6.0	low	1	0	1	0
parthenolide	1	germacranolide		2007	2007	17.0	low	0	1	0	0
angiotensin ii	1	amino acid zwitterion; angiotensin II	human metabolite	2017	2017	7.0	low	0	0	1	0
sb 203580	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent	2007	2007	17.0	low	0	1	0	0
sb 216763	8	indoles; maleimides		2005	2015	15.6	low	0	5	3	0
enzastaurin	1	indoles; maleimides		2011	2011	13.0	low	0	0	1	0
3-nitrotyrosine	1	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid		2006	2006	18.0	low	0	1	0	0
5-hydroxymethylfurfural	1	arenecarbaldehyde; furans; primary alcohol	indicator; Maillard reaction product	2018	2018	6.0	low	1	0	1	0
benzofurans	1			2014	2014	10.0	low	0	0	1	0
bardoxolone methyl	1	cyclohexenones		2017	2017	7.0	low	0	0	1	0
lithium chloride	7	inorganic chloride; lithium salt	antimanic drug; geroprotector	2004	2017	16.3	low	0	5	2	0
tosylphenylalanyl chloromethyl ketone	1	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor	2015	2015	9.0	low	0	0	1	0
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea	2			2010	2011	13.5	low	0	1	1	0
purvalanol a	1	purvalanol		2005	2005	19.0	low	0	1	0	0
cannabidiol	1	olefinic compound; phytocannabinoid; resorcinols	antimicrobial agent; plant metabolite	2006	2006	18.0	low	0	1	0	0
sesquiterpenes	1			2007	2007	17.0	low	0	1	0	0
curcumin	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger	2023	2023	1.0	low	0	0	0	1
meso-1,2-diphenylethylenediamine, (r-(r,s))-isomer	1			2018	2018	6.0	low	1	0	1	0
fumonisin b1	1	diester; fumonisin; primary amino compound; triol	carcinogenic agent; metabolite	2007	2007	17.0	low	0	1	0	0
lithium	2	alkali metal atom		2012	2015	10.5	low	0	0	2	0
ovalbumin	1			2007	2007	17.0	low	0	1	0	0
sb 225002	1	nitrophenol		2016	2016	8.0	low	0	0	1	0
sb 415286	4	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	2005	2013	16.2	low	0	3	1	0
dinoprostone	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic	2016	2016	8.0	low	0	0	1	0
kaempferol	1	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite	2015	2015	9.0	low	0	0	1	0
coenzyme q10	1	ubiquinones	antioxidant; ferroptosis inhibitor; human metabolite	2018	2018	6.0	low	1	0	1	0
ubiquinone 8	1	ubiquinones	biomarker	2018	2018	6.0	low	1	0	1	0
menaquinone 6	1			2018	2018	6.0	low	1	0	1	0
sirolimus	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor	2005	2005	19.0	low	0	1	0	0
menaquinone 7	1	menaquinone	bone density conservation agent; cofactor; Escherichia coli metabolite; human blood serum metabolite; Mycoplasma genitalium metabolite	2018	2018	6.0	low	1	0	1	0
dexmedetomidine	1	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative	2017	2017	7.0	low	0	0	1	0
strontium	1	alkaline earth metal atom		2018	2018	6.0	low	1	0	1	0
alternariol	1	benzochromenone; phenols	EC 3.1.1.8 (cholinesterase) inhibitor; metabolite; mycotoxin	2016	2016	8.0	low	0	0	1	0
alternariol monomethyl ether	1	aromatic ether; benzochromenone	antifungal agent; fungal metabolite; mycotoxin	2016	2016	8.0	low	0	0	1	0
benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-	1			2014	2014	10.0	low	0	0	1	0
mocetinostat	4	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent	2006	2018	14.5	low	0	3	1	0
np 031112	1	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent	2020	2020	4.0	low	0	0	1	0
apremilast	1	aromatic ether; N-acetylarylamine; phthalimides; sulfone	non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor	2018	2018	6.0	low	1	0	1	0
losartan potassium	1			2018	2018	6.0	low	1	0	1	0
n-acetylmannosamine	1			2018	2018	6.0	low	1	0	1	0
cytochrome c-t	1			2015	2015	9.0	low	0	0	1	0
ceruletide	1	oligopeptide	diagnostic agent; gastrointestinal drug	2007	2007	17.0	low	0	1	0	0
tannins	1			2018	2018	6.0	low	1	0	1	0
ubiquinone	1			2018	2018	6.0	low	1	0	1	0
glycolipids	1			2018	2018	6.0	low	1	0	1	0
piperidines	2			2013	2013	11.0	low	0	0	2	0
wzb117	1			2023	2023	1.0	low	0	0	0	1
ascorbic acid	1	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent	2006	2006	18.0	low	0	1	0	0
warfarin	1	benzenes; hydroxycoumarin; methyl ketone		2016	2016	8.0	low	0	0	1	0
transforming growth factor beta	1			2015	2015	9.0	low	0	0	1	0
okadaic acid	1	ketal		2019	2019	5.0	low	0	0	1	0
cyclin d1	3			2004	2018	11.7	low	0	1	2	0
myelin oligodendrocyte glycoprotein (35-55)	1			2013	2013	11.0	low	0	0	1	0
guanine	1	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2018	2018	6.0	low	1	0	1	0

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	2000's	2010's	post-2020
Absence Seizure	2	2014	2015	9.5	low	0	0	2	0
Ache	1	2023	2023	1.0	low	0	0	0	1
Acquired-Immune Deficiency Syndrome Dementia Complex	1	2010	2010	14.0	low	0	1	0	0
Acute Confusional Senile Dementia	6	2002	2021	8.3	low	0	1	4	1
Acute Disease	3	2007	2018	11.7	low	1	1	2	0
Acute Edematous Pancreatitis	1	2007	2007	17.0	low	0	1	0	0
Acute Ischemic Stroke	1	2023	2023	1.0	low	0	0	0	1
Acute Kidney Failure	6	2009	2021	11.7	low	0	3	2	1
Acute Kidney Injury	6	2009	2021	11.7	low	0	3	2	1
Acute Kidney Tubular Necrosis	1	2012	2012	12.0	low	0	0	1	0
Acute Lung Injury	1	2015	2015	9.0	low	0	0	1	0
Acute Lymphoid Leukemia	1	2007	2007	17.0	low	0	1	0	0
Acute Myelogenous Leukemia	1	2011	2011	13.0	low	0	0	1	0
Acute Post-operative Pain	1	2013	2013	11.0	low	0	0	1	0
Acute Promyelocytic Leukemia	1	2021	2021	3.0	low	0	0	0	1
Adenocarcinoma	1	2011	2011	13.0	low	0	0	1	0
Adenocarcinoma, Basal Cell	1	2011	2011	13.0	low	0	0	1	0
Adjuvant Arthritis	2	2006	2023	9.5	low	0	1	0	1
Adult Periodontitis	1	2018	2018	6.0	low	1	0	1	0
Affective Disorders	1	2015	2015	9.0	low	0	0	1	0
Affective Psychosis, Bipolar	3	2011	2018	8.7	low	1	0	3	0
Aging	1	2020	2020	4.0	low	0	0	1	0
AIDS Dementia Complex	1	2010	2010	14.0	low	0	1	0	0
Alcohol Abuse	1	2018	2018	6.0	low	0	0	1	0
Alcohol Drinking	1	2018	2018	6.0	low	0	0	1	0
Alcoholism	1	2018	2018	6.0	low	0	0	1	0
Allergic Encephalomyelitis	1	2013	2013	11.0	low	0	0	1	0
Allodynia	2	2013	2016	9.5	low	0	0	2	0
Alloxan Diabetes	3	2009	2016	10.7	low	0	1	2	0
Alveolar Bone Atrophy	1	2018	2018	6.0	low	1	0	1	0
Alzheimer Disease	6	2002	2021	8.3	low	0	1	4	1
Amnesia	1	2017	2017	7.0	low	0	0	1	0
Amnesia-Memory Loss	1	2017	2017	7.0	low	0	0	1	0
Angiogenesis, Pathologic	1	2011	2011	13.0	low	0	0	1	0
Ankylosing Spondylarthritis	1	2018	2018	6.0	low	1	0	1	0
Anovulation	1	2018	2018	6.0	low	1	0	1	0
Anoxia-Ischemia, Brain	1	2017	2017	7.0	low	0	0	1	0
Anxiety	1	2015	2015	9.0	low	0	0	1	0
Arteriosclerosis, Coronary	1	2018	2018	6.0	low	1	0	1	0
Arthritis	1	2023	2023	1.0	low	0	0	0	1
Arthritis, Rheumatoid	3	2006	2023	9.0	low	0	1	1	1
Asthma	1	2007	2007	17.0	low	0	1	0	0
Asthma, Bronchial	1	2007	2007	17.0	low	0	1	0	0
Astrocytoma, Grade IV	1	2010	2010	14.0	low	0	1	0	0
Astrocytosis	1	2017	2017	7.0	low	0	0	1	0
Atrophy, Muscle	1	2017	2017	7.0	low	0	0	1	0
Autosomal Dominant Juvenile Parkinson Disease	1	2016	2016	8.0	low	0	0	1	0
Bacterial Infections, Gram-Negative	1	2018	2018	6.0	low	1	0	1	0
Benign Neoplasms	3	2004	2022	9.7	low	0	1	1	1
Bipolar Disorder	3	2011	2018	8.7	low	1	0	3	0
Blast Crisis	1	2007	2007	17.0	low	0	1	0	0
Blast Phase	1	2007	2007	17.0	low	0	1	0	0
Bleeding	1	2006	2006	18.0	low	0	1	0	0
Blood Poisoning	3	2005	2007	18.0	low	0	3	0	0
Blood Pressure, High	2	2018	2018	6.0	low	2	0	2	0
Body Weight	2	2006	2009	16.5	low	0	2	0	0
Brain Inflammation	1	2010	2010	14.0	low	0	1	0	0
Brain Ischemia	3	2008	2015	13.3	low	0	2	1	0
Burns	1	2005	2005	19.0	low	0	1	0	0
Cancer of Colon	1	2005	2005	19.0	low	0	1	0	0
Cancer of Ovary	1	2017	2017	7.0	low	0	0	1	0
Cancer of Prostate	1	2011	2011	13.0	low	0	0	1	0
Cancer of the Thyroid	1	2018	2018	6.0	low	1	0	1	0
Cardiovascular Stroke	1	2008	2008	16.0	low	0	1	0	0
Cells, Neoplasm Circulating	1	2018	2018	6.0	low	1	0	1	0
Central Retinal Edema, Cystoid	1	2023	2023	1.0	low	0	0	0	1
Cerebral Infarction, Middle Cerebral Artery	1	2023	2023	1.0	low	0	0	0	1
Cerebral Ischemia	3	2008	2015	13.3	low	0	2	1	0
Chronic Disease	3	2018	2021	5.0	low	1	0	2	1
Chronic Illness	3	2018	2021	5.0	low	1	0	2	1
Chronic Kidney Diseases	1	2017	2017	7.0	low	0	0	1	0
Circulatory Collapse	1	2007	2007	17.0	low	0	1	0	0
Cirrhosis	1	2015	2015	9.0	low	0	0	1	0
Colitis	2	2006	2018	12.0	low	0	1	1	0
Colonic Neoplasms	1	2005	2005	19.0	low	0	1	0	0
Complications of Diabetes Mellitus	1	2017	2017	7.0	low	0	0	1	0
Congenital Myotonic Dystrophy	2	2012	2018	9.0	low	0	0	2	0
Congenital Zika Syndrome	1	2020	2020	4.0	low	0	0	1	0
Constriction, Pathologic	1	2016	2016	8.0	low	0	0	1	0
Constriction, Pathological	1	2016	2016	8.0	low	0	0	1	0
Coronary Artery Disease	1	2018	2018	6.0	low	1	0	1	0
Cross Infection	1	2018	2018	6.0	low	1	0	1	0
Cyst	1	2015	2015	9.0	low	0	0	1	0
Degenerative Diseases, Central Nervous System	3	2014	2021	7.3	low	0	0	2	1
Delayed Effects, Prenatal Exposure	1	2013	2013	11.0	low	0	0	1	0
Dementia Praecox	1	2013	2013	11.0	low	0	0	1	0
Depression, Endogenous	1	2018	2018	6.0	low	0	0	1	0
Depressive Disorder	1	2018	2018	6.0	low	0	0	1	0
Diabetes Mellitus	3	2017	2018	6.7	low	1	0	3	0
Diabetes Mellitus, Adult-Onset	3	2004	2018	11.0	low	1	1	2	0
Diabetes Mellitus, Gestational	1	2018	2018	6.0	low	1	0	1	0
Diabetes Mellitus, Type 2	3	2004	2018	11.0	low	1	1	2	0
Diabetes, Gestational	1	2018	2018	6.0	low	1	0	1	0
Diabetic Angiopathies	1	2015	2015	9.0	low	0	0	1	0
Diabetic Glomerulosclerosis	1	2020	2020	4.0	low	0	0	1	0
Diabetic Nephropathies	1	2020	2020	4.0	low	0	0	1	0
Diabetic Retinopathy	1	2023	2023	1.0	low	0	0	0	1
Disease Models, Animal	15	2010	2021	8.0	low	0	1	13	1
Disease, Pulmonary	1	2018	2018	6.0	low	1	0	1	0
Dyskinesia, Drug-Induced	1	2016	2016	8.0	low	0	0	1	0
Dyskinesia, Medication-Induced	1	2016	2016	8.0	low	0	0	1	0
Electrolytes	1	2018	2018	6.0	low	1	0	1	0
Encephalitis	1	2010	2010	14.0	low	0	1	0	0
Endotoxemia	2	2005	2007	18.0	low	0	2	0	0
Familial Nonmedullary Thyroid Cancer	1	2018	2018	6.0	low	1	0	1	0
Fibrosis	1	2015	2015	9.0	low	0	0	1	0
Glial Cell Tumors	1	2013	2013	11.0	low	0	0	1	0
Glioblastoma	1	2010	2010	14.0	low	0	1	0	0
Glioma	1	2013	2013	11.0	low	0	0	1	0
Glomerulonephritis, Lupus	1	2015	2015	9.0	low	0	0	1	0
Gram-Negative Bacterial Infections	1	2018	2018	6.0	low	1	0	1	0
Granulocytic Leukemia, Chronic	2	2007	2011	15.0	low	0	1	1	0
Health Care Associated Infection	1	2018	2018	6.0	low	1	0	1	0
Hemorrhage	1	2006	2006	18.0	low	0	1	0	0
Hemorrhagic Shock	1	2014	2014	10.0	low	0	0	1	0
Hip Fractures	1	2018	2018	6.0	low	1	0	1	0
Hypercapnia	1	2018	2018	6.0	low	1	0	1	0
Hypertension	2	2018	2018	6.0	low	2	0	2	0
Hypoxia-Ischemia, Brain	1	2017	2017	7.0	low	0	0	1	0
Idiopathic Parkinson Disease	1	2004	2004	20.0	low	0	1	0	0
Infarction, Middle Cerebral Artery	1	2023	2023	1.0	low	0	0	0	1
Inflammation	6	2006	2023	11.0	low	0	3	2	1
Inflammatory Response Syndrome, Systemic	1	2006	2006	18.0	low	0	1	0	0
Injuries, Spinal Cord	2	2006	2019	11.5	low	0	1	1	0
Injury, Ischemia-Reperfusion	12	2007	2021	10.5	low	0	5	6	1
Injury, Myocardial Reperfusion	4	2008	2018	11.5	low	0	2	2	0
Innate Inflammatory Response	6	2006	2023	11.0	low	0	3	2	1
Insulin Resistance	2	2017	2018	6.5	low	1	0	2	0
Insulin Sensitivity	2	2017	2018	6.5	low	1	0	2	0
Intertrochanteric Fractures	1	2018	2018	6.0	low	1	0	1	0
Ischemic Stroke	1	2023	2023	1.0	low	0	0	0	1
Kahler Disease	1	2008	2008	16.0	low	0	1	0	0
Kidney Diseases	2	2005	2021	11.0	low	0	1	0	1
Kidney Tubular Necrosis, Acute	1	2012	2012	12.0	low	0	0	1	0
Kidney, Polycystic	1	2015	2015	9.0	low	0	0	1	0
Leucocythaemia	1	2007	2007	17.0	low	0	1	0	0
Leukemia	1	2007	2007	17.0	low	0	1	0	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	2	2007	2011	15.0	low	0	1	1	0
Leukemia, Myeloid, Acute	1	2011	2011	13.0	low	0	0	1	0
Leukemia, Promyelocytic, Acute	1	2021	2021	3.0	low	0	0	0	1
Local Neoplasm Recurrence	1	2018	2018	6.0	low	1	0	1	0
Lung Diseases	1	2018	2018	6.0	low	1	0	1	0
Lung Injury, Acute	1	2015	2015	9.0	low	0	0	1	0
Lupus Nephritis	1	2015	2015	9.0	low	0	0	1	0
Macular Edema	1	2023	2023	1.0	low	0	0	0	1
Malignant Melanoma	1	2011	2011	13.0	low	0	0	1	0
Melanoma	1	2011	2011	13.0	low	0	0	1	0
Mood Disorders	1	2015	2015	9.0	low	0	0	1	0
Motor Disorders	1	2023	2023	1.0	low	0	0	0	1
MS (Multiple Sclerosis)	1	2013	2013	11.0	low	0	0	1	0
Multiple Myeloma	1	2008	2008	16.0	low	0	1	0	0
Multiple Sclerosis	1	2013	2013	11.0	low	0	0	1	0
Muscular Atrophy	1	2017	2017	7.0	low	0	0	1	0
Myocardial Infarction	1	2008	2008	16.0	low	0	1	0	0
Myotonic Dystrophy	2	2012	2018	9.0	low	0	0	2	0
Necrosis	1	2012	2012	12.0	low	0	0	1	0
Neoplasms	3	2004	2022	9.7	low	0	1	1	1
Nerve Degeneration	1	2004	2004	20.0	low	0	1	0	0
Nerve Pain	1	2016	2016	8.0	low	0	0	1	0
Nervous System Diseases	1	2004	2004	20.0	low	0	1	0	0
Nervous System Disorders	1	2004	2004	20.0	low	0	1	0	0
Neuralgia	1	2016	2016	8.0	low	0	0	1	0
Neurodegenerative Diseases	3	2014	2021	7.3	low	0	0	2	1
Obesity	1	2018	2018	6.0	low	1	0	1	0
Ovarian Neoplasms	1	2017	2017	7.0	low	0	0	1	0
Pain	1	2023	2023	1.0	low	0	0	0	1
Pain, Postoperative	1	2013	2013	11.0	low	0	0	1	0
Palmoplantaris Pustulosis	1	2018	2018	6.0	low	1	0	1	0
Pancreatitis	1	2007	2007	17.0	low	0	1	0	0
Parasite Infections	1	2004	2004	20.0	low	0	1	0	0
Parkinson Disease	1	2004	2004	20.0	low	0	1	0	0
Parkinsonian Disorders	1	2016	2016	8.0	low	0	0	1	0
Polyarthritis	1	2023	2023	1.0	low	0	0	0	1
Polycystic Kidney Diseases	1	2015	2015	9.0	low	0	0	1	0
Polycystic Ovarian Syndrome	1	2018	2018	6.0	low	1	0	1	0
Polycystic Ovary Syndrome	1	2018	2018	6.0	low	1	0	1	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma	1	2007	2007	17.0	low	0	1	0	0
Pregnancy	4	2013	2018	7.2	low	3	0	4	0
Prostatic Neoplasms	1	2011	2011	13.0	low	0	0	1	0
Proteinuria	4	2015	2020	7.8	low	0	0	4	0
Psoriasis	1	2018	2018	6.0	low	1	0	1	0
Renal Insufficiency, Chronic	1	2017	2017	7.0	low	0	0	1	0
Reperfusion Injury	12	2007	2021	10.5	low	0	5	6	1
Rheumatoid Arthritis	3	2006	2023	9.0	low	0	1	1	1
Schizophrenia	1	2013	2013	11.0	low	0	0	1	0
Seizures	2	2014	2015	9.5	low	0	0	2	0
Sensitivity and Specificity	1	2018	2018	6.0	low	1	0	1	0
Sepsis	3	2005	2007	18.0	low	0	3	0	0
Shock	1	2007	2007	17.0	low	0	1	0	0
Spinal Cord Injuries	2	2006	2019	11.5	low	0	1	1	0
Spondylitis, Ankylosing	1	2018	2018	6.0	low	1	0	1	0
Systemic Inflammatory Response Syndrome	1	2006	2006	18.0	low	0	1	0	0
Thyroid Neoplasms	1	2018	2018	6.0	low	1	0	1	0
Urinary Tract Infections	1	2018	2018	6.0	low	1	0	1	0
Zika Virus Infection	1	2020	2020	4.0	low	0	0	1	0

Safety/Toxicity (2)

Article	Year
Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice. Brain research, , Sep-18, Volume: 1581	2014
The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3β. Biochemical pharmacology, , Jan-15, Volume: 81, Issue:2	2011

Bioavailability (1)

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5	2019

Dosage (1)

Article	Year
Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders. Journal of medicinal chemistry, , Nov-25, Volume: 58, Issue:22	2015

Natural Sources (1)

Article	Year
Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease. PLoS genetics, , Volume: 13, Issue:3	2017